Why Is Emergent BioSolutions (EBS) Stock Up 70% Today?
- In today's market, one of the biggest winners generating outsized interest is Emergent Biosolutions (NYSE: EBS ). This mid-cap biotech company remains a unique turnaround story for investors, and many appear to be placing their bets on this company to come out of the pile as a key winner.
- 02/21/2024
|
Contrarian Calls: 7 Analyst ‘Sell' Ratings That Should Be ‘Buys'
- While it's usually a solid principle to bet alongside Wall Street's top experts, sometimes, they don't get it right, which brings us to contrarian analyst picks. You know how I've been supporting my arguments with analyst ratings and price targets?
- 01/31/2024
|
Emergent (EBS) Gets $235.8M DoD Contract for Anthrax Vaccine
- Emergent (EBS) signs a deal with the U.S. Department of Defense to supply its anthrax vaccine initially for a five-year period, with an option to extend it for another five years.
- 01/12/2024
|
Emergent BioSolutions to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 11, 2024
- GAITHERSBURG, Md., Jan. 09, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE: EBS), a global company providing solutions that address public health threats and brings lifesaving, life-extending products to market, today announced that Haywood Miller, Interim Chief Executive Officer and Rich Lindahl, Chief Financial Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Thursday, January 11, 2024, at 9:00 a.m. PT.
- 01/09/2024
|
Emergent BioSolutions stock pulls back, after rallying last week in wake of Biden administration's endorsement of overdose medications
- Shares of Emergent BioSolutions Inc. EBS slumped 2.8% in afternoon trading Tuesday, after surging more than 11% over the past two sessions, including Friday's 8.3% rally. The rally to end last week came in the wake of an announcement by the Biden administration that overdose reversal medications like naloxone, also known has Narcan, will be made available at safety stations in federal facilities.
- 12/26/2023
|
Emergent (EBS) Gets $75M BARDA Contract for Anthrax Vaccine
- The BARDA is exercising an option to procure additional doses of Emergent BioSolutions' (EBS) recently approved anthrax vaccine. Deliveries will likely be completed by the end of first-quarter 2024.
- 11/29/2023
|
Emergent BioSolutions Inc. (EBS) Q3 2023 Earnings Call Transcript
- Emergent BioSolutions Inc. (NYSE:EBS ) Q3 2023 Earnings Conference Call November 8, 2023 5:00 PM ET Company Participants Haywood Miller - Interim Chief Executive Officer Paul Williams - Senior Vice President and Head, Product Business Rich Lindahl - Executive Vice President and CFO Conference Call Participants Nick Lorusso - TD Cowen Frank DiLorenzo - Singular Research Operator Good afternoon, everyone. I am the operator for today's call.
- 11/08/2023
|
UPDATE: Emergent BioSolutions to Release Third Quarter 2023 Financial Results and Conduct Conference Call on November 8, 2023
- GAITHERSBURG, Md., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) has rescheduled its conference call to Wednesday, November 8, at 5:00 pm eastern time to discuss the financial results for the third quarter of 2023, recent business developments, and financial outlook for full year 2023. The call will no longer take place on November 2, 2023.
- 10/30/2023
|
Emergent BioSolutions to Release Third Quarter 2023 Financial Results and Conduct Conference Call on November 2, 2023
- GAITHERSBURG, Md., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, November 2, 2023, at 5:00 pm eastern time to discuss the financial results for the third quarter of 2023, recent business developments, and financial outlook for full year 2023.
- 10/19/2023
|
Why Is Emergent Biosolutions (EBS) Down 22.6% Since Last Earnings Report?
- Emergent Biosolutions (EBS) reported earnings 30 days ago. What's next for the stock?
- 09/07/2023
|
Emergent Biosolutions to make Narcan opioid overdose treatment available without prescription starting in September
- Emergent Biosolutions Inc. EBS, -7.92% said Wednesday its Narcan nasal spray that's an antidote for an opioid overdose will be available without a prescription starting in September. The Gaithersburg, Md.
- 08/30/2023
|
Emergent BioSolutions Is Clearly Risky, But The Reward Could Be Substantial
- Emergent BioSolutions is facing equity issuance and significant debt covenants in Q1 2024, but at its core, this is a robust pharma supplier to the U.S. government. The underlying value of the business is likely in excess of the price, even taking account of probable dilution, and debt covenants can likely be met on 2023 guidance. If the company can deliver on expectations over the coming months and into 2024, then returns for equity holders could be substantial, with $35/share possible.
- 08/23/2023
|
Why Emergent BioSolutions Stock Is Tumbling Today
- Emergent BioSolutions will be replaced on the S&P SmallCap 600 index. The move is a result of the company's market cap plunging since 2020.
- 08/22/2023
|
Down -28.45% in 4 Weeks, Here's Why You Should You Buy the Dip in Emergent Biosolutions (EBS)
- The heavy selling pressure might have exhausted for Emergent Biosolutions (EBS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
- 08/17/2023
|
Down -26.38% in 4 Weeks, Here's Why You Should You Buy the Dip in Emergent Biosolutions (EBS)
- The heavy selling pressure might have exhausted for Emergent Biosolutions (EBS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
- 08/16/2023
|
Emergent (EBS) Q2 Earnings Miss Estimates, Revenues Beat
- Emergent (EBS) reports wider-than-expected second-quarter loss. The company lowered its 2023 guidance for some products and services.
- 08/09/2023
|
Emergent Biosolutions (EBS) Reports Q2 Loss, Tops Revenue Estimates
- Emergent Biosolutions (EBS) came out with a quarterly loss of $1.06 per share versus the Zacks Consensus Estimate of a loss of $0.98. This compares to loss of $0.86 per share a year ago.
- 08/08/2023
|
2023 Layoff Tracker: Tyson Foods, Emergent BioSolutions Cut Hundreds Of Jobs
- Layoffs continue apace after more than 136,000 employees were cut by major U.S. companies in the first quarter of 2023.
- 08/08/2023
|
2023 Layoff Tracker: Emergent BioSolutions Cuts 400 Jobs
- Layoffs continue apace after more than 136,000 employees were cut by major U.S. companies in the first quarter of 2023.
- 08/08/2023
|
Emergent BioSolutions to lay off about 400 employees
- Emergent BioSolutions Inc said on Tuesday it plans to lay off about 400 employees across all businesses and cut back operations at some of its facilities.
- 08/08/2023
|
Emergent BioSolutions to Release Second Quarter 2023 Financial Results and Conduct Conference Call on August 8, 2023
- GAITHERSBURG, Md., July 25, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Tuesday, August 8, 2023, at 5:00 pm eastern time to discuss the financial results for the second quarter of 2023, recent business developments, revenue guidance for the third quarter of 2023, and financial outlook for full year 2023.
- 07/25/2023
|
Emergent's (EBS) Cyfendus Anthrax Vaccine Gets FDA Nod
- Emergent's (EBS) shares rise as its anthrax vaccine, Cyfendus (AV7909), gets FDA approval, offering preventive measures for people aged 18 to 65, who were exposed to the harmful bacillus anthracis germ.
- 07/21/2023
|
US FDA approves Emergent BioSolutions' anthrax vaccine
- Emergent BioSolutions said on Thursday the U.S. Food and Drug Administration has approved its anthrax vaccine.
- 07/20/2023
|
Why Emergent BioSolutions Stock Dived by 9% Today
- The contract manufacturer announced a top-level executive transition. This transition is fairly sudden.
- 06/27/2023
|
Better Recovery-Story Buy: Emergent BioSolutions or Invitae?
- Emergent BioSolutions just got a nod from regulators for over-the-counter use of a product to fight opioid overdose. Invitae is making progress on a plan to reach positive cash flow.
- 06/26/2023
|
Is Emergent BioSolutions Stock a Buy Now?
- Emergent BioSolutions saw its stock plummet due to a bunch of problems in 2021. Its pipeline is unimpressive, and its services revenue isn't anything special.
- 06/09/2023
|
Why Is Emergent Biosolutions (EBS) Down 21.4% Since Last Earnings Report?
- Emergent Biosolutions (EBS) reported earnings 30 days ago. What's next for the stock?
- 06/08/2023
|
Down 75%, Can Emergent BioSolutions Turn Things Around?
- Emergent BioSolutions' top line has been nosediving in recent quarters. The company's operations are also unprofitable, and the business is burning through cash.
- 06/07/2023
|
New Strong Sell Stocks for May 17th
- BIDU, EBS and FRO have been added to the Zacks Rank #5 (Strong Sell) List on May 17, 2023.
- 05/17/2023
|
Why Emergent BioSolutions Stock Inched Slightly Higher Today
- It has sold off a clutch of assets to a European peer. It's received an upfront payment of $270 million, and could earn up to an additional $110 million in milestone payouts.
- 05/15/2023
|
Emergent (EBS) Q1 Earnings Miss Estimates, Revenues Beat
- Emergent (EBS) reports wider-than-expected first-quarter loss. The company updates its 2023 guidance for selected categories.
- 05/10/2023
|
Emergent BioSolutions Inc. (EBS) Q1 2023 Earnings Call Transcript
- Emergent BioSolutions Inc. (NYSE:EBS ) Q1 2023 Earnings Conference Call May 9, 2023 5:00 PM ET Company Participants Bob Burrows - VP, IR Bob Kramer - President and CEO Paul Williams - Senior Vice President, Products Business Rich Lindahl - CFO Conference Call Participants Brandon Folkes - Cantor Fitzgerald Christopher Sakai - Singular Research Operator Good day, and thank you for standing by. Welcome to the Emergent BioSolutions First Quarter 2020 Financial Results Conference Call.
- 05/09/2023
|
Emergent Biosolutions (EBS) Reports Q1 Loss, Tops Revenue Estimates
- Emergent Biosolutions (EBS) came out with a quarterly loss of $3.17 per share versus the Zacks Consensus Estimate of a loss of $1.67. This compares to earnings of $0.18 per share a year ago.
- 05/09/2023
|
Emergent BioSolutions to Release First Quarter 2023 Financial Results and Conduct Conference Call on May 9, 2023
- GAITHERSBURG, Md., April 19, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Tuesday, May 9, 2023, at 5:00 pm eastern time to discuss the financial results for the first quarter of 2023, recent business developments, revenue guidance for the second quarter of 2023, and financial outlook for full year 2023.
- 04/19/2023
|
Emergent Biosciences (EBS) Surges 28% in a Week: Here's Why
- Shares of Emergent (EBS) have been rising following the FDA's approval to an OTC version of its Narcan nasal spray.
- 04/03/2023
|
Emergent's (EBS) Narcan Gets OTC Status for Opioid Overdose
- Following the FDA approval, Emergent's (EBS) Narcan nasal spray becomes the first OTC product approved for emergency treatment of opioid overdose. This product will be made available by late summer of this year.
- 03/30/2023
|
3 Stocks Capturing Options Traders' Attention
- The major indexes are on the rise today, as Wall Street remains optimistic regarding the bank sector's recovery.
- 03/30/2023
|
Why Emergent BioSolutions Stock Is Soaring Today
- The FDA approved the use of Narcan as an over-the-counter treatment for opioid overdoses on Wednesday. Narcan has been available as a prescription product in the U.S. since 2016.
- 03/30/2023
|
Emergent Biosolutions (EBS) Surges 5.1%: Is This an Indication of Further Gains?
- Emergent Biosolutions (EBS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
- 03/30/2023
|
Emergent Biosciences (EBS) Stock Pops as FDA Approves Over-the-Counter Narcan
- In a fresh development for the medical and financial communities, the U.S. Food and Drug Administration (FDA) approved Emergent Biosciences' (NASDAQ: EBS ) Narcan nasal spray as an over-the-counter (OTC) emergency opioid overdose treatment. As you might expect, EBS stock traders are responding to this news with high-volume buying activity.
- 03/29/2023
|
FDA approves over-the-counter sales of lifesaving opioid overdose treatment Narcan nasal spray
- The FDA's decision means people will be able to buy the 4mg nasal spray without a prescription in supermarkets, convenience stores and vending machines.
- 03/29/2023
|
Why Emergent BioSolutions Stock Is Sinking Today
- J.P. Morgan analyst Jessica Fye downgraded Emergent BioSolutions from neutral to underweight. Fye also slashed the price target for the stock from $23 to $9.
- 03/17/2023
|
Why Emergent BioSolutions Stock Tumbled by Almost 12% Today
- It's not a good day for investors when their company reports a shocking plunge into the red.
- 02/28/2023
|
Emergent's (EBS) Q4 Earnings Miss, Sales Beat Estimates
- Emergent (EBS) reported mixed fourth-quarter 2022 results. While the company significantly misses the mark on earnings, it beat sales estimates.
- 02/28/2023
|
Emergent BioSolutions Inc. (EBS) Q4 2022 Earnings Call Transcript
- Emergent BioSolutions Inc. (NYSE:EBS ) Q4 2022 Earnings Conference Call February 27, 2023 5:00 PM ET Company Participants Bob Burrows - Vice President, Investor Relations Bob Kramer - President and CEO Rich Lindahl - Chief Financial Officer Conference Call Participants Nick Lenard - JPMorgan Brandon Folkes - Cantor Boris Peaker - Cowen Operator Good day and thank you for standing by. Welcome to the Emergent BioSolutions Fourth Quarter and Full Year 2022 Financial Results Conference Call.
- 02/27/2023
|
Emergent Biosolutions (EBS) Reports Q4 Loss, Tops Revenue Estimates
- Emergent Biosolutions (EBS) delivered earnings and revenue surprises of -196.88% and 7.47%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- 02/27/2023
|
Emergent BioSolutions: Positive NARCAN FDA Panel, Divesting Travel Health, Raising Rating To Buy
- Emergent BioSolutions has shown a remarkable turnaround since challenging Q3:22 results with a $380 million procurement contract and restructuring plan. Now, a definitive step toward a NARCAN over-the-counter approval.
- 02/19/2023
|
Emergent's stock jumps after FDA panel favors over-the-counter sales of Narcan
- Shares of Emergent BioSolutions Inc. EBS, +12.52% rallied about 19% in premarket trading on Thursday, the day after a Food and Drug Administration advisory committee voted in favor of allowing over-the-counter sales of Narcan, the opioid overdose reversal medication. The FDA is not required to follow the advice of the committee but often does.
- 02/16/2023
|
Emergent Biosolutions (EBS) Moves 12.5% Higher: Will This Strength Last?
- Emergent Biosolutions (EBS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
- 02/16/2023
|
Emergent BioSolutions to Release Fourth Quarter 2022 Financial Results and Conduct Conference Call on February 27, 2023
- GAITHERSBURG, Md., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Monday, February 27, 2023, at 5:00 pm eastern time to discuss the financial results for the fourth quarter of 2022, recent business developments, and financial outlook for full year 2023.
- 02/06/2023
|
Emergent (EBS) to Start Restructuring Plan, Lays Off 5% Workforce
- Once this restructuring activity is completed, Emergent BioSolutions (EBS) expects to result in annualized savings of over $60 million. It also slightly raised its total revenue guidance for 2022.
- 01/10/2023
|
Pharma Stock Falls Amid Workforce Reduction Plans
- Emergent BioSolutions Inc (NYSE:EBS) is in the news today, after the pharmaceutical company announced it was cutting its workforce by roughly 5%.
- 01/09/2023
|
Emergent BioSolutions to cut 5% of its workforce in reorganization effort
- Emergent BioSolutions Inc. EBS, +9.80% is cutting 132 jobs, or approximately 5% of its workforce in a reorganization that the company says will sharpen its strategic focus on core businesses. The biotech described its core businesses as medical countermeasures and commercial products, including NARCAN nasal spray, as well as contract development and manufacturing services.
- 01/09/2023
|
Why Is Emergent Biosolutions (EBS) Down 3.7% Since Last Earnings Report?
- Emergent Biosolutions (EBS) reported earnings 30 days ago. What's next for the stock?
- 12/08/2022
|
Emergent (EBS) OTC Narcan Filing Gets FDA Priority Review Tag
- The FDA grants priority review to Emergent's regulatory filing seeking approval for an OTC version of its Narcan nasal spray. A final decision is expected by March 2023-end.
- 12/07/2022
|
4 Toxic Stocks More So Hazardous Amid Volatile Times
- Just like identifying stocks with growth potential, pinpointing toxic stocks and offloading them at the right time is crucial to guard one's portfolio from big losses. EBS, WDC, TWKS and DZSI are a few such toxic stocks.
- 11/30/2022
|
Emergent's (EBS) Q3 Earnings and Revenues Miss Estimates
- Emergent's (EBS) third-quarter 2022 earnings and revenues miss estimates. EBS issues fresh guidance for its CDMO services
- 11/09/2022
|
Emergent BioSolutions Inc. (EBS) Q3 2022 Earnings Call Transcript
- Emergent BioSolutions Inc. (NYSE:EBS ) Q3 2022 Earnings Conference Call November 8, 2022 5:00 PM ET Company Participants Bob Burrows - Vice President, Investor Relations Bob Kramer - President & Chief Executive Officer Rich Lindahl - Chief Financial Officer Conference Call Participants Jessica Fye - JPMorgan Keay Nakae - Chardan Brandon Folkes - Cantor Operator Good day and thank you for standing. Welcome to the Emergent BioSolutions Third Quarter 2022 Earnings Conference Call.
- 11/08/2022
|
Emergent Biosolutions (EBS) Reports Q3 Loss, Misses Revenue Estimates
- Emergent Biosolutions (EBS) delivered earnings and revenue surprises of -2,016.67% and 10.51%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
- 11/08/2022
|
Ranking the 7 Top Small-Cap Stocks to Buy From Best to Worst
- These top small-cap stocks to buy present daring investors with significant upside. Fundamentally, companies with a relatively diminutive profile typically command higher growth potential.
- 10/24/2022
|
Emergent BioSolutions to Release Third Quarter 2022 Financial Results and Conduct Conference Call on November 8, 2022
- GAITHERSBURG, Md., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Tuesday, November 8, 2022, at 5:00 pm eastern time to discuss the financial results for the third quarter of 2022, recent business developments, and financial outlook for full year 2022.
- 10/18/2022
|
Emergent Biosolutions (EBS) Down 20% Since Last Earnings Report: Can It Rebound?
- Emergent Biosolutions (EBS) reported earnings 30 days ago. What's next for the stock?
- 08/31/2022
|
3 Top Monkeypox Stocks to Buy Right Now
- With the latest outbreak now reported in all 50 states per ABC News, investors may want to consider the top monkeypox stocks to buy right now. From an investment perspective, this latest health threat poses powerful catalysts.
- 08/24/2022
|
Emergent BioSolutions to Participate in Investor Conferences
- GAITHERSBURG, Md., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company's executive management team will participate in the following investor conferences:
- 08/10/2022
|
Emergent's (EBS) Q2 Earnings and Revenues Miss Estimates
- Emergent's (EBS) second-quarter 2022 earnings and revenues miss estimates. EBS issues fresh guidance for its CDMO services.
- 08/02/2022
|
Why Emergent BioSolutions Stock Is Sinking Today
- The company reported disappointing Q2 results.
- 08/02/2022
|
MonkeyPox Stocks To Buy Right Now? 3 To Know
- Should investors be watching these monkeypox stocks right now?
- 08/02/2022
|
Emergent BioSolutions Inc. (EBS) CEO Bob Kramer on Q2 2022 Results - Earnings Call Transcript
- Emergent BioSolutions Inc. (NYSE:EBS ) Q2 2022 Results Conference Call August 1, 2022 5:00 PM ET Company Participants Bob Burrows - Vice President of Investor Relations Bob Kramer - President and Chief Executive Officer Rich Lindahl - Chief Financial Officer Conference Call Participants Brandon Folkes - Cantor Jessica Fye - JPMorgan Joichi Sakai - Singular Research Operator Thank you for standing by, and welcome to the Emergent BioSolutions Second Quarter 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode.
- 08/01/2022
|
Emergent Biosolutions (EBS) Reports Q2 Loss, Misses Revenue Estimates
- Emergent Biosolutions (EBS) delivered earnings and revenue surprises of -236.51% and 16.64%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
- 08/01/2022
|
Monkeypox Stocks GOVX, VRAX, SIGA Rocket on Vaccine Shortage Fears
- Monkeypox stocks are rallying amid worries about a shortage of vaccines for the illness in the U.S. Additionally, in recent days, New York state, New York City and San Francisco have issued emergency orders related to monkeypox. Several related names rallied in pre-market trading today and are still up since the market opened this morning.
- 08/01/2022
|
Why Emergent BioSolutions Stock Is Jumping This Week
- Worries about the monkeypox outbreak have driven Emergent's shares higher.
- 07/28/2022
|
Emergent BioSolutions to Release Second Quarter 2022 Financial Results and Conduct Conference Call on August 1, 2022
- GAITHERSBURG, Md., July 18, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Monday, August 1, 2022, at 5:00 pm eastern time to discuss the financial results for the second quarter of 2022, recent business developments, revenue guidance for the third quarter of 2022, and financial outlook for full year 2022.
- 07/18/2022
|
Monkeypox Stocks BVNRY, EBS, CMRX, SIGA Heat Up on U.S. Vaccine Stockpile
- Stocks related to the treatment of monkeypox are heating up today on news that the U.S. is building a vaccine stockpile and will offer vaccine appointments to individuals who are at risk of contracting the virus. The post Monkeypox Stocks BVNRY, EBS, CMRX, SIGA Heat Up on U.S. Vaccine Stockpile appeared first on InvestorPlace.
- 06/29/2022
|
Emergent's (EBS) Anthrax Vaccine BLA Gets FDA Acceptance
- The FDA accepts Emergent's (EBS) BLA seeking approval for its new anthrax vaccine, AV7909. A decision is expected in April next year.
- 06/27/2022
|
Emergent BioSolutions says FDA has accepted its anthrax vaccine candidate for review
- Emergent BioSolutions Inc. EBS, +7.19% said Friday the U.S. Food and Drug Administration has accepted for review its application for approval of its anthrax vaccine. Dubbed AV7909, the vaccine is aimed at people aged 18 through 65 years who have been exposed to anthrax for use along with recommended antibacterial drugs.
- 06/24/2022
|
Two Pharma Companies That Will Profit From The MonkeyPox Outbreak
- The monkeypox outbreak has affected 780 people since identified on May 13, 2022. Vaccines are key to curtailing the spread of Monekey Pox. Two pharma companies, Geovax Labs Inc. and Emergent Biosolutions, have already benefited from the outbreak.
- 06/12/2022
|
7 No-Brainer Biotech Stocks to Add to Your Buy List
- With the broader markets grumbling, investors should consider biotech stocks to buy for their permanently relevant profile. The post 7 No-Brainer Biotech Stocks to Add to Your Buy List appeared first on InvestorPlace.
- 06/09/2022
|
7 Monkeypox Stocks That May Take Off in Q2
- SIGA Technologies (SIGA) may lead on the list of monkeypox stocks that could soar, but Bavarian Nordic seems to be leading the sales race. The post 7 Monkeypox Stocks That May Take Off in Q2 appeared first on InvestorPlace.
- 06/09/2022
|
Emergent (EBS) Stock Down as J&J Ends COVID-19 CDMO Contract
- Emergent (EBS) sends contract breach notice to J&J, following the latter's decision to end their contract for CDMO services for its COVID-19 vaccine. J&J also cites contract breach as the basis for termination.
- 06/07/2022
|
Contract manufacturer Emergent says J&J breached vaccine contract
- Contract manufacturer Emergent BioSolutions Inc said on Monday U.S. drugmaker Johnson & Johnson had breached an agreement by failing to buy the minimum quantity of COVID-19 vaccines made by the company.
- 06/06/2022
|
Emergent BioSolutions to Participate in Investor Conferences
- GAITHERSBURG, Md., June 02, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company's executive management team will participate in the following investor conferences:
- 06/02/2022
|
Emergent BioSolutions: A Top Pick For The Monkeypox Outbreak
- Emergent BioSolutions' stock has spiked up over the past week as a monkeypox outbreak begins to spread to Europe and North America. The company is my Top Pick for monkeypox. Emergent's smallpox vaccine, ACAM2000, is expected to be effective against monkeypox due to its close relation to the variola virus that causes smallpox. ACAM2000 is already in the national stockpile.
- 05/29/2022
|
7 Monkeypox Stocks to Watch Right Now
- Wondering what are the best monkeypox stocks to watch? Here are the companies producing vaccines to help fight the spread of the virus.
- 05/24/2022
|
Vaccine-maker shares soar on monkeypox outbreak
- CNBC's Meg Tirrell joins 'Squawk Box' to break down the companies with vaccines against monkeypox as multiple countries respond to a growing number of cases.
- 05/24/2022
|
Are These 4 Stocks Smart Buys With the Monkeypox Outbreak?
- The monkeypox opportunity could already be baked into the prices of these stocks.
- 05/24/2022
|
Why Emergent BioSolutions Stock Is Jumping Today
- Monkeypox concerns are boosting the stock.
- 05/23/2022
|
Emergent BioSolutions opened 15% up on Monday: here's why
- Emergent BioSolutions Inc (NYSE: EBS) opened another 15% up in the stock market this morning as global cases of Monkeypox continued to rise over the weekend. How does the outbreak affect Emergent BioSolutions?
- 05/23/2022
|
Why Emergent Biosolutions Stock Is Rising Today
- Emergent Biosolutions Inc (NYSE: EBS) shares are trading higher Monday amid increasing monkeypox concerns. A monkeypox outbreak has been reported in at least a dozen countries.
- 05/23/2022
|
6 Stocks To Watch Amid Monkeypox Outbreak
- A Monkeypox outbreak has been reported in several European countries, two cases in Canada and one confirmed case in a man from Massachusetts. What's going on?
- 05/20/2022
|
Monkeypox Stocks: SIGA, EBS and TNXP Move Higher on Smallpox Vaccines, Treatments
- Monkeypox stocks SIGA, EBS and TNXP are all advancing as fears mount over monkeypox. The disease is related to smallpox.
- 05/20/2022
|
Monkeypox Fears Drive Smallpox Antiviral Makers Higher
- Emergent BioSolutions (EBS) stock was up almost 12% while SIGA Technologies (SIGA) rose 17.1% on Thursday.
- 05/20/2022
|
Monkeypox Case Reported in U.S. Emergent BioSolutions Makes a Vaccine.
- The ACAM2000 vaccine can be used to prevent the spread of monkeypox, according to the CDC.
- 05/19/2022
|
Why Emergent BioSciences Stock Is Soaring Today
- A monkeypox outbreak could boost sales for the company's smallpox vaccine.
- 05/19/2022
|
7 High-Risk, High-Reward Small-Cap Stocks to Buy Now
- Many small-cap stocks in the S&P 600 Small Cap Index aren't big names, but they have the change of bringing big rewards. The post 7 High-Risk, High-Reward Small-Cap Stocks to Buy Now appeared first on InvestorPlace.
- 05/13/2022
|
Emergent's (EBS) Q1 Earnings Miss, Revenues Beat Estimates
- Emergent's (EBS) first-quarter 2022 earnings miss estimates while sales beat the mark. EBS suspends its CDMO guidance for 2022 until it gets a better picture of the COVID-19 vaccine requirements.
- 04/29/2022
|
Emergent BioSolutions Suspends CDMO Guidance As It Awaits Clarity On COVID-19 Vaccine Requirements
- Emergent BioSolutions Inc (NYSE: EBS) reported Q1 sales of $307.5 million, down 10% Y/Y, beating the consensus of $283 million. Total product sales increased 72% to $237.1 million, while Contract development & manufacturing (CDMO) revenues declined 67% to $60.8 million.
- 04/29/2022
|
Emergent BioSolutions Inc. (EBS) CEO Bob Kramer on Q1 2022 Results - Earnings Call Transcript
- Emergent BioSolutions Inc. (NYSE:EBS ) Q1 2022 Results Conference Call April 28, 2022 5:00 PM ET Company Participants Bob Burrows - VP, IR Bob Kramer - President and CEO Rich Lindahl - CFO Conference Call Participants Brandon Folkes - Cantor Fitzgerald Lisa Springer - Singular Research Operator Good day, and thank you for standing by. Welcome to the First Quarter 2022 Emergent BioSolutions Earnings Conference Call.
- 04/28/2022
|
Emergent Biosolutions (EBS) Q1 Earnings Lag Estimates
- Emergent Biosolutions (EBS) delivered earnings and revenue surprises of -25% and 3.86%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
- 04/28/2022
|
New Strong Sell Stocks for April 28th
- LAZR, EBS, and ROCK have been added to the Zacks Rank #5 (Strong Sell) List on April 28, 2022
- 04/28/2022
|
Drug/Biotech Stocks Q1 Earnings Due on Apr 28: MRK, LLY & More
- Let us look at the five biotech/pharma companies, slated to release quarterly results on Apr 28.
- 04/27/2022
|
Emergent Biosolutions - Still in the Doghouse
- In early 2021, in the eye of the Covid storm, there was a mix-up in the manufacturing of the Covid-19 vaccine developed by Johnson & Johnson ( JNJ , Financial) and manufactured by the contractor Emergent BioSolutions Inc. ( EBS , Financial). At Emergent's Bayview site in Maryland, where the AstraZeneca ( AZN , Financial) Covid vaccine was also manufactured, workers had accidentally mixed up ingredients of the two vaccines.
- 04/25/2022
|
Emergent BioSolutions to Release First Quarter 2022 Financial Results and Conduct Conference Call on April 28, 2022
- GAITHERSBURG, Md., April 08, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, April 28, 2022, at 5:00 pm eastern time to discuss the financial results for the first quarter of 2022, recent business developments, revenue guidance for the second quarter of 2022, and financial outlook for full year 2022.
- 04/08/2022
|
Emergent BioSolutions to Participate in Investor Conferences
- GAITHERSBURG, Md., March 14, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company's executive management team will participate in the following investor conferences:
- 03/14/2022
|
Emergent (EBS) Begins Dosing in Phase I Cyanide Poisoning Study
- Emergent (EBS) initiates dosing in a phase I study evaluating stabilized isoamyl nitrite, the company's investigational single-use intranasal spray for treating acute cyanide poisoning.
- 03/14/2022
|
New Strong Sell Stocks for March 11th
- AVVIY, EBS, and NVEI have been added to the Zacks Rank #5 (Strong Sell) List on March 11, 2022.
- 03/11/2022
|
Emergent BioSolutions Stock Fell Today -- Is It a Buy?
- There's considerable uncertainty about the company's near-term prospects.
- 02/25/2022
|
Emergent's (EBS) Q4 Earnings & Sales Beat, CDMO View Cut
- Emergent's (EBS) fourth-quarter 2021 earnings and sales beat estimates. The company lowers its guidance for 2022 CDMO services revenues and adjusted net income.
- 02/25/2022
|
Why Emergent BioSciences Stock Is Slipping Today
- The company disappointed investors with its 2022 guidance.
- 02/25/2022
|
Emergent BioSolutions Inc. (EBS) CEO Bob Kramer on Q4 2021 Results - Earnings Call Transcript
- Emergent BioSolutions Inc. (EBS) CEO Bob Kramer on Q4 2021 Results - Earnings Call Transcript
- 02/24/2022
|
Drug/Biotech Stocks' Q4 Earnings on Feb 24: MRNA, EBS & More
- Let us take a look at five biotech/drug companies, namely, MRNA, EDIT, VIR, EBS and AERI, which are due to release their quarterly results on Feb 24.
- 02/23/2022
|
Emergent BioSolutions: Still A Bargain Regardless Of Diminished Growth Forecasts
- Emergent BioSolutions has been an exiled ticker following the vaccine mix-up at the company's Bayview Facility last year. Although the company has addressed the issues in Bayview, it looks as if the market has expelled EBS as a good investment at this point in time.
- 02/13/2022
|
Emergent BioSolutions to Release Fourth Quarter 2021 Financial Results and Conduct Conference Call on February 24, 2022
- GAITHERSBURG, Md., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, February 24, 2022 at 5:00 pm eastern time to discuss the financial results for the fourth quarter 2021, recent business developments, financial outlook for full year 2022, and revenue guidance for the first quarter of 2022.
- 02/07/2022
|
4 Companies Growing Earnings Fast
- The S&P 500 saw the trailing 12-month real earnings per share of its member companies increase by a compound annual growth rate of 11.6% over the past five years. The index, which stood at a price of $4,500.53 per share as of Friday, has climbed more than 95% over the past five years.
- 02/06/2022
|
Emergent BioSolutions to Participate in Investor Conferences
- GAITHERSBURG, Md., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company's executive management team will participate in the following investor conferences in the first quarter of 2022:
- 01/03/2022
|
Emergent (EBS) Begins Dosing in Study on Influenza Vaccine
- Emergent (EBS) initiates a phase I study evaluating EBS-UFV-001, the company's investigational universal influenza vaccine candidate.
- 12/17/2021
|
Emergent begins clinical trial for universal flu vaccine candidate
- Emergent BioSolutions Inc. EBS, +3.55% said Thursday that it began dosing participants in a Phase 1 clinical trial for its universal influenza vaccine candidate. The randomized, double-blind, placebo-controlled dose-escalation study is being conducted in Australia; 60 healthy adults will be enrolled in the study.
- 12/16/2021
|
Canada to allow import of J&J vaccine doses made at Emergent facility
- The Canadian health regulator said on Wednesday it would allow Johnson & Johnson to import its COVID-19 vaccine made at contract manufacturer Emergent BioSolutions Inc's plant in Baltimore, Maryland.
- 11/24/2021
|
Emergent BioSolutions: Rapid-Return Trade With More Legs
- The modification/loss of a contract coupled with a weak earnings report sent the stock tumbling 40%.
- 11/16/2021
|
Why Emergent BioSolutions Popped by Over 4% Today
- The company has given 250 million reasons why investors should buy its stock.
- 11/12/2021
|
See Why Emergent BioSolutions Stock Plunged 37% On Friday?
- After a fiasco surrounding the contamination of COVID-19 vaccine doses in its facilities, Emergent BioSolutions Inc's (NYSE: EBS) manufacturing deal with the US government has come to an end. CEO Bob Kramer said that the two parties "mutually agreed" to terminate the contract, evaporating about $180 million in deal value.
- 11/05/2021
|
Emergent Biosolutions shares plunge by more than 37% after U.S. cancels deal with Covid vaccine maker
|
Emergent slumps as U.S. terminates COVID-19 vaccine manufacturing deal
- Shares of Emergent BioSolutions Inc tumbled 15% on Friday, following the termination of a U.S. government contract to reserve capacity and expand manufacturing of third-party COVID-19 vaccines at its sites.
- 11/05/2021
|
Emergent BioSolutions Inc. (EBS) CEO Bob Kramer on Q3 2021 Results - Earnings Call Transcript
- Emergent BioSolutions Inc. (EBS) CEO Bob Kramer on Q3 2021 Results - Earnings Call Transcript
- 11/04/2021
|
Emergent BioSolutions to Release Third Quarter 2021 Financial Results and Conduct a Conference Call on November 4, 2021
- GAITHERSBURG, Md., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, November 4, 2021 at 5:00 pm eastern time to discuss the financial results for the third quarter of 2021, recent business developments, and financial outlook for full year 2021.
- 10/18/2021
|
Emergent BioSolutions Announces Initiation of Pivotal Phase 3 Study Evaluating the Safety and Immunogenicity of Its Single-Dose Chikungunya Vaccine Candidate, CHIKV VLP
- GAITHERSBURG, Md., Oct. 15, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced the first participant dosed in its pivotal phase 3 study evaluating the safety and immunogenicity of the company's investigational chikungunya virus (CHIKV) virus-like particle (VLP) vaccine candidate, CHIKV VLP, in a single dose. CHIKV VLP is the only VLP-based vaccine currently in clinical development for active immunization against chikungunya disease.
- 10/15/2021
|
What's Happening With Emergent Biosolutions Stock?
- The stock price of Emergent Biosolutions, a specialty biopharmaceutical company, has seen a fall of 15% over the last twenty-one trading days, while it is down 42% year-t0-date. EBS stock has had a tough year so far, with its manufacturing unit in Baltimore facing the heat after contamination of.
- 09/24/2021
|
Shuman, Glenn & Stecker Investigates Emergent BioSolutions, Inc.
- DENVER--(BUSINESS WIRE)--Shuamn, Glenn & Stecker investigates Emergent BioSolutions, Inc. (NYSE: EBS).
- 09/21/2021
|
Emergent (EBS) Inks COVID-19 Manufacturing Deal With Providence
- Emergent (EBS) is set to provide manufacturing services for doses of Providence Therapeutics' COVID-19 vaccine candidate as well as for its bulk drug substance.
- 09/15/2021
|
Emergent Secures Contract To Manufacture Providence Therapeutics' COVID-19 Vaccine Candidate
- Emergent BioSolutions Inc (NYSE: EBS) has signed a five-year agreement with Providence Therapeutics valued at about $90 million to develop and manufacture its COVID-19 vaccine candidate. Emergent will produce drug substances for Providence's vaccine candidate, PTX-COVID19-B, and provide services for finished products at its Winnipeg facility in Canada.
- 09/14/2021
|
Emergent BioSolutions Secures Multi-Year Development and Manufacturing Agreement with Providence Therapeutics for its mRNA COVID-19 Vaccine Candidate, PTX-COVID19-B
- GAITHERSBURG, Md. and CALGARY, Alberta, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) and Providence Therapeutics today announced they have entered into a five-year contract development and manufacturing (CDMO) services agreement spanning Emergent's integrated capabilities, including development services, bulk drug substance formulation and drug product manufacturing, to support Providence's COVID-19 messenger RNA (mRNA) vaccine development. In 2022, Emergent will manufacture tens of millions of doses of PTX-COVID19-B drug product, as well as batches of PTX-COVID19-B formulated bulk drug substance with the potential to yield hundreds of millions more doses, for global populations in need of pandemic relief.
- 09/14/2021
|
Emergent BioSolutions: Positive Outlook Despite Current Lawsuit
- Emergent BioSolutions: Positive Outlook Despite Current Lawsuit
- 09/02/2021
|
Emergent BioSolutions' COVID-19 Human Immune Globulin Product Candidate to be Evaluated in NIH-Sponsored Phase 3 Clinical Trial (INSIGHT-012) of Hyperimmune Intravenous Immunoglobulin for Outpatient Treatment of COVID-19
- GAITHERSBURG, Md., Aug. 25, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced the initiation of a Phase 3 clinical trial that will evaluate its investigational SARS-CoV-2 Immune Globulin Intravenous (Human) (COVID-HIG) plasma-derived therapy as a potential outpatient treatment for patients with coronavirus disease (COVID-19) that are at high risk of progression to severe disease, including adults 55 and older and those 18 and older who are immunocompromised.
- 08/25/2021
|
Emergent BioSolutions to Participate in Investor Conferences
- GAITHERSBURG, Md., Aug. 23, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company's senior management team will participate in the following investor conferences:
- 08/23/2021
|
New Strong Sell Stocks for August 2nd
- ATTO, BLDP, NTB, CCJ and EBS have been added to the Zacks Rank #5 (Strong Sell) List on August 2, 2021.
- 08/02/2021
|
Emergent (EBS) Misses on Q2 Earnings, to Restart Bayview Unit
- Emergent's (EBS) second-quarter 2021 earnings miss estimates. Revenues also fail to meet expectations.
- 07/30/2021
|
U.S. authorities probing Emergent BioSolutions over COVID-19 vaccine issues -filing
- Drug manufacturer Emergent BioSolutions Inc on Friday said it has received inquiries and subpoenas from a swathe of U.S. authorities related to its abilities to manufacture COVID-19 bulk drug substance.
- 07/30/2021
|
Emergent Biosolutions' (EBS) CEO Bob Kramer on Q2 2021 Results - Earnings Call Transcript
- Emergent Biosolutions' (EBS) CEO Bob Kramer on Q2 2021 Results - Earnings Call Transcript
- 07/29/2021
|
Emergent Biosolutions (EBS) Lags Q2 Earnings and Revenue Estimates
- Emergent Biosolutions (EBS) delivered earnings and revenue surprises of -81.77% and -4.39%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
- 07/29/2021
|
Emergent BioSolutions Stock Higher As COVID-19 Vaccine Production To Resume At Baltimore Plant
- Emergent BioSolutions Inc (NYSE: EBS) will resume production of Johnson & Johnson's (NYSE: JNJ) COVID-19 vaccine at its troubled Baltimore facility, where operations were stopped in April after millions of doses were found to be contaminated. The development comes after J&J last week slashed the 2021 production target of its single-dose vaccine to between 500 million and 600 million doses from its original goal to produce 1 billion shots.
- 07/29/2021
|
Emergent BioSolutions to Resume Manufacturing Covid-19 Vaccine at Bayview Facility
- GAITHERSBURG, Md., July 29, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that the U.S. Food and Drug Administration (FDA) is allowing Emergent's Bayview manufacturing facility to resume production of Johnson & Johnson's (J&J) Covid-19 vaccine bulk drug substance. This resumption of manufacturing follows extensive reviews by FDA, weeks of diligent work, and close coordination with J&J and FDA to execute on Emergent's quality enhancement plan.
- 07/29/2021
|
Reverse the Silence Campaign Casts a National Spotlight on Overdose Risks Associated with Opioid Use
- GAITHERSBURG, Md., July 26, 2021 (GLOBE NEWSWIRE) -- An alliance of national nonprofit organizations comprised of Community Anti-Drug Coalitions of America (CADCA), Mothers Against Prescription Drug Abuse (MAPDA), SAFE Project, and Shatterproof, sponsored by Emergent BioSolutions Inc., (NYSE:EBS) today announced the launch of a new public awareness campaign, Reverse the Silence, which features television and radio spots that educate and help support people who may be at risk or know someone at risk of an opioid overdose.
- 07/26/2021
|
These Companies Have Seen Large Returns From 2020 Government Investment
- Much focus on investment comes from the private sector, particularly those of the venture capitalist persuasion. But one of the biggest investors this country has is the federal government.
- 07/23/2021
|
Emergent BioSolutions to Release Second Quarter 2021 Financial Results and Conduct a Conference Call on July 29, 2021
- GAITHERSBURG, Md., July 15, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, July 29, 2021 at 5:00 pm eastern time to discuss the financial results for the second quarter of 2021, recent business developments, revenue guidance for the third quarter of 2021, and financial outlook for full year 2021.
- 07/15/2021
|
Can Emergent BioSolutions Recover From Its Recent Blunders?
- Yes, but it probably won't be an easy path.
- 07/03/2021
|
Faruqi & Faruqi, LLP is Investigating Emergent BioSolutions (EBS) on Behalf of its Shareholders
- New York, New York--(Newsfile Corp. - June 23, 2021) - Faruqi & Faruqi, LLP, a leading minority and Woman-owned national securities law firm, is investigating potential misconduct at Emergent BioSolutions Inc. ("Emergent BioSolutions" or the "Company") (NYSE: EBS).The investigation focuses on whether the Company's Board of Directors and/or officers breached their fiduciary duties. Request more information now by clicking here: www.faruqilaw.com/EBS. There is no cost or obligation to you.Take ActionIf you currently own...
- 06/23/2021
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Emergent Biosolutions Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 21, 2021 - EBS
- New York, New York--(Newsfile Corp. - June 21, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Emergent Biosolutions Inc. ("Emergent Bio") (NYSE: EBS) between April 24, 2020 and April 16, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the District of Maryland. To get more...
- 06/21/2021
|
Final Deadline Today: Rosen, Global Investor Counsel, Reminds Emergent BioSolutions Inc. Investors with Losses Over $100K of the Updated June 21 Deadline in Securities Class Action Due to the Recently Declared Federal Court Holiday - EBS
- New York, New York--(Newsfile Corp. - June 21, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Emergent BioSolutions Inc. (NYSE: EBS) between April 24, 2020 through April 16, 2021, inclusive (the "Class Period"), of the important June 21, 2021 lead plaintiff deadline.SO WHAT: If you purchased Emergent securities during the Class Period you may be entitled to compensation without payment of any out of pocket...
- 06/21/2021
|
FINAL DEADLINE TODAY: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Emergent BioSolutions Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - June 21, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Emergent BioSolutions Inc. ("Emergent BioSolutions" or "the Company") (NYSE: EBS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between April 24, 2020 and April 16, 2021,...
- 06/21/2021
|
Final Deadline Monday: Rosen, A Top Ranked Law Firm, Reminds Emergent BioSolutions Inc. Investors with Losses Over $100K of the Updated June 21 Deadline in Securities Class Action Due to the Recently Declared Federal Court Holiday - EBS
- New York, New York--(Newsfile Corp. - June 20, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Emergent BioSolutions Inc. (NYSE: EBS) between April 24, 2020 through April 16, 2021, inclusive (the "Class Period"), of the important June 21, 2021 lead plaintiff deadline.SO WHAT: If you purchased Emergent securities during the Class Period you may be entitled to compensation without payment of any out of pocket...
- 06/20/2021
|
DEADLINE TOMORROW: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Emergent BioSolutions Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- LOS ANGELES--(BUSINESS WIRE)---- $EBS #EBS--DEADLINE TOMORROW: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Emergent BioSolutions Inc.
- 06/20/2021
|
UPDATED DEADLINE MONDAY: ROSEN, SKILLED INVESTOR COUNSEL, Reminds Emergent BioSolutions Inc. Investors With Losses Over $100K of the Updated June 21 Deadline in Securities Class Action Due to the Recently Declared Federal Court Holiday - EBS
- NEW YORK, June 18, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Emergent BioSolutions Inc. (NYSE: EBS) between April 24, 2020 through April 16, 2021, inclusive (the "Class Period"), of the important June 21, 2021 lead plaintiff deadline. SO WHAT: If you purchased Emergent securities during the Class Period, you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
- 06/18/2021
|
DEADLINE TODAY: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Emergent BioSolutions Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - June 18, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Emergent BioSolutions Inc. ("Emergent BioSolutions" or "the Company") (NYSE: EBS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between July 6, 2020 and March 31, 2021,...
- 06/18/2021
|
Final Deadline for Investors to Actively Participate in Emergent BioSolutions Inc. (EBS) Class Action: Bronstein, Gewirtz & Grossman, LLC
- New York, New York--(Newsfile Corp. - June 18, 2021) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Emergent BioSolutions Inc. ("Emergent" or "the Company") (NYSE: EBS) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Emergent securities between July 6, 2020 and March 31, 2021, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting...
- 06/18/2021
|
EBS DEADLINE TOMORROW: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Emergent BioSolutions Inc. Investors to Secure Counsel Before Important Friday Deadline in Securities Class Action - EBS
- New York, New York--(Newsfile Corp. - June 17, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Emergent BioSolutions Inc. (NYSE: EBS) between April 24, 2020 through April 16, 2021, inclusive (the "Class Period"), of the important June 18, 2021 lead plaintiff deadline.SO WHAT: If you purchased Emergent securities during the Class Period you may be entitled to compensation without payment of any out of...
- 06/17/2021
|
Two Days Left to Actively Participate in Emergent BioSolutions Inc. (EBS) Class Action: Bronstein, Gewirtz & Grossman, LLC
- NEW YORK--(BUSINESS WIRE)--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Emergent BioSolutions Inc. ("Emergent" or "the Company") (NYSE: EBS) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Emergent securities between July 6, 2020 and March 31, 2021, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site:
- 06/17/2021
|
DEADLINE TOMORROW: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Emergent BioSolutions Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - June 17, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Emergent BioSolutions Inc. ("Emergent BioSolutions" or "the Company") (NYSE: EBS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between July 6, 2020 and March 31, 2021,...
- 06/17/2021
|
Kessler Topaz Meltzer & Checker, LLP: Final Deadline Reminder for Emergent BioSolutions Inc. Investors – EBS
- RADNOR, Pa.--(BUSINESS WIRE)---- $EBS #classaction--Kessler Topaz Meltzer & Checker, LLP: Final Deadline Reminder for Emergent BioSolutions Inc. Investors – EBS
- 06/17/2021
|
EBS LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving Emergent Biosolutions Inc.
- New York, New York--(Newsfile Corp. - June 17, 2021) - The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased Emergent Biosolutions Inc. ("Emergent Bio") (NYSE: EBS) between April 24, 2020 and April 16, 2021.If you suffered a loss, contact us at the link below. There is no cost or obligation to you.http://www.wongesq.com/pslra-1/emergent-biosolutions-inc-loss-submission-form?prid=16968&wire=5
- 06/17/2021
|
EBS LAWSUIT FILED: Jakubowitz Law Pursues Claims on Behalf of Emergent Biosolutions Inc. Shareholders
- New York, New York--(Newsfile Corp. - June 17, 2021) - Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders Emergent Biosolutions Inc. (NYSE: EBS).CLICK HERE FOR MORE DETAILS:https://claimyourloss.com/securities/emergent-biosolutions-inc-loss-submission-form/?id=16965&from=5
- 06/17/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Emergent BioSolutions Inc. - EBS
- NEW YORK, June 16, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Emergent BioSolutions Inc. ("Emergent" or the "Company") (NYSE: EBS). Such investors are advised to contact Robert S.
- 06/16/2021
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Emergent Biosolutions Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 18, 2021 - EBS
- New York, New York--(Newsfile Corp. - June 16, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Emergent Biosolutions Inc. ("Emergent Bio") (NYSE: EBS) between April 24, 2020 and April 16, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the District of Maryland. To get more...
- 06/16/2021
|
Final Deadline Approaching on June 18, 2021: Kessler Topaz Meltzer & Check, LLP Reminds Emergent BioSolutions Inc. Investors of Class Action Lawsuit Deadline
- Radnor, Pennsylvania--(Newsfile Corp. - June 16, 2021) - The law firm of Kessler Topaz Meltzer & Check, LLP reminds investors of Emergent BioSolutions Inc. (NYSE: EBS) ("Emergent") that the firm has filed a securities fraud class action lawsuit has been filed on behalf of those who purchased or acquired Emergent common stock between April 24, 2020, and April 16, 2021, inclusive (the "Class Period"). This action, captioned Roth v. Emergent BioSolutions Inc., et...
- 06/16/2021
|
FRIDAY DEADLINE NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Emergent BioSolutions Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - June 16, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Emergent BioSolutions Inc. ("Emergent BioSolutions" or "the Company") (NYSE: EBS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between July 6, 2020 and March 31, 2021,...
- 06/16/2021
|
Last Few Days to Actively Participate in Emergent BioSolutions Inc. (EBS) Class Action: Bronstein, Gewirtz & Grossman, LLC
- New York, New York--(Newsfile Corp. - June 16, 2021) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Emergent BioSolutions Inc. ("Emergent" or "the Company") (NYSE: EBS) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Emergent securities between July 6, 2020 and March 31, 2021, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting...
- 06/16/2021
|
EBS LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving Emergent Biosolutions Inc.
- New York, New York--(Newsfile Corp. - June 16, 2021) - The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased Emergent Biosolutions Inc. (NYSE: EBS) ("Emergent Bio") between April 24, 2020 and April 16, 2021.If you suffered a loss, contact us at the link below. There is no cost or obligation to you.http://www.wongesq.com/pslra-1/emergent-biosolutions-inc-loss-submission-form?prid=16926&wire=5
- 06/16/2021
|
EBS ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of June 18, 2021 in the Class Action Filed on Behalf of Emergent Biosolutions Inc. Limited Shareholders
- New York, New York--(Newsfile Corp. - June 15, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Emergent Biosolutions Inc. (NYSE: EBS) alleging that the Company violated federal securities laws.Class Period: April 24, 2020 and April 16, 2021Lead Plaintiff Deadline: June 18, 2021Learn more about your recoverable losses in EBS:
- 06/15/2021
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Emergent Biosolutions Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 18, 2021 - EBS
- New York, New York--(Newsfile Corp. - June 15, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Emergent Biosolutions Inc. ("Emergent Bio") (NYSE: EBS) between April 24, 2020 and April 16, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the District of Maryland. To get more information...
- 06/15/2021
|
FRIDAY DEADLINE REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Emergent BioSolutions Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - June 15, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Emergent BioSolutions Inc. ("Emergent BioSolutions" or "the Company") (NYSE: EBS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between July 6, 2020 and March 31, 2021,...
- 06/15/2021
|
EBS LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving Emergent Biosolutions Inc.
- New York, New York--(Newsfile Corp. - June 14, 2021) - The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased Emergent Biosolutions Inc. ("Emergent Bio") (NYSE: EBS) between April 24, 2020 and April 16, 2021.If you suffered a loss, contact us at the link below. There is no cost or obligation to you.http://www.wongesq.com/pslra-1/emergent-biosolutions-inc-loss-submission-form?prid=16874&wire=5
- 06/14/2021
|
5 Defensive Stocks Trading With Low Book Value
- According to the GuruFocus All-in-One Screener, a Premium feature, the following guru-owned defensive companies have grown their book value per share over the past decade through June 14.
- 06/14/2021
|
EBS ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of June 18, 2021 in the Class Action Filed on Behalf of Emergent Biosolutions Inc. Limited Shareholders
- New York, New York--(Newsfile Corp. - June 14, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Emergent Biosolutions Inc. (NYSE: EBS) alleging that the Company violated federal securities laws.Class Period: April 24, 2020 and April 16, 2021Lead Plaintiff Deadline: June 18, 2021Learn more about your recoverable losses in EBS:
- 06/14/2021
|
Deadline Approaching for Emergent BioSolutions Investors: Berger Montague Reminds Investors of Approaching Deadline in Securities Fraud Class Action Against Emergent BioSolutions Inc. (EBS); Lead Plaintiff Deadline is June 18, 2021
- Philadelphia, Pennsylvania--(Newsfile Corp. - June 14, 2021) - Berger Montague reminds investors of the upcoming deadline of June 18, 2021 for investors to seek lead plaintiff status in a securities fraud class action against Emergent BioSolutions Inc. ("Emergent" or the "Company") brought on behalf of Emergent investors who purchased the Company's securities (NYSE: EBS) between April 24, 2020 and April 16, 2021 (the "Class Period"). If you purchased Emergent securities during the Class Period and...
- 06/14/2021
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Emergent Biosolutions Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 18, 2021 - EBS
- New York, New York--(Newsfile Corp. - June 14, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Emergent Biosolutions Inc. (NYSE: EBS) ("Emergent Bio") between April 24, 2020 and April 16, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the District of Maryland. To get more information go to:https://www.zlk.com/pslra-1/emergent-biosolutions-inc-loss-submission-form?prid=16842&wire=5or...
- 06/14/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Emergent BioSolutions Inc. - EBS
- New York, New York--(Newsfile Corp. - June 12, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Emergent BioSolutions Inc. ("Emergent" or the "Company") (NYSE: EBS). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Emergent and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the...
- 06/12/2021
|
COVID-19 Vaccine Drug Substance Manufactured by Emergent BioSolutions Authorized as Part of Johnson & Johnson's Emergency Use Authorization
- GAITHERSBURG, Md., June 11, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that two batches of COVID-19 vaccine manufactured by Emergent BioSolutions at its Baltimore Bayview facility were determined to be suitable for use by the U.S. Food & Drug Administration (FDA) and have been authorized as part of Johnson & Johnson's Emergency Use Authorization (EUA).
- 06/11/2021
|
FDA Authorizes 10M JNJ COVID-19 Vaccine Doses, Asks To Discard 60M From Emergent Plant: NYT
- The FDA has asked Johnson & Johnson (NYSE: JNJ) to discard 60 million doses of its COVID-19 vaccine manufactured at the troubled Emergent BioSolutions Inc's (NYSE: EBS) Baltimore plant, the New York Times reported, citing people familiar with the matter. A further 10 million JNJ doses would be allowed to be distributed with a warning that there was no guarantee that Emergent BioSolutions had followed proper practices.
- 06/11/2021
|
Emergent BioSolutions: Value And Fear Go Hand In Hand
- Value opportunities appear because of fear, which is reflected in the stock price of the company.
- 06/11/2021
|
EMERGENT BIOSOLUTIONS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuits Against Emergent BioSolutions Inc. - EBS
- New Orleans, Louisiana--(Newsfile Corp. - June 10, 2021) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until June 18, 2021 to file lead plaintiff applications in securities class action lawsuits against Emergent BioSolutions Inc. (NYSE: EBS), if they purchased the Company's shares between April 24, 2020 and April 16, 2021, inclusive (the "Class Period"). These actions are pending...
- 06/10/2021
|
Deadline in 8 Days: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Class Action Lawsuit Against Emergent BioSolutions Inc. (EBS)
- Radnor, Pennsylvania--(Newsfile Corp. - June 10, 2021) - The law firm of Kessler Topaz Meltzer & Check, LLP reminds investors of Emergent BioSolutions Inc. (NYSE: EBS) ("Emergent") that Kessler Topaz Meltzer & Check, LLP has filed a securities fraud class action lawsuit has been filed on behalf of those who purchased or acquired Emergent common stock between April 24, 2020, and April 16, 2021, inclusive (the "Class Period"). This action, captioned Roth v. Emergent...
- 06/10/2021
|
EBS Investor Alert: Shareholder Class Action Lawsuit Filed
- Boston, Massachusetts--(Newsfile Corp. - June 9, 2021) - The Thornton Law Firm alerts investors that a class action lawsuit has been filed on behalf of investors of Emergent BioSolutions Inc. (NYSE: EBS). The case is currently in the lead plaintiff stage. Investors who purchased EBS stock or other securities between April 24, 2020 and April 16, 2021 may contact the Thornton Law Firm's investor protection team by visiting www.tenlaw.com/cases/Emergent for more information. Investors may...
- 06/09/2021
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Emergent Biosolutions Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 18, 2021 - EBS
- New York, New York--(Newsfile Corp. - June 9, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Emergent Biosolutions Inc. (NYSE: EBS) ("Emergent Bio") between April 24, 2020 and April 16, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the District of Maryland. To get more information go to:https://www.zlk.com/pslra-1/emergent-biosolutions-inc-loss-submission-form?prid=16721&wire=5or...
- 06/09/2021
|
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Emergent Biosolutions Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 18, 2021 - (EBS)
- New York, New York--(Newsfile Corp. - June 8, 2021) - The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders of Emergent Biosolutions Inc. (NYSE: EBS).Shareholders who purchased shares of EBS during the class period listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/emergent-biosolutions-inc-loss-submission-form/?id=16710&from=5
- 06/08/2021
|
EBS LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving Emergent Biosolutions Inc.
- New York, New York--(Newsfile Corp. - June 8, 2021) - The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased Emergent Biosolutions Inc. ("Emergent Bio") (NYSE: EBS) between April 24, 2020 and April 16, 2021.If you suffered a loss, contact us at the link below. There is no cost or obligation to you.http://www.wongesq.com/pslra-1/emergent-biosolutions-inc-loss-submission-form?prid=16701&wire=5
- 06/08/2021
|
Class Action Lawsuit Deadline: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Filed Against Emergent BioSolutions Inc.
- RADNOR, Pa., June 8, 2021 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP announces that the firm has filed a securities fraud class action against Emergent BioSolutions Inc. (NYSE: EBS) ("Emergent") on behalf investors who purchased or acquired Emergent common stock between April 24, 2020, and April 16, 2021 , inclusive (the "Class Period").
- 06/08/2021
|
EBS ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of June 18, 2021 in the Class Action Filed on Behalf of Emergent Biosolutions Inc. Limited Shareholders
- New York, New York--(Newsfile Corp. - June 8, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Emergent Biosolutions Inc. (NYSE: EBS) alleging that the Company violated federal securities laws.Class Period: April 24, 2020 and April 16, 2021Lead Plaintiff Deadline: June 18, 2021Learn more about your recoverable losses in EBS:
- 06/08/2021
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Emergent Biosolutions Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 18, 2021 - EBS
- New York, New York--(Newsfile Corp. - June 7, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Emergent Biosolutions Inc. ("Emergent Bio") (NYSE: EBS) between April 24, 2020 and April 16, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the District of Maryland. To get more information...
- 06/07/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Emergent BioSolutions Inc. - EBS
- New York, New York--(Newsfile Corp. - June 5, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Emergent BioSolutions Inc. ("Emergent" or the "Company") (NYSE: EBS). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Emergent and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the...
- 06/05/2021
|
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Emergent BioSolutions Inc. Investors with Losses to Secure Counsel Before Important June 18 Deadline in Securities Class Action - EBS
- NEW YORK, June 4, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Emergent BioSolutions Inc. (NYSE: EBS) between April 24, 2020 through April 16, 2021, inclusive (the "Class Period"), of the important June 18, 2021 lead plaintiff deadline. SO WHAT: If you purchased Emergent securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
- 06/04/2021
|
EBS Shareholder Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Shareholders of Emergent BioSolutions Inc. of Deadline in Securities Fraud Class Action Lawsuit
- Radnor, Pennsylvania--(Newsfile Corp. - June 4, 2021) - The law firm of Kessler Topaz Meltzer & Check, LLP reminds investors of Emergent BioSolutions Inc. (NYSE: EBS) ("Emergent") that Kessler Topaz Meltzer & Check, LLP has filed a securities fraud class action lawsuit has been filed on behalf of those who purchased or acquired Emergent common stock between April 24, 2020, and April 16, 2021, inclusive (the "Class Period"). This action, captioned Roth v. Emergent...
- 06/04/2021
|
EMERGENT BIOSOLUTIONS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess Of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuits Against Emergent BioSolutions Inc. - EBS
- New Orleans, Louisiana--(Newsfile Corp. - June 3, 2021) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until June 18, 2021 to file lead plaintiff applications in securities class action lawsuits against Emergent BioSolutions Inc. (NYSE: EBS), if they purchased the Company's shares between April 24, 2020 and April 16, 2021, inclusive (the "Class Period"). These actions arepending in...
- 06/03/2021
|
EBS LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving Emergent Biosolutions Inc.
- New York, New York--(Newsfile Corp. - June 3, 2021) - The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased Emergent Biosolutions Inc. ("Emergent Bio") (NYSE: EBS) between July 6, 2020 and March 31, 2021.If you suffered a loss, contact us at the link below. There is no cost or obligation to you.http://www.wongesq.com/pslra-1/emergent-biosolutions-inc-loss-submission-form?prid=16550&wire=5
- 06/03/2021
|
EBS ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of June 18, 2021 in the Class Action Filed on Behalf of Emergent Biosolutions Inc. Limited Shareholders
- New York, New York--(Newsfile Corp. - June 3, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Emergent Biosolutions Inc. (NYSE: EBS) alleging that the Company violated federal securities laws.Class Period: July 6, 2020 and March 31, 2021Lead Plaintiff Deadline: June 18, 2021Learn more about your recoverable losses in EBS:
- 06/03/2021
|
HAGENS BERMAN Encourages Emergent BioSolutions (EBS) Investors to Contact the Firm Now, June 18th Deadline Approaching in Securities Fraud Lawsuit
- San Francisco, California--(Newsfile Corp. - June 3, 2021) - Hagens Berman urges Emergent BioSolutions Inc. (NYSE: EBS) investors with $100k or more losses to submit your losses now. Class Period: Apr. 24, 2020 - Apr. 16, 2021Lead Plaintiff Deadline: June 18, 2021Visit: www.hbsslaw.com/investor-fraud/ebs Contact an Attorney Now: EBS@hbsslaw.com 844-916-0895Emergent BioSolutions (NYSE: EBS) Securities Fraud Class Action:Throughout the class period, Defendants touted Emergent's deals to...
- 06/03/2021
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Emergent Biosolutions Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 18, 2021 - EBS
- New York, New York--(Newsfile Corp. - June 3, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Emergent Biosolutions Inc. ("Emergent Bio") (NYSE: EBS) between July 6, 2020 and March 31, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the District of Maryland. To get more...
- 06/03/2021
|
Investor Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline in Securities Fraud Class Action Lawsuit Filed Against Emergent BioSolutions Inc.
- RADNOR, Pa., June 2, 2021 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP reminds Emergent BioSolutions Inc. (NYSE: EBS) ("Emergent") investors that the firm has filed a securities fraud class action lawsuit has been filed on behalf of those who purchased or acquired Emergent common stock between April 24, 2020, and April 16, 2021 , inclusive (the "Class Period").
- 06/02/2021
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Emergent Biosolutions Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 18, 2021 - EBS
- New York, New York--(Newsfile Corp. - June 2, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Emergent Biosolutions Inc. ("Emergent Bio") (NYSE: EBS) between July 6, 2020 and March 31, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the District of Maryland. To get more information...
- 06/02/2021
|
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Emergent Biosolutions Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 18, 2021 - (EBS)
- New York, New York--(Newsfile Corp. - June 1, 2021) - The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders of Emergent Biosolutions Inc..Shareholders who purchased shares of EBS during the class period listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.CONTACT US HERE:
- 06/01/2021
|
EBS LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving Emergent Biosolutions Inc.
- New York, New York--(Newsfile Corp. - June 1, 2021) - The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased Emergent Biosolutions Inc. ("Emergent Bio") (NYSE: EBS) between July 6, 2020 and March 31, 2021.If you suffered a loss, contact us at the link below. There is no cost or obligation to you.http://www.wongesq.com/pslra-1/emergent-biosolutions-inc-loss-submission-form?prid=16432&wire=5
- 06/01/2021
|
EBS ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of June 18, 2021 in the Class Action Filed on Behalf of Emergent Biosolutions Inc. Limited Shareholders
- New York, New York--(Newsfile Corp. - June 1, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Emergent Biosolutions Inc. (NYSE: EBS) alleging that the Company violated federal securities laws.Class Period: July 6, 2020 and March 31, 2021Lead Plaintiff Deadline: June 18, 2021Learn more about your recoverable losses in EBS:
- 06/01/2021
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Emergent Biosolutions Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 18, 2021 - EBS
- New York, New York--(Newsfile Corp. - June 1, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Emergent Biosolutions Inc. ("Emergent Bio") (NYSE: EBS) between July 6, 2020 and March 31, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the District of Maryland. To get more information...
- 06/01/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Emergent BioSolutions Inc. - EBS
- NEW YORK, June 1, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Emergent BioSolutions Inc. ("Emergent" or the "Company") (NYSE: EBS). Such investors are advised to contact Robert S.
- 06/01/2021
|
CLASS ACTION ALERT: Kessler Topaz Meltzer & Check, LLP Reminds Emergent BioSolutions Inc. Shareholders of Securities Fraud Class Action Lawsuit
- Radnor, Pennsylvania--(Newsfile Corp. - May 31, 2021) - The law firm of Kessler Topaz Meltzer & Check, LLP announces that Kessler Topaz Meltzer & Check, LLP has filed a securities fraud class action against Emergent BioSolutions Inc. (NYSE: EBS) ("Emergent") on behalf investors who purchased or acquired Emergent common stock between April 24, 2020, and April 16, 2021, inclusive (the "Class Period"). This action, captioned Roth v. Emergent BioSolutions Inc., et al., Case No....
- 05/31/2021
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Emergent Biosolutions Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 18, 2021 - EBS
- New York, New York--(Newsfile Corp. - May 30, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Emergent Biosolutions Inc. ("Emergent Bio") (NYSE: EBS) between July 6, 2020 and March 31, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the District of Maryland. To get more information...
- 05/30/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Emergent BioSolutions Inc. - EBS
- New York, New York--(Newsfile Corp. - May 29, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Emergent BioSolutions Inc. ("Emergent" or the "Company") (NYSE: EBS). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Emergent and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the...
- 05/29/2021
|
EBS Breaking Notice: Rosen, Trusted National Trial Counsel, Encourages Emergent BioSolutions Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - EBS
- New York, New York--(Newsfile Corp. - May 29, 2021) - WHY:. Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Emergent BioSolutions Inc. (NYSE: EBS) between April 24, 2020 through April 16, 2021, inclusive (the "Class Period"), of the important June 18, 2021 lead plaintiff deadline.SO WHAT: If you purchased Emergent securities during the Class Period you may be entitled to compensation without payment of any out of...
- 05/29/2021
|
Kessler Topaz Meltzer & Check, LLP: Reminds Investors of Securities Fraud Class Action Filed Against Emergent BioSolutions Inc.
- RADNOR, Pa., May 28, 2021 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP announces that Kessler Topaz Meltzer & Check, LLP has filed a securities fraud class action against Emergent BioSolutions Inc. (NYSE: EBS) ("Emergent") on behalf investors who purchased or acquired Emergent common stock between April 24, 2020, and April 16, 2021 , inclusive (the "Class Period").
- 05/28/2021
|
Emergent BioSolutions Poised To Receive FDA Nod to Restart J&J COVID-19 Shot Production at Baltimore Plant After Mishap: WSJ
- The FDA and Johnson & Johnson (NYSE: JNJ) are expected to announce that contamination problems at Emergent BioSolutions Inc's (NYSE: EBS) Baltimore Bayview plant have been resolved, and production is set to resume, the Wall Street Journal reported. The deal with the FDA could free up already manufactured doses of the vaccine that have been in quarantine and allow for the production of new doses.
- 05/28/2021
|
EMERGENT BIOSOLUTIONS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuits Against Emergent Biosolutions Inc. - EBS
- New Orleans, Louisiana--(Newsfile Corp. - May 28, 2021) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until June 18, 2021 to file lead plaintiff applications in securities class action lawsuits against Emergent BioSolutions Inc. (NYSE: EBS), if they purchased the Company's shares between April 24, 2020 and April 16, 2021, inclusive (the "Class Period"). These actions arepending in...
- 05/28/2021
|
EBS INVESTOR REMINDER: Kessler Topaz Meltzer & Check, LLP Announces Deadline in Securities Fraud Class Action Lawsuit Filed Against Emergent BioSolutions Inc.
- Radnor, Pennsylvania--(Newsfile Corp. - May 27, 2021) - The law firm of Kessler Topaz Meltzer & Check, LLP announces that the firm has filed a securities fraud class action against Emergent BioSolutions Inc. (NYSE: EBS) ("Emergent") on behalf investors who purchased or acquired Emergent common stock between April 24, 2020, and April 16, 2021, inclusive (the "Class Period"). This action, captioned Roth v. Emergent BioSolutions Inc., et al., Case No. 1:21-cv-01189-PX (the "Roth Action"),...
- 05/27/2021
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Emergent Biosolutions Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 18, 2021 - EBS
- New York, New York--(Newsfile Corp. - May 27, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Emergent Biosolutions Inc. ("Emergent Bio") (NYSE: EBS) between July 6, 2020 and March 31, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the District of Maryland. To get more information...
- 05/27/2021
|
Emergent BioSolutions's Single-Dose Chikungunya Vaccine Candidate Effective Even After Two Years of Vaccination
- Emergent BioSolutions Inc (NYSE: EBS) has announced two-year persistence data from its Phase 2 study evaluating its investigational chikungunya virus, virus-like particle (CHIKV VLP) vaccine candidate. The CHIKV VLP vaccine is the only single-dose VLP-based vaccine currently in clinical development for active immunization against chikungunya disease, the company said.
- 05/26/2021
|
Emergent BioSolutions Announces Positive Two-Year Persistence Data From Phase 2 Study Evaluating CHIKV VLP, the Company's Chikungunya Virus Virus-Like Particle Vaccine Candidate
- GAITHERSBURG, Md., May 26, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced two-year persistence data from its Phase 2 clinical study evaluating the safety and immunogenicity of the company's investigational chikungunya virus virus-like particle (CHIKV VLP) vaccine candidate in 415 healthy adults. Emergent's CHIKV VLP vaccine, the only single-dose VLP-based vaccine currently in clinical development for active immunization against chikungunya disease, continued to demonstrate a favorable safety profile and had generated a dose-related increase in neutralizing antibody response against the chikungunya virus as previously reported. Two years post-vaccination, SNA responses were 19 times higher than pre-vaccination titers following a single adjuvanted 40 µg dose of the CHIKV VLP vaccine, supporting the persistence of the immune response. All subjects in the single-dose regimen remained seropositive at their one-year and two-year visits. The vaccine candidate was well-tolerated and no significant vaccine-related safety concerns were identified. The majority of solicited adverse events were mild or moderate in severity and the most frequent was local injection site pain.
- 05/26/2021
|
EBS ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of June 18, 2021 in the Class Action Filed on Behalf of Emergent Biosolutions Inc. Limited Shareholders
- New York, New York--(Newsfile Corp. - May 26, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Emergent Biosolutions Inc. (NYSE: EBS) alleging that the Company violated federal securities laws.Class Period: July 6, 2020 and March 31, 2021Lead Plaintiff Deadline: June 18, 2021Learn more about your recoverable losses in EBS:
- 05/26/2021
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Emergent Biosolutions Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 18, 2021 - EBS
- New York, New York--(Newsfile Corp. - May 25, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Emergent Biosolutions Inc. ("Emergent Bio") (NYSE: EBS) between July 6, 2020 and March 31, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the District of Maryland. To get more information...
- 05/25/2021
|
EBS LAWSUIT FILED: Jakubowitz Law Pursues Claims on Behalf of Emergent Biosolutions Inc. Shareholders
- New York, New York--(Newsfile Corp. - May 25, 2021) - Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders Emergent Biosolutions Inc. (NYSE: EBS).CLICK HERE FOR MORE DETAILS:https://claimyourloss.com/securities/emergent-biosolutions-inc-loss-submission-form/?id=16172&from=5
- 05/25/2021
|
EBS LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving Emergent Biosolutions Inc.
- New York, New York--(Newsfile Corp. - May 25, 2021) - The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased Emergent Biosolutions Inc. ("Emergent Bio") (NYSE: EBS) between July 6, 2020 and March 31, 2021.If you suffered a loss, contact us at the link below. There is no cost or obligation to you.http://www.wongesq.com/pslra-1/emergent-biosolutions-inc-loss-submission-form?prid=16125&wire=5Allegations against EBS include that the Company made materially false and/or...
- 05/25/2021
|
EBS ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of June 18, 2021 in the Class Action Filed on Behalf of Emergent Biosolutions Inc. Limited Shareholders
- New York, New York--(Newsfile Corp. - May 24, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Emergent Biosolutions Inc. (NYSE: EBS) alleging that the Company violated federal securities laws.Class Period: July 6, 2020 and March 31, 2021Lead Plaintiff Deadline: June 18, 2021Learn more about your recoverable losses in EBS:
- 05/24/2021
|
HAGENS BERMAN Encourages Emergent BioSolutions (EBS) Investors to Contact the Firm Now, Securities Fraud Class Action Filed
- San Francisco, California--(Newsfile Corp. - May 24, 2021) - Hagens Berman urges Emergent BioSolutions Inc. (NYSE: EBS) investors with $100k or more losses to submit your losses now. Class Period: Apr. 24, 2020 - Apr. 16, 2021Lead Plaintiff Deadline: June 18, 2021Visit: www.hbsslaw.com/investor-fraud/ebs Contact an Attorney Now: EBS@hbsslaw.com 844-916-0895Emergent BioSolutions (NYSE: EBS) Securities Fraud Class Action:Throughout the class period, Defendants touted Emergent's deals to...
- 05/24/2021
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Emergent Biosolutions Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 18, 2021 - EBS
- New York, New York--(Newsfile Corp. - May 24, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Emergent Biosolutions Inc. ("Emergent Bio") (NYSE: EBS) between July 6, 2020 and March 31, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the District of Maryland. To get more...
- 05/24/2021
|
Shareholder Alert: Kessler Topaz Meltzer & Check, LLP Reminds Shareholders of Emergent BioSolutions Inc. of Securities Class Action Lawsuit
- Radnor, Pennsylvania--(Newsfile Corp. - May 24, 2021) - The law firm of Kessler Topaz Meltzer & Check, LLP announces that Kessler Topaz Meltzer & Check, LLP has filed a securities fraud class action against Emergent BioSolutions Inc. (NYSE: EBS) ("Emergent") on behalf investors who purchased or acquired Emergent common stock between April 24, 2020, and April 16, 2021, inclusive (the "Class Period"). This action, captioned Roth v. Emergent BioSolutions Inc., et al., Case No....
- 05/24/2021
|
Emergent BioSolutions Stock News: Berger Montague Announces Investigation Into Securities Fraud Allegations Against Emergent BioSolutions Inc. (EBS); Lead Plaintiff Deadline is June 18, 2021
- Philadelphia, Pennsylvania--(Newsfile Corp. - May 23, 2021) - Berger Montague announces its investigation into securities fraud allegations against Emergent BioSolutions Inc. ("Emergent" or the "Company") on behalf of Emergent investors who purchased the Company's securities (NYSE: EBS) between April 24, 2020 and April 16, 2021 (the "Class Period"). If you purchased Emergent securities during the Class Period and would like to speak to Berger Montague about the investigation, please contact attorneys Andrew Abramowitz at aabramowitz@bm.net...
- 05/23/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Emergent BioSolutions Inc. - EBS
- New York, New York--(Newsfile Corp. - May 22, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Emergent BioSolutions Inc. ("Emergent" or the "Company") (NYSE: EBS). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Emergent and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the...
- 05/22/2021
|
EBS Stock News: Berger Montague Investigates Alleged Securities Fraud Claims Against Emergent BioSolutions Inc. (EBS); Lead Plaintiff Deadline is June 18, 2021
- Philadelphia, Pennsylvania--(Newsfile Corp. - May 22, 2021) - Berger Montague is investigating securities fraud allegations against Emergent BioSolutions Inc. ("Emergent" or the "Company") on behalf of investors who purchased the Company's securities (NYSE: EBS) between April 24, 2020 and April 16, 2021 (the "Class Period"). If you purchased Emergent securities during the Class Period and are interested in learning more about Berger Montague's investigation, please contact attorneys Andrew Abramowitz at aabramowitz@bm.net or (215) 875-3015, or...
- 05/22/2021
|
EBS News: Berger Montague Investigates Securities Fraud Allegations Against Emergent BioSolutions Inc. (EBS); Lead Plaintiff Deadline is June 18, 2021
- Philadelphia, Pennsylvania--(Newsfile Corp. - May 21, 2021) - Berger Montague is investigating potential securities fraud claims against Emergent BioSolutions Inc. ("Emergent" or the "Company") on behalf of Emergent investors who purchased securities (NYSE: EBS) between April 24, 2020 and April 16, 2021 (the "Class Period"). If you purchased Emergent securities during the Class Period and would like to discuss Berger Montague's investigation, please contact attorneys Andrew Abramowitz at aabramowitz@bm.net or (215) 875-3015, or Donnell Much...
- 05/21/2021
|
Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline for Securities Fraud Class Action Lawsuit Filed Against Emergent BioSolutions Inc.
- Radnor, Pennsylvania--(Newsfile Corp. - May 21, 2021) - The law firm of Kessler Topaz Meltzer & Check, LLP announces that the firm has filed a securities fraud class action against Emergent BioSolutions Inc. (NYSE: EBS) ("Emergent") on behalf investors who purchased or acquired Emergent common stock between April 24, 2020, and April 16, 2021, inclusive (the "Class Period"). This action, captioned Roth v. Emergent BioSolutions Inc., et al., Case No. 1:21-cv-01189-PX (the "Roth Action"),...
- 05/21/2021
|
EBS LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving Emergent Biosolutions Inc.
- New York, New York--(Newsfile Corp. - May 21, 2021) - The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased Emergent Biosolutions Inc. (NYSE: EBS) ("Emergent Bio") between July 6, 2020 and March 31, 2021.If you suffered a loss, contact us at the link below. There is no cost or obligation to you.http://www.wongesq.com/pslra-1/emergent-biosolutions-inc-loss-submission-form?prid=16031&wire=5
- 05/21/2021
|
EMERGENT BIOSOLUTIONS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess Of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuits Against Emergent BioSolutions Inc. - EBS
- New Orleans, Louisiana--(Newsfile Corp. - May 20, 2021) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until June 18, 2021 to file lead plaintiff applications in securities class action lawsuits against Emergent BioSolutions Inc. (NYSE: EBS), if they purchased the Company's shares between April 24, 2020 and April 16, 2021, inclusive (the "Class Period"). These actions arepending in...
- 05/20/2021
|
EBS ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of June 18, 2021 in the Class Action Filed on Behalf of Emergent Biosolutions Inc. Limited Shareholders
- New York, New York--(Newsfile Corp. - May 20, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Emergent Biosolutions Inc. (NYSE: EBS) alleging that the Company violated federal securities laws.Class Period: July 6, 2020 and March 31, 2021Lead Plaintiff Deadline: June 18, 2021Learn more about your recoverable losses in EBS:
- 05/20/2021
|
HAGENS BERMAN Encourages Emergent BioSolutions (EBS) Investors to Contact the Firm Now, Securities Fraud Class Action Filed
- San Francisco, California--(Newsfile Corp. - May 20, 2021) - Hagens Berman urges Emergent BioSolutions Inc. (NYSE: EBS) investors with $100k or more losses to submit your losses now. Class Period: Apr. 24, 2020 - Apr. 16, 2021Lead Plaintiff Deadline: June 18, 2021Visit: www.hbsslaw.com/investor-fraud/ebs Contact an Attorney Now: EBS@hbsslaw.com 844-916-0895Emergent BioSolutions (NYSE: EBS) Securities Fraud Class Action:Throughout the class period, Defendants touted Emergent's deals to...
- 05/20/2021
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Emergent Biosolutions Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 18, 2021 - EBS
- New York, New York--(Newsfile Corp. - May 20, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Emergent Biosolutions Inc. ("Emergent Bio") (NYSE: EBS) between July 6, 2020 and March 31, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the District of Maryland. To get more information...
- 05/20/2021
|
Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Emergent BioSolutions Inc. (EBS)
- BENSALEM, Pa., May 20, 2021 /PRNewswire/ -- Law Offices of Howard G.
- 05/20/2021
|
EBS ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of June 18, 2021 in the Class Action Filed on Behalf of Emergent Biosolutions Inc. Limited Shareholders
- New York, New York--(Newsfile Corp. - May 19, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Emergent Biosolutions Inc. (NYSE: EBS) alleging that the Company violated federal securities laws.Class Period: July 6, 2020 and March 31, 2021Lead Plaintiff Deadline: June 18, 2021Learn more about your recoverable losses in EBS:
- 05/19/2021
|
EBS Breaking News: Rosen, Leading Trial Attorneys, Encourages Emergent BioSolutions Inc. Investors to Secure Counsel Before Important June 18 Deadline in Securities Class Action - EBS
- New York, New York--(Newsfile Corp. - May 19, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Emergent BioSolutions Inc. (NYSE: EBS) between April 24, 2020 through April 16, 2021, inclusive (the "Class Period"), of the important June 18, 2021 lead plaintiff deadline.SO WHAT: If you purchased Emergent securities during the Class Period you may be entitled to compensation without payment of any out of pocket...
- 05/19/2021
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Emergent Biosolutions Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 18, 2021 - EBS
- New York, New York--(Newsfile Corp. - May 19, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Emergent Biosolutions Inc. ("Emergent Bio") (NYSE: EBS) between July 6, 2020 and March 31, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the District of Maryland. To get more information...
- 05/19/2021
|
Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline in Securities Fraud Class Action Against Emergent BioSolutions Inc.
- Radnor, Pennsylvania--(Newsfile Corp. - May 19, 2021) - The law firm of Kessler Topaz Meltzer & Check, LLP reminds Emergent BioSolutions Inc. (NYSE: EBS) ("Emergent") investors that the firm has filed a securities fraud class action lawsuit on behalf of those who purchased or acquired Emergent common stock between April 24, 2020 and April 16, 2021, inclusive (the "Class Period"). This action, captioned Roth v. Emergent BioSolutions Inc., et al., Case No. 1:21-cv-01189-PX...
- 05/19/2021
|
Emergent CEO says FDA is holding over 100 million J&J Covid vaccine doses for further testing after botched doses
|
Emergent says J&J vaccine snafu caused by challenge of making two vaccines at scale
- Emergent BioSolutions Inc. executives said part of the blame for a snafu in manufacturing the COVID-19 vaccine developed by Johnson & Johnson at its Baltimore plant that led to the destruction of millions of doses was due to the fact it was trying to produce two vaccines at scale. Emergent, a contract drug manufacturer, outlined some of the problems and its plan to fix them in a letter to the U.S. Food and Drug Administration that was released on Wednesday by a House subcommittee ahead of testimony by Emergent's Chief Executive Robert Kramer and Executive Chairman Fuad El-Hibri.
- 05/19/2021
|
Emergent BioSolutions Stock Falls As Executives Face Questions As Part Of Botched Vaccine Probe
- The House Select Subcommittee on the Coronavirus announced last month that they were opening an investigation into Emergent BioSolutions Inc (NYSE: EBS), with two top executives from the company to testify at the hearing today. Founder and Chairman Fuad El-Hibri, and its CEO, Robert G.
- 05/19/2021
|
LAWSUIT FILED: Emergent BioSolutions Inc. Sued for Violations of the Federal Securities Laws; Investors Should Contact Block & Leviton LLP
- Boston, Massachusetts--(Newsfile Corp. - May 19, 2021) - Block & Leviton LLP announces that a lawsuit for violations of the federal securities laws has been filed against Emergent BioSolutions Inc. (NYSE: EBS) and certain of its executives. Investors who have lost money should contact the firm to learn more about how they might recover those losses. For more details, visit https://www.blockleviton.com/cases/ebs. The deadline to move for appointment as lead plaintiff is June 18, 2021.What is...
- 05/19/2021
|
ROSEN, A TOP RANKED LAW FIRM, Encourages Emergent BioSolutions Inc. Investors to Secure Counsel Before Important June 18 Deadline in Securities Class Action - EBS
- NEW YORK, May 18, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Emergent BioSolutions Inc. (NYSE: EBS) between April 24, 2020 through April 16, 2021, inclusive (the "Class Period"), of the important June 18, 2021 lead plaintiff deadline. SO WHAT: If you purchased Emergent securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
- 05/18/2021
|
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Emergent BioSolutions Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- LOS ANGELES--(BUSINESS WIRE)---- $EBS #EBS--SHAREHOLDER ACTION REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Emergent BioSolutions Inc.
- 05/18/2021
|
Emergent BioSolutions News: Berger Montague Investigates Potential Securities Fraud Claims Against Emergent BioSolutions Inc. (EBS); Lead Plaintiff Deadline is June 18, 2021
- Philadelphia, Pennsylvania--(Newsfile Corp. - May 18, 2021) - Berger Montague announces its investigation into potential securities fraud claims against Emergent BioSolutions Inc. (NYSE: EBS) ("Emergent" or the "Company"). The Firm is investigating these claims on behalf of investors who purchased Emergent securities between April 24, 2020 and April 16, 2021 (the "Class Period").If you purchased Emergent securities during the Class Period, would like to discuss Berger Montague's investigation, or have questions concerning your rights or interests,...
- 05/18/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Emergent BioSolutions Inc. - EBS
- NEW YORK, May 18, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Emergent BioSolutions Inc. ("Emergent" or the "Company") (NYSE: EBS). Such investors are advised to contact Robert S.
- 05/18/2021
|
IYH: Healthcare Dashboard For May
- IYH: Healthcare Dashboard For May
- 05/17/2021
|
Kessler Topaz Meltzer & Check, LLP Files A Shareholder Class Action Lawsuit Against Emergent Biosolutions Inc. (NYSE: EBS) For Violations Of Federal Securities Laws With Expanded Class Period
- RADNOR, Pa., May 17, 2021 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP announces that the firm has filed a securities fraud class action against Emergent BioSolutions Inc. (NYSE: EBS) ("Emergent") on behalf investors who purchased or acquired Emergent common stock between April 24, 2020, and April 16, 2021 , inclusive (the "Class Period").
- 05/17/2021
|
INVESTOR ACTION NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Emergent BioSolutions Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - May 17, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Emergent BioSolutions Inc. ("Emergent BioSolutions" or "the Company") (NYSE: EBS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between July 6, 2020 and March 31, 2021,...
- 05/17/2021
|
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts Emergent BioSolutions (EBS) Investors to EXPANDED FRAUDULENT PERIOD in Securities Fraud Action: Investors Should Secure Counsel
- San Francisco, California--(Newsfile Corp. - May 17, 2021) - Hagens Berman urges Emergent BioSolutions Inc. (NYSE: EBS) investors with $100k or more losses to submit your losses now. Class Period: Apr. 24, 2020 - Apr. 16, 2021Lead Plaintiff Deadline: June 18, 2021Visit: www.hbsslaw.com/investor-fraud/ebsContact an Attorney Now: EBS@hbsslaw.com844-916-0895Emergent BioSolutions (NYSE: EBS) Securities Fraud Class Action:Throughout the class period, Defendants touted Emergent's deals to produce J&J's and AstraZeneca's vaccine candi
- 05/17/2021
|
Kessler Topaz Meltzer & Check, LLP Files a Shareholder Class Action Lawsuit Against Emergent BioSolutions Inc. (EBS) for Violations of Federal Securities Laws with Expanded Class Period
- Radnor, Pennsylvania--(Newsfile Corp. - May 15, 2021) - The law firm of Kessler Topaz Meltzer & Check, LLP announces that the firm has filed a securities fraud class action against Emergent BioSolutions Inc. (NYSE: EBS) ("Emergent") on behalf investors who purchased or acquired Emergent common stock between April 24, 2020, and April 16, 2021, inclusive (the "Class Period"). This action, captioned Roth v. Emergent BioSolutions Inc., et al., Case No. 1:21-cv-01189-CCB (the "Roth Action"),...
- 05/15/2021
|
EBS INVESTOR ALERT: SHAREHOLDER LAWSUIT FILED
- Boston, Massachusetts--(Newsfile Corp. - May 15, 2021) - The Thornton Law Firm alerts investors that a class action lawsuit has been filed on behalf of investors of Emergent BioSolutions Inc. (NYSE: EBS). The case is currently in the lead plaintiff stage. Investors who purchased EBS stock or other securities between July 6, 2020 and March 31, 2021 may contact the Thornton Law Firm's investor protection team by visiting www.tenlaw.com/cases/Emergent for more information. Investors may also...
- 05/15/2021
|
Kessler Topaz Meltzer & Check, LLP Files a Shareholder Class Action Lawsuit Against Emergent BioSolutions Inc. (NYSE: EBS) for Violations of Federal Securities Laws With Expanded Class Period
- RADNOR, Pa.--(BUSINESS WIRE)---- $EBS #classaction--Kessler Topaz Meltzer & Check, LLP Files Lawsuit Against Emergent BioSolutions Inc. With Expanded Class Period
- 05/14/2021
|
EBS ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of June 18, 2021 in the Class Action Filed on Behalf of Emergent Biosolutions Inc. Limited Shareholders
- New York, New York--(Newsfile Corp. - May 14, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Emergent Biosolutions Inc. (NYSE: EBS) alleging that the Company violated federal securities laws.Class Period: July 6, 2020 and March 31, 2021Lead Plaintiff Deadline: June 18, 2021Learn more about your recoverable losses in EBS:
- 05/14/2021
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Emergent Biosolutions Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 18, 2021 - EBS
- New York, New York--(Newsfile Corp. - May 14, 2021) - To: All persons or entities who purchased or otherwise acquired securities of Emergent Biosolutions Inc. ("Emergent Bio") (NYSE: EBS) between July 6, 2020 and March 31, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the District of Maryland. To get more information go to:https://www.zlk.com/pslra-1/emergent-biosolutions-inc-loss-submission-form?prid=15880&wire=5or contact Joseph E. Levi, Esq. either via email...
- 05/14/2021
|
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Emergent BioSolutions Inc. (EBS) Investors
- LOS ANGELES, May 14, 2021 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of persons and entities that purchased or otherwise acquired Emergent BioSolutions Inc. ("Emergent" or the "Company") (NYSE: EBS) common stock between July 6, 2020 and March 31, 2021 , inclusive (the "Class Period").
- 05/14/2021
|
INVESTOR ACTION REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Emergent BioSolutions Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - May 14, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Emergent BioSolutions Inc. ("Emergent BioSolutions" or "the Company") (NYSE: EBS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between July 6, 2020 and March 31, 2021,...
- 05/14/2021
|
Emergent (EBS) Issues Plan to Resume Bayview Facility Operation
- Emergent (EBS) starts to make improvements at its Baview facility in order to meet FDA's standard and resume production of J&J's COVID-19 vaccine.
- 05/14/2021
|
EMERGENT BIOSOLUTIONS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Emergent BioSolutions Inc. - EBS
- New Orleans, Louisiana--(Newsfile Corp. - May 13, 2021) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until June 18, 2021 to file lead plaintiff applications in a securities class action lawsuit against Emergent BioSolutions Inc. (NYSE: EBS), if they purchased the Company's shares between July 6, 2020 and March 31, 2021, inclusive (the "Class Period"). This action is...
- 05/13/2021
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Emergent Biosolutions Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 18, 2021 - EBS
- New York, New York--(Newsfile Corp. - May 13, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Emergent Biosolutions Inc. ("Emergent Bio") (NYSE: EBS) between July 6, 2020 and March 31, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the District of Maryland. To get more information...
- 05/13/2021
|
Emergent BioSolutions Stock: Berger Montague Investigates Potential Securities Fraud Claims Against Emergent BioSolutions Inc. (EBS); Lead Plaintiff Deadline is June 18, 2021
- Philadelphia, Pennsylvania--(Newsfile Corp. - May 13, 2021) - May 13, 2021 - Berger Montague announces its investigation into potential securities fraud claims against Emergent BioSolutions Inc. (NYSE: EBS) ("Emergent" or the "Company"). The Firm is investigating these claims on behalf of investors who purchased Emergent securities between July 6, 2020 and March 31, 2021 (the "Class Period").If you purchased Emergent securities during the Class Period, would like to discuss Berger Montague's investigation, or have...
- 05/13/2021
|
INVESTOR ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Emergent BioSolutions Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - May 13, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Emergent BioSolutions Inc. ("Emergent BioSolutions" or "the Company") (NYSE: EBS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between July 6, 2020 and March 31, 2021,...
- 05/13/2021
|
EBS LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving Emergent Biosolutions Inc.
- New York, New York--(Newsfile Corp. - May 12, 2021) - The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors who purchased Emergent Biosolutions Inc. ("Emergent Bio") (NYSE: EBS) between July 6, 2020 and March 31, 2021.If you suffered a loss, contact us at the link below. There is no cost or obligation to you.http://www.wongesq.com/pslra-1/emergent-biosolutions-inc-loss-submission-form?prid=15791&wire=5
- 05/12/2021
|
ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Emergent BioSolutions Inc. Investors with Losses to Secure Counsel Before Important June 18 Deadline in Securities Class Action - EBS
- New York, New York--(Newsfile Corp. - May 12, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Emergent BioSolutions Inc. (NYSE: EBS) between July 6, 2020 through March 31, 2021, inclusive (the "Class Period"), of the important June 18, 2021 lead plaintiff deadline.SO WHAT: If you purchased Emergent BioSolutions securities during the Class Period you may be entitled to compensation without payment of any out of pocket...
- 05/12/2021
|
Important Deadline Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Emergent BioSolutions Inc. Investors of Securities Fraud Class Action Lawsuit
- RADNOR, Pa., May 12, 2021 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP reminds investors of Emergent BioSolutions Inc. (NYSE: EBS) ("Emergent") that a securities fraud class action lawsuit has been filed on behalf of those who purchased or acquired Emergent common stock between July 6, 2020 and March 31, 2021 , inclusive (the "Class Period").
- 05/12/2021
|
EBS ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of June 18, 2021 in the Class Action Filed on Behalf of Emergent Biosolutions Inc. Limited Shareholders
- New York, New York--(Newsfile Corp. - May 12, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Emergent Biosolutions Inc. (NYSE: EBS) alleging that the Company violated federal securities laws.Class Period: July 6, 2020 and March 31, 2021Lead Plaintiff Deadline: June 18, 2021Learn more about your recoverable losses in EBS:
- 05/12/2021
|
Emergent Initiates Quality Enhancement Plan For Troubled Baltimore Vaccine Facility
- Emergent BioSolutions Inc (NYSE: EBS) has been in headlines after its Baltimore plant has drawn the scrutiny of the FDA. A manufacturing mix-up ruined 15 million Johnson & Johnson (NYSE: JNJ) COVID-19 vaccine doses at the Baltimore plant.
- 05/12/2021
|
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Emergent BioSolutions Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - May 12, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Emergent BioSolutions Inc. ("Emergent BioSolutions" or "the Company") (NYSE: EBS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between July 6, 2020 and March 31, 2021,...
- 05/12/2021
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Emergent Biosolutions Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 18, 2021 - EBS
- New York, New York--(Newsfile Corp. - May 12, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Emergent Biosolutions Inc. (NYSE: EBS) ("Emergent Bio") between July 6, 2020 and March 31, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the District of Maryland. To get more...
- 05/12/2021
|
EBS LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving Emergent Biosolutions Inc.
- New York, New York--(Newsfile Corp. - May 11, 2021) - The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased Emergent Biosolutions Inc. ("Emergent Bio") (NYSE: EBS) between July 6, 2020 and March 31, 2021.If you suffered a loss, contact us at the link below. There is no cost or obligation to you.http://www.wongesq.com/pslra-1/emerg
- 05/11/2021
|
EBS Reminder: Kessler Topaz Meltzer & Check, LLP - Deadline Reminder for Emergent BioSolutions Inc. Investors
- Radnor, Pennsylvania--(Newsfile Corp. - May 11, 2021) - The law firm of Kessler Topaz Meltzer & Check, LLP reminds investors that a securities fraud class action lawsuit has been filed against Emergent BioSolutions Inc. (NYSE: EBS) ("Emergent") on behalf of those who purchased or acquired Emergent common stock between July 6, 2020 and March 31, 2021, inclusive (the "Class Period").Deadline Reminder: Investors who purchased or acquired Emergent common stock during the Class Period...
- 05/11/2021
|
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Emergent BioSolutions Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - May 11, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Emergent BioSolutions Inc. ("Emergent BioSolutions" or "the Company") (NYSE: EBS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between July 6, 2020 and March 31, 2021,...
- 05/11/2021
|
ROSEN, A TOP RANKED LAW FIRM, Encourages Emergent BioSolutions Inc. Investors with Losses to Secure Counsel Before Important Deadline – EBS
- NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Emergent BioSolutions Inc. (NYSE: EBS) between July 6, 2020 through March 31, 2021, inclusive (the “Class Period”), of the important June 18, 2021 lead plaintiff deadline. SO WHAT: If you purchased Emergent BioSolutions securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangem
- 05/10/2021
|
EBS INVESTOR DEADLINE: HAGENS BERMAN, National Trial Attorneys, Encourages Emergent BioSolutions (EBS) Investors with $100k+ Losses to Contact its Attorneys Now, Securities Class Action Filed
- San Francisco, California--(Newsfile Corp. - May 10, 2021) - Hagens Berman urges Emergent BioSolutions Inc. (NYSE: EBS) investors with $100k or more losses to submit your losses now.Class Period: July 6, 2020 - Mar. 31, 2021Lead Plaintiff Deadline: June 18, 2021Visit: www.hbsslaw.com/investor-fraud/ebsContact an Attorney Now: EBS@hbsslaw.com844-916-0895Emergent BioSolutions (NYSE: EBS) Securities Fraud Class Action:Throughout the class period, Defendants touted Emergent's deals with J&J and AstraZeneca to produce their vaccine candi
- 05/10/2021
|
SHAREHOLDER ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Emergent BioSolutions Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - May 10, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Emergent BioSolutions Inc. ("Emergent BioSolutions" or "the Company") (NYSE: EBS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between July 6, 2020 and March 31, 2021,...
- 05/10/2021
|
Kessler Topaz Meltzer & Check, LLP: Securities Fraud Class Action Filed Against Emergent BioSolutions Inc.
- Radnor, Pennsylvania--(Newsfile Corp. - May 8, 2021) - The law firm of Kessler Topaz Meltzer & Check, LLP reminds investors that a securities fraud class action lawsuit has been filed against Emergent BioSolutions Inc. (NYSE: EBS) ("Emergent") on behalf of those who purchased or acquired Emergent common stock between July 6, 2020 and March 31, 2021, inclusive (the "Class Period").Deadline Reminder: Investors who purchased or acquired Emergent common stock during the Class Period...
- 05/08/2021
|
EBS Investor Alert: Shareholder Class Action Lawsuit Filed
- Boston, Massachusetts--(Newsfile Corp. - May 8, 2021) - The Thornton Law Firm alerts investors that a class action lawsuit has been filed on behalf of investors of Emergent BioSolutions Inc. (NYSE: EBS). The case is currently in the lead plaintiff stage. Investors who purchased EBS stock or other securities between July 6, 2020 and March 31, 2021 may contact the Thornton Law Firm's investor protection team by visiting www.tenlaw.com/cases/Emergent for more information. Investors may also...
- 05/08/2021
|
Emergent BioSolutions Inc. Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Filed Against Emergent BioSolutions Inc.
- RADNOR, Pa., May 7, 2021 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP reminds Emergent BioSolutions Inc. (NYSE: EBS) ("Emergent") investors that a securities fraud class action lawsuit has been filed on behalf of those who purchased or acquired Emergent common stock between July 6, 2020 and March 31, 2021 , inclusive (the "Class Period").
- 05/07/2021
|
INVESTOR ACTION NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Emergent BioSolutions Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - May 7, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Emergent BioSolutions Inc. ("Emergent BioSolutions" or "the Company") (NYSE: EBS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between July 6, 2020 and March 31, 2021,...
- 05/07/2021
|
EBS ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of June 18, 2021 in the Class Action Filed on Behalf of Emergent Biosolutions Inc. Limited Shareholders
- New York, New York--(Newsfile Corp. - May 7, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Emergent Biosolutions Inc. (NYSE: EBS) alleging that the Company violated federal securities laws.Class Period: July 6, 2020 and March 31, 2021Lead Plaintiff Deadline: June 18, 2021Learn more about your recoverable losses in EBS:
- 05/07/2021
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Emergent Biosolutions Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 18, 2021 - EBS
- New York, New York--(Newsfile Corp. - May 6, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Emergent Biosolutions Inc. ("Emergent Bio") (NYSE: EBS) between July 6, 2020 and March 31, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the District of Maryland. To get more information...
- 05/06/2021
|
INVESTOR ACTION REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Emergent BioSolutions Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - May 6, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Emergent BioSolutions Inc. ("Emergent BioSolutions" or "the Company") (NYSE: EBS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between July 6, 2020 and March 31, 2021,...
- 05/06/2021
|
EBS LAWSUIT FILED: JAKUBOWITZ LAW PURSUES CLAIMS ON BEHALF OF EMERGENT BIOSOLUTIONS INC. SHAREHOLDERS
- New York, New York--(Newsfile Corp. - May 6, 2021) - Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders Emergent Biosolutions Inc. (NYSE: EBS).CLICK HERE FOR MORE DETAILS:https://claimyourloss.com/securities/emergent-biosolutions-inc-loss-submission-form/?id=15553&from=5
- 05/06/2021
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Emergent Biosolutions Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 18, 2021 - EBS
- New York, New York--(Newsfile Corp. - May 5, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Emergent Biosolutions Inc. ("Emergent Bio") (NYSE: EBS) between July 6, 2020 and March 31, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the District of Maryland. To get more information...
- 05/05/2021
|
EBS INVESTOR DEADLINE: HAGENS BERMAN, National Trial Attorneys, Encourages Emergent BioSolutions (EBS) Investors with $100k+ Losses to Contact its Attorneys Now, Securities Class Action Filed
- San Francisco, California--(Newsfile Corp. - May 5, 2021) - Hagens Berman urges Emergent BioSolutions Inc. (NYSE: EBS) investors with $100k or more losses to submit your losses now. Class Period: July 6, 2020 - Mar. 31, 2021Lead Plaintiff Deadline: June 18, 2021Visit: www.hbsslaw.com/investor-fraud/ebsContact an Attorney Now: EBS@hbsslaw.com844-916-0895Emergent BioSolutions (NYSE: EBS) Securities Fraud Class Action:Throughout the class period, Defendants touted Emergent's deals with J&J and AstraZeneca to produce their vaccine cand
- 05/05/2021
|
Emergent BioSolutions to Participate in Investor Conferences
- GAITHERSBURG, Md., May 05, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company's senior management team will participate in the following investor conferences:
- 05/05/2021
|
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Emergent Biosolutions Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 18, 2021 - EBS
- New York, New York--(Newsfile Corp. - May 5, 2021) - The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders of Emergent Biosolutions Inc. (NYSE: EBS).Shareholders who purchased shares of EBS during the class period listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/emergent-biosolutions-inc-loss-submission-form/?id=15520&from=5CLASS PERIOD : July 6
- 05/05/2021
|
EBS LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving Emergent Biosolutions Inc.
- New York, New York--(Newsfile Corp. - May 5, 2021) - The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased Emergent Biosolutions Inc. ("Emergent Bio") (NYSE: EBS) between July 6, 2020 and March 31, 2021.If you suffered a loss, contact us at the link below. There is no cost or obligation to you.http://www.wongesq.com/pslra-1/emergent-biosolutions-inc-loss-submission-form?prid=15505&wire=5
- 05/05/2021
|
INVESTOR ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Emergent BioSolutions Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - May 5, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Emergent BioSolutions Inc. ("Emergent BioSolutions" or "the Company") (NYSE: EBS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between July 6, 2020 and March 31, 2021,...
- 05/05/2021
|
EBS ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of June 18, 2021 in the Class Action Filed on Behalf of Emergent Biosolutions Inc. Limited Shareholders
- New York, New York--(Newsfile Corp. - May 5, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Emergent Biosolutions Inc. (NYSE: EBS) alleging that the Company violated federal securities laws.Class Period: July 6, 2020 and March 31, 2021Lead Plaintiff Deadline: June 18, 2021Learn more about your recoverable losses in EBS:
- 05/05/2021
|
ROSEN, A LEADING AND LONGSTANDING LAW FIRM, Encourages Emergent BioSolutions Inc. Investors with Losses to Secure Counsel Before Important Deadline - EBS
- NEW YORK, May 4, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Emergent BioSolutions Inc. (NYSE: EBS) between July 6, 2020 through March 31, 2021, inclusive (the "Class Period"), of the important June 18, 2021 lead plaintiff deadline. SO WHAT: If you purchased Emergent BioSolutions securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
- 05/04/2021
|
Why Emergent BioSolutions Stock Dropped 30% in April
- The company went from hero to zero in the fight against COVID-19.
- 05/04/2021
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Emergent Biosolutions Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 18, 2021 - EBS
- New York, New York--(Newsfile Corp. - May 4, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Emergent Biosolutions Inc. ("Emergent Bio") (NYSE: EBS) between July 6, 2020 and March 31, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the District of Maryland. To get more information...
- 05/04/2021
|
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Emergent BioSolutions Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - May 4, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Emergent BioSolutions Inc. ("Emergent BioSolutions" or "the Company") (NYSE: EBS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between July 6, 2020 and March 31, 2021,...
- 05/04/2021
|
EBS Investor Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Emergent BioSolutions Inc. Investors of Class Action and Encourages Investors to Contact the Firm
- New York, New York--(Newsfile Corp. - May 4, 2021) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Emergent BioSolutions Inc. ("Emergent" or "the Company") (NYSE: EBS) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Emergent securities between July 6, 2020 and March 31, 2021, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting...
- 05/04/2021
|
Is Emergent BioSolutions Still a Buy After Its Coronavirus Vaccine Flub?
- Shareholders beware: The hits just won't stop coming.
- 05/04/2021
|
Emergent BioSolutions: Punished For Answering The Call To Immediate Action
- Emergent BioSolutions has had a rough go over the past couple of months resulting from a cross-contamination mishap at their Baltimore facility. Due to the cross contamination, the company had to toss millions of Johnson & Johnson vaccines. Consequently, the FDA put a halt on vaccine production at that facility.
- 05/03/2021
|
EBS ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of June 18, 2021 in the Class Action Filed on Behalf of Emergent Biosolutions Inc. Limited Shareholders
- New York, New York--(Newsfile Corp. - May 3, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Emergent Biosolutions Inc. (NYSE: EBS) alleging that the Company violated federal securities laws.Class Period: July 6, 2020 and March 31, 2021Lead Plaintiff Deadline: June 18, 2021Learn more about your recoverable losses in EBS:
- 05/03/2021
|
Shareholder Alert: Kessler Topaz Meltzer & Check, LLP Reminds Shareholders of Securities Fraud Class Action Lawsuit Filed Against Emergent BioSolutions Inc.
- Radnor, Pennsylvania--(Newsfile Corp. - May 3, 2021) - The law firm of Kessler Topaz Meltzer & Check, LLP reminds investors of Emergent BioSolutions Inc. (NYSE: EBS) ("Emergent") that a securities fraud class action lawsuit has been filed on behalf of those who purchased or acquired Emergent common stock between July 6, 2020 and March 31, 2021, inclusive (the "Class Period").Lead Plaintiff Deadline: June 18, 2021Website: https://www.ktmc.com/new-cases/emergent-biosolutions-inc-ebs?utm_source=PR&utm_medium=Link&utm_campaign=emergentContact: James Maro, Esq. (484) 270-1453Adrienne Bell, Esq. (484)...
- 05/03/2021
|
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Emergent BioSolutions Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - May 3, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Emergent BioSolutions Inc. ("Emergent BioSolutions" or "the Company") (NYSE: EBS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between July 6, 2020 and March 31, 2021,...
- 05/03/2021
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Emergent Biosolutions Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 18, 2021 - EBS
- New York, New York--(Newsfile Corp. - May 3, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Emergent Biosolutions Inc. (NYSE: EBS) ("Emergent Bio") between July 6, 2020 and March 31, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the District of Maryland. To get more information go...
- 05/03/2021
|
Kessler Topaz Meltzer & Check, LLP: Securities Fraud Class Action Lawsuit Filed Against Emergent BioSolutions Inc.
- RADNOR, Pa., May 1, 2021 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP reminds investors that a securities fraud class action lawsuit has been filed against Emergent BioSolutions Inc. (NYSE: EBS) ("Emergent") on behalf of those who purchased or acquired Emergent common stock between July 6, 2020 and March 31, 2021 , inclusive (the "Class Period").
- 05/01/2021
|
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Emergent BioSolutions Inc. Investors with Losses to Secure Counsel Before Important Deadline - EBS
- New York, New York--(Newsfile Corp. - May 1, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Emergent BioSolutions Inc. (NYSE: EBS) between July 6, 2020 through March 31, 2021, inclusive (the "Class Period") of the important June 18, 2021 lead plaintiff deadline.SO WHAT: If you purchased Emergent BioSolutions securities during the Class Period you may be entitled to compensation without payment of any out...
- 05/01/2021
|
Emergent Biosolutions CEO walks back denial regarding cross contamination
- CNBC's Meg Tirrell reports Robert Kramer, the president and CEO of Emergent Biosolutions has walked back his comments on cross-contamination after denying it on CNBC TV.
- 04/30/2021
|
Emergent BioSolutions Has Supply Of 60M Johnson & Johnson COVID-19 Vaccine Doses Awaiting Approval: Bloomberg
- Emergent BioSolutions Inc (NYSE: EBS) has manufactured over 115 million doses of drug substance used in the Johnson & Johnson (NYSE: JNJ) COVID-19 vaccine, 60 million doses of which are in vials and ready to deploy at U.S. regulators' discretion, reports Bloomberg. The contract manufacturer has been producing the J&J single-shot vaccine since late 2020, according to a source.
- 04/30/2021
|
Deadline Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Filed Against Emergent BioSolutions Inc. (EBS)
- Radnor, Pennsylvania--(Newsfile Corp. - April 30, 2021) - The law firm of Kessler Topaz Meltzer & Check, LLP reminds investors of Emergent BioSolutions Inc. (NYSE: EBS) ("Emergent") that a securities fraud class action lawsuit has been on behalf of those who purchased or acquired Emergent common stock between July 6, 2020 and March 31, 2021, inclusive (the "Class Period").Deadline Reminder: Investors who purchased or acquired Emergent common stock during the Class Period may,...
- 04/30/2021
|
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Emergent BioSolutions Inc. (EBS)
- LOS ANGELES--(BUSINESS WIRE)---- $EBS #CLASSACTION--Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming June 18, 2021 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Emergent BioSolutions Inc. (“Emergent” or the “Company”) (NYSE: EBS) common stock between July 6, 2020 and March 31, 2021, inclusive (the “Class Period”). If you suffered a loss on your Emergent investments or would like to inquire about potentially pursu
- 04/30/2021
|
SHAREHOLDER ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Emergent BioSolutions Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, CA ----(Newsfile Corp. - April 30, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Emergent BioSolutions Inc. ("Emergent BioSolutions" or "the Company") (NYSE: EBS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between July 6, 2020 and March 31,...
- 04/30/2021
|
Emergent (EBS) Beats on Q1 Earnings, Cuts Contract Revenue View
- Emergent's (EBS) earnings in the first quarter of 2021 beat estimates while revenues miss the same. It lowers guidance for revenues from CDMO services.
- 04/30/2021
|
New Strong Sell Stocks for April 30th
- ARAY, EBS, FARM, SHLX, and TPB have been added to the Zacks Rank #5 (Strong Sell) List on April 30, 2021
- 04/30/2021
|
Emergent BioSolutions, Inc. (EBS) CEO Robert Kramer on Q1 2021 Results - Earnings Call Transcript
- Emergent BioSolutions, Inc. (EBS) CEO Robert Kramer on Q1 2021 Results - Earnings Call Transcript
- 04/30/2021
|
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Emergent BioSolutions Inc. Investors with Losses Exceeding $100K to Secure Counsel Before Important Deadline - EBS
- NEW YORK, April 29, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Emergent BioSolutions Inc. (NYSE: EBS) between July 6, 2020 through March 31, 2021, inclusive (the "Class Period") of the important June 18, 2021 lead plaintiff deadline. SO WHAT: If you purchased Emergent BioSolutions securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
- 04/29/2021
|
EMERGENT BIOSOLUTIONS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Emergent BioSolutions Inc. - EBS
- New Orleans, Louisiana--(Newsfile Corp. - April 29, 2021) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until June 18, 2021 to file lead plaintiff applications in a securities class action lawsuit against Emergent BioSolutions Inc. (NYSE: EBS), if they purchased the Company's shares between July 6, 2020 and March 31, 2021, inclusive (the "Class Period"). This action is...
- 04/29/2021
|
Emergent Biosolutions (EBS) Q1 Earnings Top Estimates
- Emergent Biosolutions (EBS) delivered earnings and revenue surprises of 57.73% and -6.95%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
- 04/29/2021
|
Emergent BioSolutions: Q1 Earnings Insights
- Shares of Emergent BioSolutions (NYSE:EBS) decreased in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share rose 15200.00% over the past year to $1.53, which beat the estimate of $1.12.
- 04/29/2021
|
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Emergent BioSolutions (EBS) Investors with $100k+ Losses to Contact its Attorneys Now, Securities Fraud Class Action Filed, Application Deadline Established
- San Francisco, California--(Newsfile Corp. - April 29, 2021) - Hagens Berman urges Emergent BioSolutions Inc. (NYSE: EBS) investors with $100k or more losses to submit your losses now.Class Period: July 6, 2020 - Mar. 31, 2021Lead Plaintiff Deadline: June 18, 2021Visit: www.hbsslaw.com/investor-fraud/EBSContact an Attorney Now: EBS@hbsslaw.com844-916-0895Emergent BioSolutions (NYSE: EBS) Securities Fraud Class Action:Throughout the class period, Defendants touted Emergent's deals with J&J and AstraZeneca to produce their vaccine can
- 04/29/2021
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Emergent Biosolutions Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 18, 2021 - EBS
- New York, New York--(Newsfile Corp. - April 29, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Emergent Biosolutions Inc. ("Emergent Bio") (NYSE: EBS) between July 6, 2020 and March 31, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the District of Maryland. To get more information...
- 04/29/2021
|
INVESTOR ACTION NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Emergent BioSolutions Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - April 29, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Emergent BioSolutions Inc. ("Emergent BioSolutions" or "the Company") (NYSE: EBS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between July 6, 2020 and March 31, 2021,...
- 04/29/2021
|
EBS Investor Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Emergent BioSolutions Inc. Investors of Class Action and Encourages Investors to Contact the Firm
- NEW YORK--(BUSINESS WIRE)--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Emergent BioSolutions Inc. ("Emergent" or "the Company") (NYSE: EBS) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Emergent securities between July 6, 2020 and March 31, 2021, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/ebs. Th
- 04/29/2021
|
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Emergent Biosolutions Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 18, 2021 - EBS
- New York, New York--(Newsfile Corp. - April 28, 2021) - The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders of Emergent Biosolutions Inc..Shareholders who purchased shares of EBS during the class period listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/emergent-biosolutions-inc-loss-submission-form/?id=15264&from=5CLASS PERIOD : July 6, 2020 to March 31,...
- 04/28/2021
|
EBS Stock: Berger Montague Investigates Potential Securities Fraud Claims Against Emergent BioSolutions Inc. (EBS); Lead Plaintiff Deadline is June 18, 2021
- Philadelphia, Pennsylvania--(Newsfile Corp. - April 28, 2021) - Berger Montague is investigating potential securities fraud claims against Emergent BioSolutions Inc. (NYSE: EBS) ("Emergent" or the "Company") on behalf of investors who purchased Emergent securities between July 6, 2020 and March 31, 2021 (the "Class Period"). If you purchased Emergent securities during the Class Period, have questions concerning your rights or interests, or would like to discuss Berger Montague's investigation, please contact attorneys Andrew Abramowitz...
- 04/28/2021
|
EBS LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving Emergent Biosolutions Inc.
- New York, New York--(Newsfile Corp. - April 28, 2021) - The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased Emergent Biosolutions Inc. ("Emergent Bio") (NYSE: EBS) between July 6, 2020 and March 31, 2021.If you suffered a loss, contact us at the link below. There is no cost or obligation to you.http://www.wongesq.com/pslra-1/emergent-biosolutions-inc-loss-submission-form?prid=15253&wire=5
- 04/28/2021
|
INVESTOR ACTION REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Emergent BioSolutions Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - April 28, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Emergent BioSolutions Inc. ("Emergent BioSolutions" or "the Company") (NYSE: EBS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between July 6, 2020 and March 31, 2021,...
- 04/28/2021
|
ROSEN, A TOP RANKED LAW FIRM, Encourages Emergent BioSolutions Inc. Investors with Losses to Secure Counsel Before Important Deadline – EBS
- NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Emergent BioSolutions Inc. (NYSE: EBS) between July 6, 2020 through March 31, 2021, inclusive (the “Class Period”) of the important June 18, 2021 lead plaintiff deadline. SO WHAT: If you purchased Emergent BioSolutions securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangeme
- 04/27/2021
|
Kessler Topaz Meltzer & Check, LLP Announces Investor Securities Fraud Class Action Lawsuit Filed Against Emergent BioSolutions Inc. - EBS
- Radnor, Pennsylvania--(Newsfile Corp. - April 27, 2021) - The law firm of Kessler Topaz Meltzer & Check, LLP reminds Emergent BioSolutions Inc. (NYSE: EBS) ("Emergent") investors that a securities fraud class action lawsuit has been filed in the United States District Court for the District of Maryland against Emergent on behalf of those who purchased or acquired Emergent common stock between July 6, 2020 and March 31, 2021, inclusive (the "Class Period").Lead Plaintiff Deadline:...
- 04/27/2021
|
EBS ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of June 18, 2021 in the Class Action Filed on Behalf of Emergent Biosolutions Inc. Limited Shareholders
- New York, New York--(Newsfile Corp. - April 27, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Emergent Biosolutions Inc. (NYSE: EBS) alleging that the Company violated federal securities laws.Class Period: July 6, 2020 and March 31, 2021Lead Plaintiff Deadline: June 18, 2021Learn more about your recoverable losses in EBS:
- 04/27/2021
|
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Emergent BioSolutions (EBS) Investors with $100k+ Losses to Contact its Attorneys Now, Securities Fraud Case Pending, Firm Investigating CEO's Insider Sales
- SAN FRANCISCO, April 27, 2021 /PRNewswire/ -- Hagens Berman urges Emergent BioSolutions Inc. (NYSE: EBS) investors with $100k or more losses to submit your losses now. Class Period: July 6, 2020 - Mar. 31, 2021 Lead Plaintiff Deadline: June 18, 2021 Visit: www.hbsslaw.com/investor-fraud/EBS Contact an Attorney Now: EBS@hbsslaw.com 844-916-0895 Emergent BioSolutions (NYSE: EBS) Securities Fraud Class Action: Throughout the class period, Defendants touted Emergent's deals with J&J and AstraZeneca to produce their vaccine candidates and separate production contract with the U.S. government.
- 04/27/2021
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Emergent Biosolutions Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 18, 2021 - EBS
- New York, New York--(Newsfile Corp. - April 27, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Emergent Biosolutions Inc. ("Emergent Bio") (NYSE: EBS) between July 6, 2020 and March 31, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the District of Maryland. To get more information...
- 04/27/2021
|
INVESTOR ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Emergent BioSolutions Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - April 27, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Emergent BioSolutions Inc. ("Emergent BioSolutions" or "the Company") (NYSE: EBS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between July 6, 2020 and March 31, 2021,...
- 04/27/2021
|
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Emergent BioSolutions Inc. (EBS) Investors
- LOS ANGELES--(BUSINESS WIRE)---- $EBS #investors--The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Emergent BioSolutions Inc. (EBS) Investors
- 04/27/2021
|
EBS LAWSUIT FILED: Jakubowitz Law Pursues Claims on Behalf of Emergent Biosolutions Inc. Shareholders
- New York, New York--(Newsfile Corp. - April 27, 2021) - Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders Emergent Biosolutions Inc. (NYSE: EBS).CLICK HERE FOR MORE DETAILS:https://claimyourloss.com/securities/emergent-biosolutions-inc-loss-submission-form/?id=15178&from=5
- 04/27/2021
|
Is There Any Hope Left for Emergent BioSolutions?
- The go-to government contractor is in deep trouble. Should investors buy the dip?
- 04/27/2021
|
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Emergent Biosolutions Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 18, 2021 - EBS
- New York, New York--(Newsfile Corp. - April 26, 2021) - The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders of Emergent Biosolutions Inc.Shareholders who purchased shares of EBS during the class period listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/emergent-biosolutions-inc-loss-submission-form/?id=15159&from=5CLASS PERIOD: July 6, 2020 to M
- 04/26/2021
|
EBS INVESTOR ALERT: Class Action Lawsuit Filed
- Boston, Massachusetts--(Newsfile Corp. - April 26, 2021) - The Thornton Law Firm alerts investors that a class action lawsuit has been filed on behalf of investors of Emergent BioSolutions Inc. (NYSE: EBS). The case is currently in the lead plaintiff stage. Investors who purchased EBS stock or other securities between July 6, 2020 and March 31, 2021 may contact the Thornton Law Firm's investor protection team by visiting www.tenlaw.com/cases/Emergent to submit their information. Investors may...
- 04/26/2021
|
EBS ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of June 18, 2021 in the Class Action Filed on Behalf of Emergent Biosolutions Inc. Limited Shareholders
- New York, New York--(Newsfile Corp. - April 26, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Emergent Biosolutions Inc. (NYSE: EBS) alleging that the Company violated federal securities laws.Class Period: July 6, 2020 and March 31, 2021Lead Plaintiff Deadline: June 18, 2021Learn more about your recoverable losses in EBS:
- 04/26/2021
|
LAWSUIT FILED: Emergent BioSolutions Inc. Sued for Violations of the Federal Securities Laws; Investors Should Contact Block & Leviton LLP
- Boston, Massachusetts--(Newsfile Corp. - April 26, 2021) - Block & Leviton LLP announces that a lawsuit for violations of the federal securities laws has been filed against Emergent BioSolutions Inc. (NYSE: EBS) and certain of its executives. Investors who have lost money should contact the firm to learn more about how they might recover those losses. For more details, visit https://www.blockleviton.com/cases/ebs. The deadline to move for appointment as lead plaintiff is June 18, 2021.What...
- 04/26/2021
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Emergent Biosolutions Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 18, 2021 - EBS
- New York, New York--(Newsfile Corp. - April 26, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Emergent Biosolutions Inc. (NYSE: EBS) ("Emergent Bio") between July 6, 2020 and March 31, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the District of Maryland. To get more...
- 04/26/2021
|
CEO of COVID-19 vaccine maker sold $10M in stock before company destroyed Johnson & Johnson doses
- The CEO of Emergent BioSolutions, the government contractor that destroyed 15 million doses of Johnson & Johnson's COVID-19 vaccine, sold more than $10 million worth of his stock in the company before its share prices plummeted.
- 04/26/2021
|
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Emergent BioSolutions Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- LOS ANGELES, April 26, 2021 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Emergent BioSolutions Inc. ("Emergent BioSolutions" or "the Company") (NYSE: EBS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between July 6, 2020 and March 31, 2021, inclusive (the ''Class Period''), are encouraged to contact the firm before June 18, 2021.
- 04/26/2021
|
A vaccine maker ruined 15 million doses. Its CEO sold $11 million of stock before that was public
- Emergent BioSciences' stock lost more than half of its value since the disclosure that it ruined as many as 15 million doses of Johnson & Johnson's Covid-19 vaccine at its Baltimore plant. But the company's CEO dumped more than $11 million worth of stock ahead of the stock's massive decline.
- 04/26/2021
|
Class Action Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Filed Against Emergent BioSolutions Inc.
- RADNOR, Pa., April 26, 2021 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP announces that a securities fraud class action lawsuit has been filed in the United States District Court for the District of Maryland against Emergent BioSolutions Inc. (NYSE: EBS) ("Emergent") on behalf of those who purchased or acquired Emergent common stock between July 6, 2020 and March 31, 2021 , inclusive (the "Class Period").
- 04/26/2021
|
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Emergent BioSolutions Inc. (EBS) Investors
- LOS ANGELES--(BUSINESS WIRE)---- $EBS #CLASSACTION--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, announces that a class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Emergent BioSolutions Inc. (“Emergent” or the “Company”) (NYSE: EBS) common stock between July 6, 2020 and March 31, 2021, inclusive (the “Class Period”). Emergent investors have until June 18, 2021 to file a lead plaintiff motion. If you suffered a loss on your Emerg
- 04/26/2021
|
What's in Store for Emergent (EBS) This Earnings Season?
- On Emergent's (EBS) upcoming first-quarter earnings call, investors are likely to focus on the company's update related to re-start of production at its Bayview facility.
- 04/26/2021
|
Moving Average Crossover Alert: Emergent BioSolutions (EBS)
- Emergent BioSolutions (EBS) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front
- 04/26/2021
|
EBS INVESTOR NOTICE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Emergent BioSolutions Inc. Investors with Losses Exceeding $100K to Secure Counsel Before Important Deadline - EBS
- NEW YORK, April 24, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Emergent BioSolutions Inc. (NYSE: EBS) between July 6, 2020 through March 31, 2021, inclusive (the "Class Period"). A class action lawsuit has already been filed.
- 04/24/2021
|
Investor Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Filed Against Emergent BioSolutions Inc. - EBS
- Radnor, Pennsylvania--(Newsfile Corp. - April 24, 2021) - The law firm of Kessler Topaz Meltzer & Check, LLP announces that a securities fraud class action lawsuit has been filed in the United States District Court for the District of Maryland against Emergent BioSolutions Inc. (NYSE: EBS) ("Emergent") on behalf of those who purchased or acquired Emergent common stock between July 6, 2020 and March 31, 2021, inclusive (the "Class Period").Deadline Reminder: Investors who...
- 04/24/2021
|
SHAREHOLDER ALERT: Robbins LLP Announces That Emergent BioSolutions Inc. (EBS) is Being Sued for Misleading Shareholders
- SAN DIEGO & GAITHERSBURG, Md.--(BUSINESS WIRE)---- $EBS #ClassAction--Shareholder rights law firm Robbins LLP announces that a purchaser of Emergent BioSolutions Inc (NYSE: EBS) filed a class action complaint against the Company and its officers and directors for alleged violations of the Securities Exchange Act of 1934 between July 6, 2020 and March 31, 2021. Emergent is a specialty biopharmaceutical company that develops vaccines and antibody therapeutics for infectious diseases. If you suffered a loss due to Emer
- 04/23/2021
|
Investor Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Filed Against Emergent BioSolutions Inc. - EBS
- Radnor, Pennsylvania--(Newsfile Corp. - April 23, 2021) - The law firm of Kessler Topaz Meltzer & Check, LLP announces that a securities fraud class action lawsuit has been filed in the United States District Court for the District of Maryland against Emergent BioSolutions Inc. (NYSE: EBS) ("Emergent") on behalf of those who purchased or acquired Emergent common stock between July 6, 2020 and March 31, 2021, inclusive (the "Class Period").Deadline Reminder: Investors who...
- 04/23/2021
|
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Emergent BioSolutions Inc. (EBS) Investors
- BENSALEM, Pa.--(BUSINESS WIRE)---- $EBS #CLASSACTION--Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased of Emergent BioSolutions Inc. (“Emergent” or the “Company”) (NYSE: EBS) common stock between July 6, 2020 and March 31, 2021, inclusive (the “Class Period”). Emergent investors have until June 18, 2021 to file a lead plaintiff motion. Investors suffering losses on their Emergent investments are encouraged to contact the Law Offices of Howard G.
- 04/23/2021
|
EBS Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Emergent BioSolutions Inc. Shareholders of Class Action and Encourages Investors to Contact the Firm
- NEW YORK, April 23, 2021 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Emergent BioSolutions Inc. ("Emergent" or "the Company") (NYSE: EBS) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Emergent securities between July 6, 2020 and March 31, 2021, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/ebs.
- 04/23/2021
|
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Emergent BioSolutions Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- LOS ANGELES--(BUSINESS WIRE)---- $EBS #EBS--SHAREHOLDER ACTION REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Emergent BioSolutions Inc.
- 04/23/2021
|
EMERGENT BIOSOLUTIONS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Emergent BioSolutions Inc. - EBS
- New Orleans, Louisiana--(Newsfile Corp. - April 22, 2021) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until June 18, 2021 to file lead plaintiff applications in a securities class action lawsuit against Emergent BioSolutions Inc. (NYSE: EBS), if they purchased the Company's shares between July 6, 2020 and March 31, 2021, inclusive (the "Class Period"). This action is...
- 04/22/2021
|
Kessler Topaz Meltzer & Check, LLP Announces a Securities Fraud Class Action Lawsuit Filed Against Emergent BioSolutions Inc. (EBS)
- RADNOR, Pa.--(BUSINESS WIRE)---- $EBS #classaction--Kessler Topaz Meltzer & Check, LLP Announces a Securities Fraud Class Action Lawsuit Filed Against Emergent BioSolutions Inc. (EBS)
- 04/22/2021
|
EBS ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of June 18, 2021 in the Class Action Filed on Behalf of Emergent Biosolutions Inc. Limited Shareholders
- New York, New York--(Newsfile Corp. - April 22, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Emergent Biosolutions Inc. (NYSE: EBS) alleging that the Company violated federal securities laws.Class Period: July 6, 2020 and March 31, 2021Lead Plaintiff Deadline: June 18, 2021Learn more about your recoverable losses in EBS:
- 04/22/2021
|
The Law Offices of Frank R. Cruz Announces Investigation of Emergent BioSolutions Inc. (EBS) on Behalf of Investors
- LOS ANGELES--(BUSINESS WIRE)---- $EBS #investors--The Law Offices of Frank R. Cruz Announces Investigation of Emergent BioSolutions Inc. (EBS) on Behalf of Investors
- 04/22/2021
|
SHAREHOLDER ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Emergent BioSolutions Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- LOS ANGELES--(BUSINESS WIRE)---- $EBS #EBS--SHAREHOLDER ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Emergent BioSolutions Inc.
- 04/22/2021
|
Is The Worst Over For Emergent Biosolutions Stock?
- Emergent Biosolutions has been in the news lately but for the wrong reasons. Earlier this month, we advised caution on EBS stock when it was revealed that a “human error” in the company's plant resulted in the contamination of a batch of Johnson & Johnson's (NYSE: JNJ) Covid-19 vaccine.
- 04/22/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Emergent BioSolutions Inc. - EBS
- New York, New York--(Newsfile Corp. - April 21, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Emergent BioSolutions Inc. ("Emergent" or the "Company") (NYSE: EBS). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Emergent and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the...
- 04/21/2021
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Emergent Biosolutions Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 18, 2021 - EBS
- New York, New York--(Newsfile Corp. - April 21, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Emergent Biosolutions Inc. ("Emergent Bio") (NYSE: EBS) between July 6, 2020 and March 31, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the District of Maryland. To get more information...
- 04/21/2021
|
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Emergent BioSolutions Inc. (EBS) on Behalf of Investors
- BENSALEM, Pa.--(BUSINESS WIRE)---- $EBS #CLASSACTION--Law Offices of Howard G. Smith announces an investigation on behalf of Emergent BioSolutions Inc. (“Emergent” or the “Company”) (NYSE: EBS) investors concerning the Company's possible violations of federal securities laws. On March 31, 2021, The New York Times published an article reporting that in late February 2021, employees at Emergent's Baltimore manufacturing plant “mixed up” ingredients of the different COVID-19 vaccines, contaminating up to 15 million dos
- 04/21/2021
|
EBS CLASS ACTION ALERT: Kessler Topaz Meltzer & Check, LLP Announces a Securities Fraud Class Action Lawsuit Filed Against Emergent BioSolutions Inc.
- RADNOR, Pa., April 21, 2021 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP announces that a securities fraud class action lawsuit has been filed in the United States District Court for the District of Maryland against Emergent BioSolutions Inc. (NYSE: EBS) ("Emergent") on behalf of those who purchased or acquired Emergent common stock between July 6, 2020 and March 31, 2021 , inclusive (the "Class Period").
- 04/21/2021
|
EMERGENT BIOSOLUTIONS INVESTOR ALERT: Shareholder Lawsuit Filed
- Boston, Massachusetts--(Newsfile Corp. - April 21, 2021) - The Thornton Law Firm alerts investors that a class action lawsuit has been filed on behalf of investors of Emergent BioSolutions Inc. (NYSE: EBS). The case is currently in the lead plaintiff stage. Investors who purchased EBS stock or other securities between July 6, 2020 and March 31, 2021 may contact the Thornton Law Firm's investor protection team by visiting www.tenlaw.com/cases/Emergent to submit their information. Investors may...
- 04/21/2021
|
FDA's Inspection Of Emergent's COVID-19 Vaccine Baltimore Plant Outlines Concerns About Sanitary Conditions, Employee Training
- The FDA concluded its inspection of Emergent BioSolutions Inc's (NYSE: EBS) troubled vaccine manufacturing plant in Baltimore after it stopped production on Monday. The agency released a couple of blistering observations on the cross-contamination, sanitary issues, and lack of staff training that caused ingredient mix-ups at the facility.
- 04/21/2021
|
FDA completes Emergent Biosolutions factory inspection, orders fixes
- CNBC's Meg Tirrell reports on updates out of the FDA on its inspection of an Emergent Biosolutions, which recently botched 15 million doses of Covid vaccine.
- 04/21/2021
|
EMERGENT BIOSOLUTIONS ALERT: Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Emergent BioSolutions, Inc. and Encourages Investors to Contact the Firm
- NEW YORK--(BUSINESS WIRE)-- #EmergentBioSolutions--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, announces that a class action lawsuit has been filed in the United States District Court for the District of Maryland on behalf of investors that purchased Emergent BioSolutions, Inc. (NYSE: EBS) common stock between July 6, 2020 and March 31, 2021, inclusive (the “Class Period”). Investors have until June 18, 2021 to apply to the Court to be appointed as lead plaintiff in the lawsui
- 04/20/2021
|
EMERGENT BIOSOLUTIONS SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Emergent Biosolutions Inc. - EBS
- NEW ORLEANS--(BUSINESS WIRE)--Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until June 18, 2021 to file lead plaintiff applications in a securities class action lawsuit against Emergent BioSolutions Inc. (NYSE: EBS), if they purchased the Company's shares between July 6, 2020 and March 31, 2021, inclusive (the “Class Period”). This action is pending in the United States District Court for the Distr
- 04/20/2021
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Emergent Biosolutions Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 18, 2021 - EBS
- New York, New York--(Newsfile Corp. - April 20, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Emergent Biosolutions Inc. ("Emergent Bio") (NYSE: EBS) between July 6, 2020 and March 31, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the District of Maryland. To get more information...
- 04/20/2021
|
Congressional investigation launched into Emergent BioSolutions' federal vaccine contracts
- Congressional investigators have requested top executives from Emergent BioSolutions to testify before the Select Subcommittee.
- 04/20/2021
|
Emergent (EBS) Bayview Unit Operation on Hold for FDA Probe
- Emergent (EBS) halts manufacturing at Bayview facility as the FDA initiates investigation of the error that led to manufacturing of faulty doses of J&J's COVID-19 vaccine.
- 04/20/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Emergent BioSolutions Inc. - EBS
- NEW YORK, April 19, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Emergent BioSolutions Inc. ("Emergent" or the "Company") (NYSE: EBS). Such investors are advised to contact Robert S.
- 04/19/2021
|
Emergent BioSolutions Stock Falls After FDA Initiates Inspection Of Bayview Facility
- Emergent BioSolutions Inc (NYSE: EBS) has had a tough month: First, the company ruined 15 million doses of Johnson & Johnson's (NYSE: JNJ) COVID-19 vaccine manufactured at its Baltimore site. Then, the FDA seized the reins of the facility and passed them on to JNJ.
- 04/19/2021
|
Why Emergent BioSolutions Stock Is Tumbling Today
- The company has halted production of COVID-19 vaccines at its Baltimore facility as an FDA inspection moves forward.
- 04/19/2021
|
Emergent BioSolutions says it has agreed with FDA not to manufacture new material at Baltimore facility
- Drug contract company Emergent BioSolutions Inc. said Monday it has made an agreement with the U.S. Food and Drug Administration not to manufacture any new material at its Bayview facility in Baltimore. The FDA started an inspection of the plant last week, after Johnson & Johnson found Emergent workers had confused ingredients for its COVID-19 vaccine with ones used in making the vaccine developed by AstraZeneca PLC and Oxford University.
- 04/19/2021
|
Emergent BioSolutions to Release First Quarter 2021 Financial Results and Conduct a Conference Call on April 29, 2021
- GAITHERSBURG, Md., April 15, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, April 29, 2021 at 5:00 pm eastern time to discuss the financial results for the first quarter of 2021, recent business developments, revenue guidance for the second quarter of 2021, and financial outlook for full year 2021.
- 04/15/2021
|
Why Emergent BioSolutions Stock Fell Today
- The pause on use of Johnson & Johnson's COVID-19 vaccine had a ripple impact.
- 04/13/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Emergent BioSolutions Inc. - EBS
- NEW YORK, April 13, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Emergent BioSolutions Inc. ("Emergent" or the "Company") (NYSE: EBS). Such investors are advised to contact Robert S.
- 04/13/2021
|
EMERGENT BIOSOLUTIONS ALERT: Bragar Eagel & Squire, P.C. is Investigating Emergent BioSolutions, Inc. on Behalf of Emergent Stockholders and Encourages Investors to Contact the Firm
- NEW YORK--(BUSINESS WIRE)-- #EmergentBioSolutions--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Emergent BioSolutions, Inc. (NYSE: EBS) on behalf of Emergent stockholders. Our investigation concerns whether Emergent has violated the federal securities laws and/or engaged in other unlawful business practices. Click here to participate in the action. On March 31, 2021, the New York Times published an article reporting on the accidental co
- 04/12/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Emergent BioSolutions Inc. - EBS
- New York, New York--(Newsfile Corp. - April 10, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Emergent BioSolutions Inc. ("Emergent" or the "Company") (NYSE: EBS). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Emergent and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the...
- 04/10/2021
|
Entwistle & Cappucci LLP Investigative Alert: Emergent BioSolutions Inc. (EBS)
- AUSTIN, Texas--(BUSINESS WIRE)--Entwistle & Cappucci LLP Investigative Alert: Emergent BioSolutions Inc. (EBS)
- 04/08/2021
|
Cramer on reports that Emergent Bio received warning over vaccine manufacturing
- Emergent BioSolutions was the subject of a warning by a top federal health official last June, according to a New York Times report. The official warned of quality control and other issues at the contract manufacturer, which recently had to dispose of millions of doses of Johnson & Johnson's (JNJ) Covid-19 vaccine because of contamination.
- 04/08/2021
|
5 Peter Lynch Growth Stocks to Consider for 2nd Quarter
- According to the Peter Lynch Growth Screen, a Premium All-in-One Screener template, five stocks with high financial strength, good revenue growth and are trading below the Peter Lynch earnings line as of Tuesday are Big Lots Inc. (NYSE:BIG), The Cooper Companies Inc. (NYSE:COO), Emergent BioSolutions Inc. (NYSE:EBS), SPAR Group Inc. (NASDAQ:SGRP) and Worthington Industries Inc. (NYSE:WOR).
- 04/06/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Emergent BioSolutions Inc. - EBS
- NEW YORK, April 6, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Emergent BioSolutions Inc. ("Emergent" or the "Company") (NYSE: EBS). Such investors are advised to contact Robert S.
- 04/06/2021
|
Johnson & Johnson Given Control of Emergent BioSolutions Factory That Botched Its Coronavirus Vaccine
- The move follows errors in the production of a batch of Johnson & Johnson's jab.
- 04/05/2021
|
Emergent (EBS) Gets Extra $23M for COVID-19 Vaccine Production
- Emergent (EBS) receives additional $23 million from BARDA to support further expansion of manufacturing capacity for Johnson & Johnson's COVID-19 vaccine.
- 04/05/2021
|
J&J (JNJ) Gets Full Charge of Emergent COVID-19 Vaccine Plant
- The U.S. government places J&J (JNJ) in charge of Emergent's Baltimore factory. The facility will cease production of AstraZeneca shots.
- 04/05/2021
|
Emergent BioSolutions' Plasma-Based Therapy Candidate Flunks COVID-19 Study; HHS Increases Task Order By $23M
- Emergent BioSolutions Inc (NYSE: EBS) has announced topline data from Phase 3 trial, dubbed as INSIGHT-013 evaluation of its investigational SARS-CoV-2 Immune Globulin Intravenous (Human) (COVID-HIG) for the treatment of hospitalized patients with COVID-19. The study was sponsored and supported by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, to assess four immunoglobulin candidates' safety and efficacy plus standard of care versus placebo plus standard of care.
- 04/05/2021
|
Emergent BioSolutions On Track with Respect to COVID-19 Contractual Commitments; Receives Modified Task Order from the U.S. Department of Health & Human Services to Support the Opportunity for Further Expansion of Manufacturing Capacity for Johnson & Johnson's COVID-19 Vaccine
- GAITHERSBURG, Md., April 04, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that the Company continues to be on track with its manufacturing agreements related to COVID-19 vaccines and confirmed that there are no changes to its financial guidance for 2021. In addition, the Company received a contract modification to increase the original task order by $23 million from Biomedical Advanced Research and Development Authority (BARDA), which is part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health & Human Services (HHS).
- 04/04/2021
|
Emergent says experimental COVID-19 treatment failed in Phase 3 trial
- Emergent BioSolutions Inc. said Friday that its experimental COVID-19 treatment did not demonstrate a clinical benefit in a late-stage clinical trial. The study was testing Emergent's immunoglobulin candidate with the standard of care, which uses Gilead Sciences Inc.'s Veklury, in hospitalized patients with COVID-19 symptoms.
- 04/02/2021
|
Emergent BioSolutions Announces Topline Data from NIAID Phase 3 ITAC Trial (INSIGHT-013) Evaluating Immunoglobulins as a Treatment for Hospitalized Patients with COVID-19
- GAITHERSBURG, Md., April 02, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today provided an update on the evaluation of its investigational SARS-CoV-2 Immune Globulin Intravenous (Human) (COVID-HIG) for the treatment of hospitalized patients with COVID-19. The Phase 3 Inpatient Treatment with Anti-Coronavirus Immunoglobulin (ITAC) trial, also known as INSIGHT-013, sponsored and supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), assessed the safety and efficacy of four immunoglobulin candidates plus standard of care versus placebo plus standard of care in hospitalized patients with COVID-19. Topline data from the ITAC trial demonstrated that the addition of anti-SARS-CoV-2 hyperimmunoglobulin to standard of care, inclusive of remdesivir, for hospitalized adult COVID-19 patients with symptoms for less than 12 days did not provide clinical benefit when compared to standard of care plus placebo. There were no serious safety concerns identified.
- 04/02/2021
|
Why Emergent BioSolutions Crashed Today
- The company appears to have fumbled part of a very high-profile job for a big partner.
- 04/01/2021
|
Emergent Biosolutions CEO on the vaccine factory mix-up
- Emergent Biosolutions CEO Robert Kramer joins CNBC's Meg Tirrell to discuss the mix up between the ingredients of the AstraZeneca vaccine and the J&J vaccine. However, the mistake was caught early on and the vials were not been released to the public.
- 04/01/2021
|
Emergent stock falls nearly 7% after news of J&J vaccine manufacturing mix-up
- Emergent stock falls nearly 7% after news of J&J vaccine manufacturing mix-up
- 04/01/2021
|
15M Doses Of JNJ COVID-19 Vaccine Batch Ruined After Ingredient Issues At Emergent Biosolutions' US Plant: NYT
- One batch of Johnson & Johnson's (NYSE: JNJ) COVID-19 vaccines failed quality standards and are not fit for use, reported the New York Times on late Wednesday. What Happened: The company had found a problem with an ingredient used in the vaccine produced at Emergent Biosolutions Inc's (NYSE: EBS) site in Baltimore.
- 04/01/2021
|
Emergent Biosolutions Stock Takes A Hit From Vaccine Mix-Up At Baltimore Plant
- Johnson & Johnson confirmed yesterday that a batch of its Covid-19 vaccine was contaminated by ingredients from AstraZeneca's vaccine at Emergent Biosolutions' manufacturing plant in Baltimore due to a “human error.” While Johnson & Johnson said it will still be on track to deliver the promised.
- 04/01/2021
|
5 Health Care Stocks Boosting Earnings
- The following health care companies have grown their earnings per share over a five-year period. According to the GuruFocus discounted cash flow calculator as of March 31, all of them also trade with a margin of safety.
- 03/31/2021
|
Coronavirus vaccine: The world is going to need billions of doses...: Emergent Biosolutions CEO
- Emergent Biosolutions CEO Robert Kramer discusses coronavirus vaccine production and distribution.
- 03/04/2021
|
Emergent BioSolutions says it can make 1 billion Covid vaccine doses annually
- Emergent CEO Bob Kramer told CNBC that the company has infrastructure in place to produce Johnson & Johnson and AstraZeneca vaccines around the clock.
- 03/03/2021
|
Emergent Biosolutions CEO talks production of Johnson & Johnson vaccine
- Emergent Biosolutions last year signed a multi-year agreement with the U.S. and Johnson & Johnson to handle domestic manufacturing of a Covid-19 vaccine. CEO Bob Kramer gives an update on the effort.
- 03/03/2021
|
Emergent BioSolutions to Participate in Investor Conferences
- GAITHERSBURG, Md., March 01, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company's senior management team will participate in the following investor conferences:
- 03/01/2021
|
What Should You Do With Emergent Biosolutions Stock After A 19% Drop In 5 Days?
- The stock price of Emergent Biosolutions, a biopharmaceutical company focused on vaccines and antibody therapeutics for infectious diseases, and opioid overdoses, has seen a 17% drop over the last ten trading days, while it's down 19% over the last five trading days, and we believe the stock may.
- 02/26/2021
|
Abercrombie, Mattel, Western Digital and More Wednesday Afternoon Analyst Calls
- With the trading day more than halfway over, the broad markets have pushed higher, seemingly recovering from Tuesday.
- 02/24/2021
|
Why Emergent BioSolutions Stock Is Sliding Today
- An analyst downgraded the stock.
- 02/19/2021
|
Emergent (EBS) Beats on Q4 Earnings, Misses on Revenues
- Emergent's (EBS) earnings in the fourth quarter of 2020 beat estimates while revenues miss the same. Sales of contract development and manufacturing services rise.
- 02/19/2021
|
Emergent BioSolutions Inc. (EBS) CEO Bob Kramer on Q4 2020 Results - Earnings Call Transcript
- Emergent BioSolutions Inc. (EBS) CEO Bob Kramer on Q4 2020 Results - Earnings Call Transcript
- 02/18/2021
|
Emergent BioSolutions: Q4 Earnings Insights
- Shares of Emergent BioSolutions (NYSE:EBS) increased in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share rose 133.76% over the past year to $3.67, which beat the estimate of $3.19.
- 02/18/2021
|
Emergent BioSolutions Reports Financial Results for Fourth Quarter and Full Year 2020
- GAITHERSBURG, Md., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the quarter and year ended December 31, 2020. The Company also reaffirmed its full year 2021 forecast.
- 02/18/2021
|
Emergent BioSolutions to Release Fourth Quarter and Full Year 2020 Financial Results and Conduct a Conference Call on February 18, 2021
- GAITHERSBURG, Md., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, February 18, 2021 at 5:00 pm eastern time to discuss the financial results for the fourth quarter and full year 2020, recent business developments, financial outlook for full year 2021, and revenue guidance for the first quarter of 2021.
- 02/04/2021
|
Humanigen and Emergent BioSolutions Announce Contract Development and Manufacturing Agreement for Phase 3 COVID-19 Therapeutic Candidate Lenzilumab™
- GAITHERSBURG, Md. & BURLINGAME, Calif.--(BUSINESS WIRE)--Emergent BioSolutions Inc. (NYSE:EBS) (Emergent) and Humanigen, Inc. (NASDAQ:HGEN) (Humanigen) today announced that they have entered into a contract development and manufacturing (CDMO) services agreement to accelerate the drug product manufacturing of lenzilumab™, an anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody designed to prevent and treat an immune hyper-response called “cytokine storm.” Eme
- 01/25/2021
|
Emergent BioSolutions: Long-Term Thesis Remains Intact
- Emergent BioSolutions remains well insulated from peers, with key COVID-19 vaccine drivers and exposure to adjacent specialty markets in public crises prevention. Additional drivers in contract manufacturing continue to present for the company, which should contribute to revenue volumes in periods to come.
- 01/14/2021
|
Emergent Biosolutions CEO discusses role in helping to bring coronavirus vaccines to market
- Emergent Biosolutions CEO Bob Kramer joined Jim Cramer on "Mad Money" to give an update on the coronavirus vaccine manufacturing front.
- 01/11/2021
|
Emergent Biosolutions CEO gives assessment on Operation Warp Speed
- Emergent Biosolutions CEO Bob Kramer gave his thoughts on the results of Operation Warp Speed to help bring a coronavirus vaccine to market.
- 01/11/2021
|
Emergent (EBS) Posts Preliminary '20 Results, Gives 2021 View
- Emergent (EBS) tightens revenue view for 2020 and expects a consistent rise in sales of contract development and manufacturing services provided to other companies.
- 01/11/2021
|
Emergent BioSolutions Announces 2021 Financial Guidance, Provides Preliminary 2020 Results
- GAITHERSBURG, Md., Jan. 10, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced its financial forecast for 2021 and selected preliminary unaudited financial results for 2020.
- 01/10/2021
|
3 Reasons Why Growth Investors Shouldn't Overlook Emergent Biosolutions (EBS)
- Emergent Biosolutions (EBS) is well positioned to outperform the market, as it exhibits above-average growth in financials.
- 01/07/2021
|
Emergent Biosolutions (EBS) Outpaces Stock Market Gains: What You Should Know
- Emergent Biosolutions (EBS) closed the most recent trading day at $97.97, moving +1.01% from the previous trading session.
- 01/06/2021
|
Is Emergent Biosolutions (EBS) Outperforming Other Medical Stocks This Year?
- Is (EBS) Outperforming Other Medical Stocks This Year?
- 01/06/2021
|
Is Emergent BioSolutions Stock a Buy?
- This biotech is about to tackle an enormous market opportunity as coronavirus vaccines receive regulatory clearance.
- 01/05/2021
|
Emergent BioSolutions to Participate in Investor Conferences
- GAITHERSBURG, Md., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company's executive management team will participate in the following investor conferences in the first quarter of 2021:
- 01/04/2021
|
Emergent BioSolutions and Mount Sinai Health System Announce Initiation of DOD-Funded Clinical Program to Evaluate COVID-19 Human Hyperimmune Globulin (COVID-HIG) Product Candidate for Prophylaxis
- GAITHERSBURG, Md. and NEW YORK, Dec. 29, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE: EBS) and Mount Sinai Health System today announced initiation of the clinical program to evaluate Emergent's COVID-19 Human Hyperimmune Globulin (COVID-HIG) product candidate in the first of two Phase 1 studies to support its use for potential post-exposure prophylaxis in individuals at high risk of exposure to SARS-CoV-2, the virus that causes COVID-19, such as front-line health care workers and military personnel.
- 12/29/2020
|
3 Bargain Stocks You Can Buy Today
- Investors have been selling these stocks, but patient investors should take advantage of the opportunity.
- 11/27/2020
|
2 Pick-and-Shovel COVID Vaccine Stocks to Watch
- Could these stocks be winners regardless of which coronavirus vaccine comes out on top?
- 11/23/2020
|
Why Emergent BioSolutions Slipped on Friday
- While profitability came in above estimates, the company missed big on the top line.
- 11/06/2020
|
Emergent BioSolutions Inc. (EBS) CEO Bob Kramer on Q3 2020 Results - Earnings Call Transcript
- Emergent BioSolutions Inc. (EBS) CEO Bob Kramer on Q3 2020 Results - Earnings Call Transcript
- 11/05/2020
|
Emergent Biosolutions (EBS) Q3 Earnings Top Estimates
- Emergent Biosolutions (EBS) delivered earnings and revenue surprises of 6.83% and -14.75%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
- 11/05/2020
|
Emergent BioSolutions: Deep Value Play With 33% Upside & Military Exposure
- Emergent BioSolutions has key niche differentiators that strengthen the operating model, with exposure to defence & public health threats. They hold the only FDA approved anthrax vaccine in their portfolio, and ~60% of total revenues are backed by US Government contract agreements.
- 10/29/2020
|
Opinion | Joe Biden’s Me-Too Covid Plan
- A mask mandate aside, Trump is already doing what Joe recommends.
- 08/21/2020
|
FDA Nods to Emergent's (EBS) Narcan Shelf Life Extension
- Emergent's (EBS) Narcan nasal spray gets an FDA nod to extend its shelf life from two years to three years.
- 08/18/2020
|
Insider Sells Emergent BioSolutions Stock
- Shares of Emergent BioSolutions Inc (NYSE:EBS) fell by 3.5% from the previous closing price. Harsanyi Zsolt filed a Form 4 with the SEC on Tuesday, August 18. The insider sold 6,609 shares at an average price of $133.71. After the transaction, the executive's stake in Emergent BioSolutions Inc. moved to 24,579 shares.Why Insider Transactions Are Important? While transactions from an insider shouldn't be used as the sole item to make an investment or trading decision, an insider buying or selling stock in their company can be a good added factor that leads to more conviction in a decision.When an insider buys stock after an important sell off, that can indicate the insider's faith in the success of the organization. Henceforth, if the stock is bought at new highs, it might be because the insider feels that the stock is not overvalued. Insiders who sell stock at new lows could be anticipating some capitulation moment. If the insider sells at new highs, it could point to the intention to "take some profit" and "lock in a gain."Transaction Codes To Focus On Wall Street tends to focus on insider transactions which take place in the open market, viewed inside a Form 4 filing via codes P for purchase and S for sale. An open-market transaction means the insider went into the market of their own volition and made an active decision about the potential path for a company and its stock moving forward.Transaction codes other than P or S are often viewed with less conviction as they are often not tied to a decision by the exec. As an example, transaction code C indicates the conversion of an option. Transaction code A indicates the insider may have been forced to sell shares in order to receive compensation the exec was promised upon being hired by a company.See more from Benzinga * Stocks That Hit 52-Week Highs On Thursday * Stocks That Hit 52-Week Highs On Wednesday * Stocks That Hit 52-Week Highs On Tuesday(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- 08/18/2020
|
Emergent BioSolutions to Participate in Virtual Investor Conferences
- GAITHERSBURG, Md., Aug. 18, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company’s executive management team will participate in the following virtual investor conferences through the end of September 2020: * 2020 NYSE Healthcare & Technology Investor Access Day August 18 – virtual one-on-one meetings only * 2020 Three Part Advisors Virtual Midwest IDEAS Investor Conference August 27 – pre-recorded presentation available beginning at 8:00am eastern * 2020 Wells Fargo Virtual Healthcare Conference September 9 – presentation at 8:00am eastern * Robert W. Baird 2020 Global Healthcare Conference September 10 – presentation at 2:35pm eastern * Morgan Stanley 18th Annual Global Healthcare Conference 2020 September 14 – presentation at 4:30pm eastern * Cantor Virtual Global Healthcare Conference 2020 September 15 – presentation at 3:20pm eastern * 2020 Singular Research Compelling Values Webcall September 17 – presentation at 12:00pm easternFor conferences where a presentation is planned, the company’s webcast presentation may include a discussion of the company’s recent business developments as well as its financial results and guidance. The webcasts will be available both live, if possible, and by replay, and will be accessible from the Emergent website www.emergentbiosolutions.com under “Investors.”About Emergent BioSolutions Emergent BioSolutions is a global life sciences company whose mission is to protect and enhance life. Through our specialty products and contract development and manufacturing services, we are dedicated to providing solutions that address public health threats. Through social responsibility, we aim to build healthier and safer communities. We aspire to deliver peace of mind to our patients and customers so they can focus on what’s most important in their lives. In working together, we envision protecting or enhancing 1 billion lives by 2030. For more information visit www.emergentbiosolutions.com. Find us on LinkedIn and follow us on Twitter @emergentbiosolu and Instagram @life_at_emergent.Investor Contact: Robert G. Burrows Vice President, Investor Relations 240-631-3280 burrowsr@ebsi.com Media Contact: Miko B. Neri Senior Director, Global Communications & Public Affairs 240-631-3392 nerim@ebsi.com
- 08/18/2020
|
Insider Sells Emergent BioSolutions Stock
- Shares of Emergent BioSolutions Inc (NYSE:EBS) fell by 3.5% from the previous closing price. Harsanyi Zsolt filed a Form 4 with the SEC on Tuesday, August 18. The insider sold 6,...
- 08/18/2020
|
UPDATE -- Emergent BioSolutions Announces FDA Approval of NARCAN® (naloxone HCl) Nasal Spray Shelf Life Extension to 36 Months
- GAITHERSBURG, Md., Aug. 17, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that the U.S. Food and Drug Administration (FDA) has approved the extension of the shelf life of NARCAN® (naloxone HCl) Nasal Spray from 24 months to 36 months. Narcan Nasal Spray was the first intranasal form of naloxone approved by FDA and Health Canada for the emergency treatment of known or suspected opioid overdose. “Emergent is pleased to receive FDA approval of the shelf life extension for NARCAN® Nasal Spray,” said Doug White, SVP and devices business unit head at Emergent. “This is an example of our continued efforts to innovate and improve product features designed to address the needs of patients, consumers, health care providers, pharmacists, and first responders.”In early July, the company launched the Generation II NARCAN® Nasal Spray device, which is identified by a red plunger and enhances temperature excursions and storage below 25°C.About NARCAN® Nasal Spray 4mg NARCAN® Nasal Spray 4mg is the first FDA-approved, needle-free presentation of naloxone for the emergency treatment of a known or suspected opioid overdose. It does not require assembly or any specialized medical training and is also the highest concentrated dose of intranasal naloxone currently available. NARCAN® Nasal Spray is not a substitute for emergency medical care, and additional doses of NARCAN® Nasal Spray may be required until emergency medical assistance arrives. Seek emergency medical assistance immediately after initial use, keeping the patient under continued surveillance.Please see Indications and Important Safety Information below.INDICATION AND IMPORTANT SAFETY INFORMATION FOR NARCAN NASAL SPRAYWhat is NARCAN Nasal Spray? * NARCAN Nasal Spray is a prescription medicine used for the emergency treatment of a known or suspected opioid overdose emergency with signs of breathing problems and severe sleepiness or not being able to respond. * NARCAN Nasal Spray is to be given right away and does not take the place of emergency medical care. Get emergency medical help right away after giving the first dose of NARCAN Nasal Spray, even if the person wakes up.NARCAN Nasal Spray is safe and effective in children for known or suspected opioid overdose.Who should not use NARCAN Nasal Spray?Do not use NARCAN Nasal Spray if you are allergic to naloxone hydrochloride or any of the ingredients in NARCAN Nasal Spray.What is the most important information I should know about NARCAN Nasal Spray? NARCAN Nasal Spray is used to temporarily reverse the effects of opioid medicines. The medicine in NARCAN Nasal Spray has no effect in people who are not taking opioid medicines. Always carry NARCAN Nasal Spray with you in case of an opioid overdose. 1. Use NARCAN Nasal Spray right away if you or your caregiver think signs or symptoms of an opioid overdose are present, even if you are not sure, because an opioid overdose can cause severe injury or death. Signs and symptoms of an opioid overdose may include: * unusual sleepiness and you are not able to awaken the person with a loud voice or by rubbing firmly on the middle of their chest (sternum) * breathing problems including slow or shallow breathing in someone difficult to awaken or who looks like they are not breathing * the black circle in the center of the colored part of the eye (pupil) is very small, sometimes called "pinpoint pupils," in someone difficult to awaken 2. Family members, caregivers, or other people who may have to use NARCAN Nasal Spray in an opioid overdose should know where NARCAN Nasal Spray is stored and how to give NARCAN Nasal Spray before an opioid overdose happens. 3. Get emergency medical help right away after giving the first dose of NARCAN Nasal Spray. Rescue breathing or CPR (cardiopulmonary resuscitation) may be given while waiting for emergency medical help. 4. The signs and symptoms of an opioid overdose can return after NARCAN Nasal Spray is given. If this happens, give another dose after 2 to 3 minutes using a new NARCAN Nasal Spray device and watch the person closely until emergency help is received.What should I tell my healthcare provider before using NARCAN Nasal Spray?Before using NARCAN Nasal Spray, tell your healthcare provider about all of your medical conditions, including if you: * have heart problems * are pregnant or plan to become pregnant. Use of NARCAN Nasal Spray may cause withdrawal symptoms in your unborn baby. Your unborn baby should be examined by a healthcare provider right away after you use NARCAN Nasal Spray. * are breastfeeding or plan to breastfeed. It is not known if NARCAN Nasal Spray passes into your breast milk.Tell your healthcare provider about the medicines you take, including prescription and over-the-counter medicines, drugs, vitamins, and herbal supplements.What are the possible side effects of NARCAN Nasal Spray?NARCAN Nasal Spray may cause serious side effects, including:Sudden opioid withdrawal symptoms which can be severe. In someone who has been using opioids regularly, opioid withdrawal symptoms can happen suddenly after receiving NARCAN Nasal Spray and may include: • body aches • yawning • diarrhea • nausea or vomiting • increased heart rate • nervousness • fever • restlessness or irritability • runny nose • shivering or trembling • sneezing • stomach cramping • goose bumps • weakness • sweating • increased blood pressure Some patients may show aggressive behavior upon abrupt reversal of an opioid overdose.In infants under 4 weeks old who have been receiving opioids regularly, sudden opioid withdrawal may be life-threatening if not treated the right way. Signs and symptoms include: seizures, crying more than usual, and increased reflexes.These are not all of the possible side effects of NARCAN Nasal Spray. Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088 or http://www.fda.gov/medwatch.NNS CON ISI 07/2020Please see full Prescribing Information.For additional information on NARCAN® Nasal Spray, please visit www.NARCAN.com.About Emergent BioSolutions Emergent BioSolutions is a global life sciences company whose mission is to protect and enhance life. Through our specialty products and contract development and manufacturing services, we are dedicated to providing solutions that address public health threats. Through social responsibility, we aim to build healthier and safer communities. We aspire to deliver peace of mind to our patients and customers so they can focus on what’s most important in their lives. In working together, we envision protecting or enhancing 1 billion lives by 2030.Investor Contact: Robert G. Burrows Vice President, Investor Relations 240-631-3280 BurrowsR@ebsi.comMedia Contact: Miko B. Neri Senior Director, Global Communications & Public Affairs 240-631-3392 NeriM@ebsi.comEmergent BioSolutions®, NARCAN® and any and all Emergent BioSolutions Inc. brands, products, services and feature names, logos and slogans are trademarks or registered trademarks of Emergent BioSolutions Inc. or its subsidiaries in the United States or other countries. PP-NAR4-US-00362 Aug 2020
- 08/17/2020
|
Has Emergent Biosolutions (EBS) Outpaced Other Medical Stocks This Year?
- Is (EBS) Outperforming Other Medical Stocks This Year?
- 08/17/2020
|
Emergent BioSolutions Announces FDA Approval of NARCAN® (naloxone HCl) Nasal Spray Shelf Life Extension to 36 Months
- GAITHERSBURG, Md., Aug. 17, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that the U.S. Food and Drug Administration (FDA) has approved the extension of the shelf life of NARCAN® (naloxone HCl) Nasal Spray from 24 months to 36 months. Narcan Nasal Spray was the first intranasal form of naloxone approved by FDA and Health Canada for the emergency treatment of known or suspected opioid overdose. “Emergent is pleased to receive FDA approval of the shelf life extension for NARCAN® Nasal Spray,” said Doug White, SVP and devices business unit head at Emergent. “This is an example of our continued efforts to innovate and improve product features designed to address the needs of patients, consumers, health care providers, pharmacists, and first responders.”In early July, the company launched the Generation II NARCAN® Nasal Spray device, which is identified by a red plunger and enhances temperature excursions and storage below 25°C.About NARCAN® Nasal Spray 4mg NARCAN® Nasal Spray 4mg is the first and only FDA-approved, needle-free presentation of naloxone for the emergency treatment of a known or suspected opioid overdose. It does not require assembly or any specialized medical training and is also the highest concentrated dose of intranasal naloxone currently available. NARCAN® Nasal Spray is not a substitute for emergency medical care, and additional doses of NARCAN® Nasal Spray may be required until emergency medical assistance arrives. Seek emergency medical assistance immediately after initial use, keeping the patient under continued surveillance.Please see Indications and Important Safety Information below.INDICATION AND IMPORTANT SAFETY INFORMATION FOR NARCAN NASAL SPRAYWhat is NARCAN Nasal Spray? * NARCAN Nasal Spray is a prescription medicine used for the emergency treatment of a known or suspected opioid overdose emergency with signs of breathing problems and severe sleepiness or not being able to respond. * NARCAN Nasal Spray is to be given right away and does not take the place of emergency medical care. Get emergency medical help right away after giving the first dose of NARCAN Nasal Spray, even if the person wakes up.NARCAN Nasal Spray is safe and effective in children for known or suspected opioid overdose.Who should not use NARCAN Nasal Spray?Do not use NARCAN Nasal Spray if you are allergic to naloxone hydrochloride or any of the ingredients in NARCAN Nasal Spray.What is the most important information I should know about NARCAN Nasal Spray? NARCAN Nasal Spray is used to temporarily reverse the effects of opioid medicines. The medicine in NARCAN Nasal Spray has no effect in people who are not taking opioid medicines. Always carry NARCAN Nasal Spray with you in case of an opioid overdose. 1. Use NARCAN Nasal Spray right away if you or your caregiver think signs or symptoms of an opioid overdose are present, even if you are not sure, because an opioid overdose can cause severe injury or death. Signs and symptoms of an opioid overdose may include: * unusual sleepiness and you are not able to awaken the person with a loud voice or by rubbing firmly on the middle of their chest (sternum) * breathing problems including slow or shallow breathing in someone difficult to awaken or who looks like they are not breathing * the black circle in the center of the colored part of the eye (pupil) is very small, sometimes called "pinpoint pupils," in someone difficult to awaken 2. Family members, caregivers, or other people who may have to use NARCAN Nasal Spray in an opioid overdose should know where NARCAN Nasal Spray is stored and how to give NARCAN Nasal Spray before an opioid overdose happens. 3. Get emergency medical help right away after giving the first dose of NARCAN Nasal Spray. Rescue breathing or CPR (cardiopulmonary resuscitation) may be given while waiting for emergency medical help. 4. The signs and symptoms of an opioid overdose can return after NARCAN Nasal Spray is given. If this happens, give another dose after 2 to 3 minutes using a new NARCAN Nasal Spray device and watch the person closely until emergency help is received.What should I tell my healthcare provider before using NARCAN Nasal Spray?Before using NARCAN Nasal Spray, tell your healthcare provider about all of your medical conditions, including if you: * have heart problems * are pregnant or plan to become pregnant. Use of NARCAN Nasal Spray may cause withdrawal symptoms in your unborn baby. Your unborn baby should be examined by a healthcare provider right away after you use NARCAN Nasal Spray. * are breastfeeding or plan to breastfeed. It is not known if NARCAN Nasal Spray passes into your breast milk.Tell your healthcare provider about the medicines you take, including prescription and over-the-counter medicines, drugs, vitamins, and herbal supplements.What are the possible side effects of NARCAN Nasal Spray?NARCAN Nasal Spray may cause serious side effects, including:Sudden opioid withdrawal symptoms which can be severe. In someone who has been using opioids regularly, opioid withdrawal symptoms can happen suddenly after receiving NARCAN Nasal Spray and may include: • body aches • yawning • diarrhea • nausea or vomiting • increased heart rate • nervousness • fever • restlessness or irritability • runny nose • shivering or trembling • sneezing • stomach cramping • goose bumps • weakness • sweating • increased blood pressure Some patients may show aggressive behavior upon abrupt reversal of an opioid overdose.In infants under 4 weeks old who have been receiving opioids regularly, sudden opioid withdrawal may be life-threatening if not treated the right way. Signs and symptoms include: seizures, crying more than usual, and increased reflexes.These are not all of the possible side effects of NARCAN Nasal Spray. Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088 or http://www.fda.gov/medwatch.NNS CON ISI 07/2020Please see full Prescribing Information.For additional information on NARCAN® Nasal Spray, please visit www.NARCAN.com.About Emergent BioSolutions Emergent BioSolutions is a global life sciences company whose mission is to protect and enhance life. Through our specialty products and contract development and manufacturing services, we are dedicated to providing solutions that address public health threats. Through social responsibility, we aim to build healthier and safer communities. We aspire to deliver peace of mind to our patients and customers so they can focus on what’s most important in their lives. In working together, we envision protecting or enhancing 1 billion lives by 2030.Investor Contact: Robert G. Burrows Vice President, Investor Relations 240-631-3280 BurrowsR@ebsi.comMedia Contact: Miko B. Neri Senior Director, Global Communications & Public Affairs 240-631-3392 NeriM@ebsi.comEmergent BioSolutions®, NARCAN® and any and all Emergent BioSolutions Inc. brands, products, services and feature names, logos and slogans are trademarks or registered trademarks of Emergent BioSolutions Inc. or its subsidiaries in the United States or other countries. PP-NAR4-US-00362 Aug 2020
- 08/17/2020
|
Emergent BioSolutions Could See Further Upside Gains
- Most of the indicators are still bullish in this name, although some profit-taking may be occurring.
- 08/13/2020
|
Indian drugmaker Biological E. to make substance used in J&J's potential COVID-19 vaccine
|
Did Hedge Funds Make The Right Call On Emergent Biosolutions Inc (EBS) ?
- We know that hedge funds generate strong, risk-adjusted returns over the long run, which is why imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors. With billions of dollars in assets, professional investors have to conduct complex analyses, spend many resources and use tools that are not […]
- 08/12/2020
|
Emergent BioSolutions Announces Successful Completion of Offering of 3.875% Senior Unsecured Notes Due 2028
- GAITHERSBURG, Md., Aug. 07, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) (the “Company”) announced today that it has completed its previously announced offering of $450 million in aggregate principal amount of its 3.875% Senior Unsecured Notes due 2028 (the “Notes”). The Notes are fully and unconditionally guaranteed on a senior unsecured basis by all of the Company’s direct and indirect subsidiaries that guarantee debt under its credit facilities. The Company has used the net proceeds of the offering to repay the $353 million outstanding under its $600 million revolving credit facility with the remainder to be used for general corporate purposes.The Notes were offered in the United States to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”), and outside the United States pursuant to Regulation S under the Securities Act. The Notes were not registered under the Securities Act and may not be offered or sold in the United States except pursuant to an exemption from the registration requirements of the Securities Act and applicable state securities laws.This press release is neither an offer to sell nor the solicitation of an offer to buy the Notes or any other securities, and there shall not be any offer to sell, solicitation of an offer to buy or sale of the Notes in any jurisdiction in which, or to any person to whom, such an offer, solicitation or sale is unlawful. Any offers of the Notes will be made only by means of an offering memorandum.About Emergent BioSolutions Emergent BioSolutions is a global life sciences company whose mission is to protect and enhance life. Through our specialty products and contract development and manufacturing services, we are dedicated to providing solutions that address public health threats. Through social responsibility, we aim to build healthier and safer communities. We aspire to deliver peace of mind to our patients and customers so they can focus on what’s most important in their lives. In working together, we envision protecting or enhancing 1 billion lives by 2030.Safe Harbor Statement This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, including statements regarding the intended use of proceeds, are forward-looking statements. We generally identify forward-looking statements by using words like "will," "believes," "expects," "anticipates," "intends," "plans," "forecasts," "estimates" and similar expressions. These forward-looking statements are based on our current intentions, beliefs and expectations regarding future events. We cannot guarantee that any forward-looking statement will be accurate. Investors should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could differ materially from our expectations. Investors are, therefore, cautioned not to place undue reliance on any forward-looking statement. Any forward-looking statement speaks only as of the date of this press release, and, except as required by law, we do not undertake to update any forward-looking statement to reflect new information, events or circumstances.There are a number of important factors that could cause our actual results to differ materially from those indicated by such forward-looking statements. In addition, new factors that could cause actual results to differ from our expectations emerge from time to time and it is not possible for management to predict all such factors, nor can it assess the impact of any such factor on the business or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward-looking statement. Investors should consider this cautionary statement as well as the risk factors identified in our periodic reports filed with the Securities and Exchange Commission when evaluating our forward-looking statements.Investor Contact: Robert G. Burrows Vice President, Investor Relations 240-631-3280 BurrowsR@ebsi.comMedia Contact: Miko B. Neri Senior Director, Global Communications & Public Affairs 240-631-3392 NeriM@ebsi.com
- 08/07/2020
|
Clovis (CLVS) Q2 Earnings Lag, Revenues Show Coronavirus Impact
- Clovis (CLVS) reports dismal second-quarter 2020 results. Sales of the company's sole marketed drug, Rubraca, decline sequentially. Shares down.
- 08/07/2020
|
Top Ranked Momentum Stocks to Buy for August 7th
- Top Ranked Momentum Stocks to Buy for August 7th
- 08/07/2020
|
Coronavirus Pandemic Fuels Big Gains In Biotech Stocks; Too Extended To Buy?
- Biotech stocks make headlines on an almost daily basis as the world rushes to find a coronavirus treatment or vaccine.
- 08/07/2020
|
The Daily Biotech Pulse: Novavax Vaccine Deals, Trevena Awaits FDA Decision, 2 IPOs
- Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 6)
ADiTx Therapeutics Inc (NASDAQ: ADTX) (announced introduction of AditxtScore for COVID-19 to be used in detecting...
- 08/07/2020
|
Emergent BioSolutions: The Indirect COVID-19 Vaccine Play Looks Undervalued (NYSE:EBS)
- The manufacturing deals for candidates set the stage for Emergent to ride the momentum of COVID-19 vaccine development.
- 08/06/2020
|
Emergent Biosolutions (EBS) is an Incredible Growth Stock: 3 Reasons Why
- Emergent Biosolutions (EBS) could produce exceptional returns because of its solid growth attributes.
- 08/06/2020
|
Emergent BioSolutions' Shares March Higher, Can It Continue?
- As of late, it has definitely been a great time to be an investor in Emergent BioSolutions.
- 08/06/2020
|
The Daily Biotech Pulse: FDA Nod For GlaxoSmithKline, Bristol-Myers Squibb Earnings, Acutus Medical IPO
- Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 5)
ABIOMED, Inc. (NASDAQ: ABMD)
Aerpio Pharmaceuticals Inc (NASDAQ: ARPO) (announced a U.S. government grant for a...
- 08/06/2020
|
Emergent BioSolutions Inc. -- Moody's assigns Ba2 CFR to Emergent BioSolutions
- Moody's Investors Service ("Moody's") assigned first-time ratings to Emergent BioSolutions Inc. ("Emergent") including a Ba2 Corporate Family Rating, a Ba2-PD Probability of Default Rating, a Ba3 senior unsecured rating, and an SGL-1 Speculative Grade Liquidity Rating. Emergent's Ba2 Corporate Family Rating reflects its niche position developing and manufacturing products that treat public health threats.
- 08/05/2020
|
Emergent BioSolutions Announces Upsize and Pricing of $450 Million of 3.875% Senior Unsecured Notes Due 2028
- GAITHERSBURG, Md., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) (the “Company”) announced today that it has priced its offering of $450 million aggregate principal amount of 3.875% Senior Unsecured Notes due 2028 (the “Notes”), representing an increase of $50 million in aggregate principal amount from the initially proposed offering size. The Notes will be fully and unconditionally guaranteed on a senior unsecured basis by all of the Company’s direct and indirect subsidiaries that guarantee debt under its credit facilities. The Company intends to use the net proceeds of the offering to repay the $353 million outstanding under its $600 million revolving credit facility with the remainder to be used for general corporate purposes. The offering is expected to close on August 7, 2020, subject to customary closing conditions.The Notes are being offered in the United States to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”), and outside the United States pursuant to Regulation S under the Securities Act.The Notes have not been registered under the Securities Act and may not be offered or sold in the United States except pursuant to an exemption from the registration requirements of the Securities Act and applicable state securities laws. This notice is being issued pursuant to and in accordance with Rule 135c under the Securities Act.This press release is neither an offer to sell nor the solicitation of an offer to buy the Notes or any other securities, and there shall not be any offer to sell, solicitation of an offer to buy or sale of the Notes in any jurisdiction in which, or to any person to whom, such an offer, solicitation or sale is unlawful. Any offers of the Notes will be made only by means of an offering memorandum.About Emergent BioSolutions Emergent BioSolutions is a global life sciences company whose mission is to protect and enhance life. Through our specialty products and contract development and manufacturing services, we are dedicated to providing solutions that address public health threats. Through social responsibility, we aim to build healthier and safer communities. We aspire to deliver peace of mind to our patients and customers so they can focus on what’s most important in their lives. In working together, we envision protecting or enhancing 1 billion lives by 2030.Safe Harbor Statement This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, including statements regarding the anticipated completion of the sale and issuance of the Notes and the intended use of proceeds, are forward-looking statements. We generally identify forward-looking statements by using words like "will," "believes," "expects," "anticipates," "intends," "plans," "forecasts," "estimates" and similar expressions. These forward-looking statements are based on our current intentions, beliefs and expectations regarding future events. We cannot guarantee that any forward-looking statement will be accurate. Investors should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could differ materially from our expectations. Investors are, therefore, cautioned not to place undue reliance on any forward-looking statement. Any forward-looking statement speaks only as of the date of this press release, and, except as required by law, we do not undertake to update any forward-looking statement to reflect new information, events or circumstances.There are a number of important factors that could cause our actual results to differ materially from those indicated by such forward-looking statements, including the uncertainties related to market conditions, the satisfaction of closing conditions and the completion of the sale and issuance of the Notes on the anticipated terms or at all. In addition, new factors that could cause actual results to differ from our expectations emerge from time to time and it is not possible for management to predict all such factors, nor can it assess the impact of any such factor on the business or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward-looking statement. Investors should consider this cautionary statement as well as the risk factors identified in our periodic reports filed with the Securities and Exchange Commission when evaluating our forward-looking statements.Investor Contact: Robert G. Burrows Vice President, Investor Relations 240-631-3280 BurrowsR@ebsi.com Media Contact: Miko B. Neri Senior Director, Global Communications & Public Affairs 240-631-3392 NeriM@ebsi.com
- 08/04/2020
|
Lion Biotechnologies Reaches 80-Plus Relative Strength Rating Benchmark
- One important metric to look for in a stock is an 80 or higher Relative Strength Rating. When you're researching the best stocks to buy and watch, be sure to pay attention to relative price strength.
- 08/04/2020
|
Emergent BioSolutions Announces Proposed Offering of $400 Million of Senior Unsecured Notes
- GAITHERSBURG, Md., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) (the “Company”) announced today that it intends to offer $400 million aggregate principal amount of senior unsecured notes with an expected maturity date of August 2028 (the “Notes”). The Notes will be fully and unconditionally guaranteed on a senior unsecured basis by all of the Company’s direct and indirect subsidiaries that guarantee debt under its credit facilities. The Company intends to use the net proceeds of the offering to repay the $353 million outstanding under its $600 million revolving credit facility with the remainder to be used for general corporate purposes. The Notes will be offered in the United States to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”), and outside the United States pursuant to Regulation S under the Securities Act. The Notes have not been registered under the Securities Act and may not be offered or sold in the United States except pursuant to an exemption from the registration requirements of the Securities Act and applicable state securities laws. This notice is being issued pursuant to and in accordance with Rule 135c under the Securities Act.This press release is neither an offer to sell nor the solicitation of an offer to buy the Notes or any other securities, and there shall not be any offer to sell, solicitation of an offer to buy or sale of Notes in any jurisdiction in which, or to any person to whom, such an offer, solicitation or sale is unlawful. Any offers of the Notes will be made only by means of an offering memorandum.About Emergent BioSolutions Emergent BioSolutions is a global life sciences company whose mission is to protect and enhance life. Through our specialty products and contract development and manufacturing services, we are dedicated to providing solutions that address public health threats. Through social responsibility, we aim to build healthier and safer communities. We aspire to deliver peace of mind to our patients and customers so they can focus on what’s most important in their lives. In working together, we envision protecting or enhancing 1 billion lives by 2030.Safe Harbor Statement This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, including statements regarding the anticipated completion of the sale and issuance of the Notes and the intended use of proceeds, are forward-looking statements. We generally identify forward-looking statements by using words like "will," "believes," "expects," "anticipates," "intends," "plans," "forecasts," "estimates" and similar expressions. These forward-looking statements are based on our current intentions, beliefs and expectations regarding future events. We cannot guarantee that any forward-looking statement will be accurate. Investors should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could differ materially from our expectations. Investors are, therefore, cautioned not to place undue reliance on any forward-looking statement. Any forward-looking statement speaks only as of the date of this press release, and, except as required by law, we do not undertake to update any forward-looking statement to reflect new information, events or circumstances.There are a number of important factors that could cause our actual results to differ materially from those indicated by such forward-looking statements, including the uncertainties related to market conditions, the satisfaction of closing conditions and the completion of the sale and issuance of the Notes on the anticipated terms or at all. In addition, new factors that could cause actual results to differ from our expectations emerge from time to time and it is not possible for management to predict all such factors, nor can it assess the impact of any such factor on the business or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward-looking statement. Investors should consider this cautionary statement as well as the risk factors identified in our periodic reports filed with the Securities and Exchange Commission when evaluating our forward-looking statements.Investor Contact: Robert G. Burrows Vice President, Investor Relations 240-631-3280 BurrowsR@ebsi.comMedia Contact: Miko B. Neri Senior Director, Global Communications & Public Affairs 240-631-3392 NeriM@ebsi.com
- 08/04/2020
|
The Daily Biotech Pulse: Voyager, AbbVie End Collaboration, Thumbs Down For DBV's Peanut Allergy Patch, Tiziana Expedites COVID-19 Trial Plans
- Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 3)
ABIOMED, Inc. (NASDAQ: ABMD)
ALX Oncology Holdings Inc (NASDAQ: ALXO)
Annexon Inc (NASDAQ: ANNX)
Atossa...
- 08/04/2020
|
Jim Cramer: 'Stop saying the market makes no sense'
- "When the pandemic's out of control, you better believe the Cramer Covid-19 Index will lead us higher," CNBC's Jim Cramer said.
- 08/03/2020
|
Composite Rating For Emergent Biosolutions Rises To 99
- Emergent Biosolutions saw its IBD SmartSelect Composite Rating jump to 99 Monday, up from 94 the day before. The upgrade means the stock currently tops 99% of all other stocks in terms of key performance metrics and technical strength.
- 08/03/2020
|
Emergent Biosolutions (NYSE:EBS) Sets New 52-Week High After Strong Earnings
- Emergent Biosolutions Inc (NYSE:EBS) hit a new 52-week high during mid-day trading on Friday following a stronger than expected earnings report. The stock traded as high as $114.13 and last traded at $108.02, with a volume of 27454 shares. The stock had previously closed at $97.02. The biopharmaceutical company reported $1.98 earnings per share (EPS) […]
- 08/02/2020
|
Emergent Biosolutions CEO: 'hyperfocused' on manufacturing COVID-19 vaccine candidates
- Emergent Biosolutions CEO Bob Kramer joins Yahoo Finance Akiko Fujita to discuss the company's earnings results and his outlook on developing a coronavirus vaccine.
- 07/31/2020
|
Emergent (EBS) Beats Q2 Earnings Estimates, Ups '20 Guidance
- Emergent's (EBS) second-quarter earnings beat estimates on robust product sales. Concurrently, it increases its annual guidance.
- 07/31/2020
|
Here's Why Emergent BioSolutions Stock Jumped Today
- The expert in bioterrorism and emerging infectious diseases had a great second quarter, with more to come.
- 07/31/2020
|
Emergent BioSolutions Inc (EBS) Q2 2020 Earnings Call Transcript
- EBS earnings call for the period ending June 30, 2020.
- 07/31/2020
|
The Daily Biotech Pulse: Sanofi-GSK Land $2.1B Funding For Coronavirus Vaccine, D-Day For GW Pharma, FDA Nod For Roche
- Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 30)
Achieve Life Sciences Inc (NASDAQ: ACHV)
Annexon Inc (NASDAQ: ANNX) (IPOed July 24)
Atossa Therapeutics...
- 07/31/2020
|
Emergent BioSolutions, Inc. (EBS) CEO Bob Kramer on Q2 2020 Results - Earnings Call Transcript
- Emergent BioSolutions, Inc. (NYSE:EBS) Q2 2020 Earnings Conference Call July 30, 2020 17:00 ET Company Participants Bob Burrows - Vice President, Investor Relations Bob Kramer - President & Chief Executive Officer Rich Lindahl - Chief Financial Officer Syed Husain - Senior Vice President & Head of CDMO Business Unit Doug White - Senior Vice President, Devices Business Unit Head Conference Call Participants Brandon Folkes - Cantor Fitzgerald Jacob Hughes - Wells Fargo Devin Geiman - Guggenheim Keay Nakae - Chardan Lisa Springer - Singular Research Presentation Operator Ladies and gentlemen, thank you for standing by and welcome to the Emergent BioSolutions Q2 Earnings Conference Call.
- 07/30/2020
|
Emergent BioSolutions Reports Financial Results for Second Quarter and Six Months Ended June 30, 2020 and Revises Upward Full Year 2020 Guidance
- * Establishes key collaborations with industry, U.S. government, and health care providers to help advance COVID-19 vaccine and therapeutic solutions * Current quarter and year-to-date performance reflect strength of core medical countermeasure business and increased impact of CDMO businessGAITHERSBURG, Md., July 30, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the three and six months ended June 30, 2020 and revised upward full year 2020 guidance.“While we mobilize to meet the threat presented by COVID-19, we are also successfully delivering on our long-term strategy,” said Robert G. Kramer Sr., president and chief executive officer of Emergent BioSolutions. “Our decades of experience in addressing public health threats have prepared us to do both these things well, ensuring that we are staying true to our mission to protect and enhance life.”FINANCIAL HIGHLIGHTS (unaudited)(in millions)Q2 2020Q2 2019$ Change% Change Total Revenues$394.7$243.2 $151.562.3% Net Income (Loss)$92.7$(9.5)$102.2* Adjusted Net Income (1)$105.7$10.2 $95.5* Adjusted EBITDA (1)$156.1$29.4 $126.7431.0% (in millions)YTD 2020YTD 2019$ Change% Change Total Revenues$587.2$433.9 $153.335.3% Net Income (Loss)$80.2$(35.6)$115.8325.3% Adjusted Net Income (1)$106.0$4.8 $101.2* Adjusted EBITDA (1)$171.4$37.6 $133.8355.9% * % change is greater than 500% Q2 2020 AND OTHER RECENT BUSINESS ACCOMPLISHMENTS * Awarded landmark public-private contract development and manufacturing (CDMO) partnership task order by the U.S. Department of Health and Human Services (HHS) under Operation Warp Speed valued at approximately $628 million for production of leading pharmaceutical and biotechnology innovators’ COVID-19 vaccine candidates through 2021 and viral drug product capacity expansion at the Company’s Rockville, Maryland facility * Signed five-year large-scale drug substance manufacturing agreement for Johnson & Johnson’s lead COVID-19 vaccine candidate beginning in 2021, valued at approximately $480 million for the first two years; follows initial agreement, valued at approximately $135 million, to provide CDMO services and secure large-scale manufacturing capacity * Signed three-year large-scale drug substance manufacturing agreement for AstraZeneca’s COVID-19 vaccine candidate, valued at approximately $174 million through 2021; follows initial agreement, valued at approximately $87 million, to provide CDMO services and secure large-scale manufacturing capacity * Awarded $34.6 million by the U.S. Department of Defense Joint Program Executive Office and formed collaboration with Mount Sinai Health System and ImmunoTek Bio Centers to advance the Company’s COVID- Human Immune Globulin (COVID-HIG) therapeutic candidate for potential post-exposure prophylaxis in populations at high risk of COVID-19 * Announced contract option valued at $258 million exercised by HHS to continue to procure AV7909 (Anthrax Vaccine Adsorbed, Adjuvanted) for delivery into the U.S. Strategic National Stockpile (SNS) over 12 months * Announced contract option valued at $176 million exercised by HHS to continue to procure ACAM2000® (Smallpox (Vaccinia) Vaccine, Live) for delivery into the SNS over 12 months * Executed contract option valued at $54 million exercised by HHS to continue to procure VIGIV [Vaccinia Immune Globulin Intravenous (Human)] for delivery into the SNS over 12 months * Announced a $75 million CDMO investment in the Company’s Canton, Massachusetts facility and drug substance expansion into viral vector and gene therapy, expected to be available in Q2 20232020 FINANCIAL PERFORMANCE (unaudited)(I) Quarter Ended June 30, 2020 (Q2) RevenuesTotal RevenuesFor Q2 2020, total revenues were $394.7 million, an increase of $151.5 million over 2019. Total revenues reflect an increase in product sales and contract development and manufacturing services revenues partially offset by a decrease in contracts and grants revenues.Product SalesFor Q2 2020, product sales were $298.5 million, an increase of $115.0 million or 63% as compared to 2019. The change primarily reflects increased sales of anthrax vaccines and ACAM2000 offset by a decrease in Other, specifically sales of raxibacumab and travel health vaccines. (in millions)Three Months Ended June 30, 2020 2019% Change Product Sales NARCAN Nasal Spray$72.8$73.0—% ACAM2000$70.0$6.5NM Anthrax vaccines$132.3$28.0NM Other$23.4$76.0(69)% Total Product Sales$298.5$183.563% Contract Development and Manufacturing Services (CDMO)For Q2 2020, revenue from the Company’s contract development and manufacturing operations was $72.6 million, an increase of $53.9 million as compared to 2019. The increase is largely due to the contribution of recently announced arrangements across development services, drug substance, and drug product with industry and government, most notably the Company's landmark public-private CDMO partnership with BARDA in support of the U.S. government's Operation Warp Speed Program.Contracts and GrantsFor Q2 2020, revenue from the Company’s development-based contracts and grants was $23.6 million, a decrease of $17.4 million as compared to 2019. The decrease primarily reflects the completion of development activities associated with the AV7909 product candidate in 2019, partially offset by recent new development awards related to the COVID-HIG product candidate during the current quarter.Operating ExpensesCost of Product Sales and Contract Development and Manufacturing ServicesFor Q2 2020, cost of product sales and contract development and manufacturing services was $129.8 million, an increase of $29.0 million or 29% as compared to 2019. The increase is primarily due to the increase in volume of product sales and CDMO services and an increase in share-based compensation expense due to a special broad-based, immediately vested equity award to employees.Research and Development (Gross and Net)For Q2 2020, gross R&D expenses were $47.9 million, a decrease of $16.0 million or 25% as compared to 2019. The decrease primarily reflects a decline in costs associated with the Company’s AV7909 product candidate and FLU-IGIV product candidate partially offset by an increase in costs associated with the Company’s chikungunya product candidate. During 2019, the Company completed its development activities for AV7909.For Q2 2020, net R&D expense, which reflects investments made in development programs that are not currently funded in whole or in part by third-party partners and is calculated as gross research and development expenses minus contracts and grants revenue, was $24.3 million, a decrease of $1.4 million or 6% as compared to 2019. The decrease is attributable to a decline in costs associated with the Company’s FLU-IGIV product candidate partially offset by an increase in costs associated with the Company’s chikungunya product candidate. The Q2 2020 and Q2 2019 net R&D expense was 7% and 11%, respectively, of adjusted revenue (total revenue less contracts & grants). (in millions)Three Months Ended June 30, 20202019% Change Research and Development Expenses$47.9$63.9(25)% Adjustments: Less Contracts and Grants Revenue$23.6$41.0(42)% Net Research and Development Expenses$24.3$22.96% Adjusted Revenue (Total Revenue less Contracts and Grants Revenue)$371.1$202.284% Net R&D as % of Adjusted Revenue (Net R&D Margin)7%11%NA Selling, General and AdministrativeFor Q2 2020, selling, general and administrative expenses were $76.0 million, an increase of $5.2 million or 7% as compared to 2019. The increase primarily reflects an increase in share-based compensation due to a special broad-based, immediately vested equity award to employees as well as staffing costs to support the Company's growth.Amortization of Intangible AssetsFor Q2 2020, amortization of intangible assets was $15.0 million, which was consistent with amortization of intangible assets of $14.7 million in Q2 2019.Income TaxesFor Q2 2020, the income tax provision in the amount of $28.0 million increased due to the Company being in a net income position as compared to a net loss position during Q2 2019.Net Income (Loss) & Adjusted Net IncomeFor Q2 2020, the Company recorded net income of $92.7 million, or $1.73 per diluted share, versus a net loss of $9.5 million, or $(0.18) per diluted share, in 2019.For Q2 2020, the Company recorded adjusted net income of $105.7 million, or $1.98 per diluted share, versus an adjusted net income of $10.2 million, or $0.20 per diluted share, in 2019. (1)Adjusted EBITDAFor Q2 2020, the Company recorded adjusted EBITDA of $156.1 million versus $29.4 million in 2019. (1)(II) Six months ended June 30, 2020 (unaudited)RevenuesTotal RevenuesFor the six months ended June 30, 2020, total revenues were $587.2 million, an increase of 35% over 2019. Total revenues reflect an increase in product sales and contract development and manufacturing services offset by a decline in contracts and grants.Product SalesFor the six months ended June 30, 2020, product sales were $446.7 million, an increase of $110.2 million or 33% as compared to 2019. The increase primarily reflects sales of anthrax vaccines, offset by decreased sales of raxibacumab and travel health vaccines reflected in Other below. (in millions)Six Months Ended June 30, 2020 2019% Change Product Sales NARCAN Nasal Spray$145.0$138.55% ACAM2000$70.0$52.035% Anthrax vaccines$184.2$39.6NM Other$47.5$106.4(55)% Total Product Sales$446.7$336.533% Contract Development and Manufacturing Services (CDMO) For the six months ended June 30, 2020, revenue from the Company’s contract development and manufacturing services operations was $94.3 million, an increase of $59.7 million or 173% as compared to 2019.
- 07/30/2020
|
Drugmakers Race to Build Covid-19 Vaccine Supply Chains
- Pharmaceutical companies that are racing to develop a vaccine for the coronavirus are already working behind the scenes to build the supply chains needed to deliver the drug to billions of people as rapidly as possible.
- 07/30/2020
|
The Daily Biotech Pulse: Bristol-Myers, Bluebird Bio Resubmit Multiple Myeloma Drug BLA, FSD To Close Medicinal Cannabis Business, Hologic's Blowout Quarter
- Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 29)
Abbott Laboratories (NYSE: ABT)
ABIOMED, Inc. (NASDAQ: ABMD)
Adamis Pharmaceuticals Corp (NASDAQ: ADMP)
Annexon...
- 07/30/2020
|
The Race To Erase COVID-19
- As new COVID-19 cases both in the US and globally continue to rise, four leading biotech companies with competing technology offerings race to bring about a medical solution.
- 07/29/2020
|
Is Emergent Biosolutions (EBS) Outperforming Other Medical Stocks This Year?
- Is (EBS) Outperforming Other Medical Stocks This Year?
- 07/28/2020
|
Emergent Signs $174M Manufacturing Deal For AstraZeneca’s Covid-19 Candidate
- Emergent BioSolutions Inc. (EBS) has signed a $174 million deal to provide contract development and manufacturing for AstraZeneca’s (AZN) COVID-19 vaccine candidate, AZD1222.As part of the agreement, Emergent will start this year to produce drug substance at large scale for commercial supply. The contract valid until 2021, follows a $87 million contract in June, which Emergent signed for the development of AstraZeneca’s vaccine candidate. Together the agreements bring AstraZeneca’s commitment to a total of $261 million.AstraZeneca, which is developing AZD1222 together with Oxford University, has in recent weeks signed supply chain agreements for the capacity to produce 2 billion doses of its vaccine candidate. The British drugmaker has inked supply deals with the U.S. and European Union countries.“Emergent is driven by our desire to advance solutions that will make an impact on this pandemic,” said Emergent CEO Robert G. Kramer. “Sharing a passion for science, we are encouraged by AstraZeneca’s investigational COVID-19 vaccine and look forward to supporting its continued progress.”Manufacturing activities under the latest agreement will be performed at Emergent’s Baltimore Bayview facility. The facility is designed for rapid manufacturing of large quantities of vaccines and treatments during public health emergencies. It has the capacity to produce tens to hundreds of millions of doses of vaccine on an annual basis, based upon the platform technology being used.AstraZeneca’s AZD1222 is one of several vaccine candidates supported by Operation Warp Speed (OWS), the U.S. government program to accelerate the development, manufacturing, and distribution of COVID-19 vaccines available for Americans by Jan. 2021.Emergent said that it will provide an update to its 2020 financial outlook incorporating expectations related to this agreement when it reports its second-quarter financial results on July 30.Shares in Emergent rose 5.5% to $94.78 at the close on Monday taking this year’s advance to an impressive 76%.Chardan Capital analyst Keay Nakae last month reiterated a Buy rating on the stock with a $86 price target.“We believe that the company has established itself as a preferred supplier of biodefense vaccines and other products to the U.S. government under multiyear sales contracts,” Nakae wrote in a note to investors. “The company’s ability to land several new manufacturing contracts since the beginning of this year is just another example of one of Emergent's key strengths, its longstanding relationships with the relevant government agencies.”The rest of the Street resonates with Nakae’s bullish outlook. The Strong Buy analyst consensus boasts 4 Buy ratings versus 1 Hold rating. Meanwhile, the $90.60 average analyst price target implies 4.4% downside potential for the shares in the next 12 months. (See EBS stock analysis on TipRanks).Related News: Pfizer, BioNTech Rise As Phase 2/3 Covid-19 Vaccine Trial Kicks Off AstraZeneca To Pay Up To $6B For Daiichi Cancer Drug Deal Novartis Unveils €150M Antibiotics Investment For Europe More recent articles from Smarter Analyst: * Walgreens Drops After CEO Steps Down * Kinder Morgan To Raise $1.25B From Bond Sale To Repay Debt Early * Kontoor Pops 11% As Goldman Flips From Bear To Bull * Chi-Med, Eli Lilly Link Up For Commercializing Elunate In China
- 07/28/2020
|
Biotech Bonanza - Second Half Outlook
- Biotech is one of the rare industries whose prospects have improved as the year has progressed. A low interest rate environment, a less hostile regulatory environment, and strong investor interest creates an ideal environment for biotechs to continue outperforming the market.
- 07/28/2020
|
Emergent BioSolutions Triples Its Coronavirus-Vaccine Manufacturing Contract With AstraZeneca
- Chalk up another contract to manufacture a coronavirus vaccine for Emergent BioSolutions (NYSE: EBS). Emergent BioSolutions, which is focused on bioterrorism and emergent diseases but also has a contract-manufacturing division, has previously partnered with Johnson & Johnson, Novavax, and Vaxart, as well as the aforementioned AstraZeneca, to help manufacture vaccines to prevent COVID-19. The previous deal between Emergent and AstraZeneca, which was established in June, provided Emergent with $87 million in exchange for setting up the manufacturing process, and an initial reservation for raw materials and capacity to manufacture AZD1222, AstraZeneca's coronavirus vaccine, which it licensed from the University of Oxford and its spin-out company, Vaccitech.
- 07/27/2020
|
Coronavirus update: U.S. case tally climbs above 4.2 million after a fifth straight day of more than 1,000 new infections
- The U.S. case tally for the coronavirus illness COVID-19 rose above 4.2 million on Monday, after a fifth straight day of more than 1,000 new infections, as...
- 07/27/2020
|
The Week Ahead In Biotech: Spotlight On GW Pharma, Ultragenyx FDA Decisions, Pfizer Earnings
- Biotech stocks moved lower in the week ended July 26, as the broader market weakness and sector-specific developments pressured stocks.
Although there were promising updates from...
- 07/26/2020
|
How NYC hospitals have become better equipped to treat COVID-19 patients
- To combat the virus, researchers have been pushing innovations in testing, drugs and blood plasma and other treatments.
- 07/22/2020
|
Emergent BioSolutions to Release Second Quarter 2020 Financial Results and Conduct Conference Call on July 30, 2020
- GAITHERSBURG, Md., July 16, 2020 -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, July 30, 2020 at 5:00 pm (Eastern Time) to discuss the.
- 07/16/2020
|
Axa Makes New Investment in Emergent Biosolutions Inc (NYSE:EBS)
- Axa purchased a new position in shares of Emergent Biosolutions Inc (NYSE:EBS) in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 5,100 shares of the biopharmaceutical company’s stock, valued at approximately $295,000. Other large investors have also recently added to or reduced their stakes […]
- 07/13/2020
|
Emergent Biosolutions (EBS) Stock Sinks As Market Gains: What You Should Know
- Emergent Biosolutions (EBS) closed at $94.23 in the latest trading session, marking a -0.26% move from the prior day.
- 07/10/2020
|
Is Emergent Biosolutions (EBS) Stock Outpacing Its Medical Peers This Year?
- Is (EBS) Outperforming Other Medical Stocks This Year?
- 07/10/2020
|
Emergent (EBS) Stock Up Year to Date on Coronavirus Vaccine Deals
- Emergent (EBS) inks deals with multiple companies to provide manufacturing services for helping them develop COVID-19 vaccine.
- 07/09/2020
|
The Daily Biotech Pulse: FDA Nod For Osmotica, OptiNose Strikes Co-promotion Deal, Orphan Drug Designation For AnaptysBio
- Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 8)
Akero Therapeutics Inc (...
- 07/09/2020
|
Emergent BioSolutions Gets Deeper Into Covid-19 Deals
- The midcap drugmaker said Wednesday it would collaborate with the Mount Sinai Health System to test a drug derived from blood plasma taken from recovered Covid-19 patients.
- 07/08/2020
|
Emergent to partner with Mount Sinai for potential plasma-derived COVID-19 therapy
- Emergent BioSolutions Inc said on Wednesday it would jointly develop and run trials for its antibody product derived from plasma of recovered COVID-19 patients as a potential treatment with the Mount Sinai Health System. Under the partnership, which also includes biotech company ImmunoTek Bio Centers, Emergent will conduct a study on high-risk frontline healthcare workers and military personnel taking the experimental therapy within 72 hours after a possible exposure to the coronavirus. The clinical research will evaluate if treatment with Emergent's antibody product will help protect high-risk individuals and limit the spread of COVID-19.
- 07/08/2020
|
Mount Sinai Health System, Emergent BioSolutions, and ImmunoTek Bio Centers Form Collaboration to Develop Emergent’s COVID-19 Hyperimmune Globulin (COVID-HIG) Product Candidate with U.S. Department of Defense Funding
- The Mount Sinai Health System, Emergent BioSolutions (EBS), and ImmunoTek Bio Centers today announced that they will collaborate to develop, manufacture, and conduct clinical trials to evaluate Emergent’s COVID-19 hyperimmune globulin product, COVID-HIG, including a post-exposure prophylaxis (PEP) study on health care providers at high risk of COVID-19 infection and other high-risk populations, with $34.6 million in funding from the U.S. Department of Defense’s (DOD) Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO-CBRND). Located in New York City, one of the early epicenters of the outbreak, Mount Sinai has experience treating more than 10,000 COVID-19 cases and was among the very first in the United States to initiate a convalescent plasma program in late March.
- 07/08/2020
|
6 Stocks to Wade Through the Spike in Coronavirus Cases
- The current health scare drives market volatility and calls for investment in consumer staples, healthcare and IT sectors for stable returns.
- 07/08/2020
|
Emergent's (EBS) 5-Year Deal to Back J&J's Coronavirus Vaccine
- Emergent BioSolutions (EBS) extends a five-year deal with J&J; to provide its CDMO services to produce the drug substance of the latter's COVID-19 vaccine candidate. Shares rise.
- 07/07/2020
|
Will Emergent BioSolutions' Shares March Higher, Can It Continue?
- As of late, it has definitely been a great time to be an investor in Emergent BioSolutions
- 07/07/2020
|
Novavax soars after U.S. government awards firm $1.6 billion for coronavirus vaccine development
- The U.S. government has awarded Novavax $1.6 billion to cover testing, commercialization and manufacturing of a potential coronavirus vaccine in the United States, with the aim of delivering 100 million doses by January 2021.
- 07/07/2020
|
U.S. government awards Novavax $1.6 billion for coronavirus vaccine
- The U.S. government has awarded Novavax Inc $1.6 billion to cover testing, commercialization and manufacturing of a potential coronavirus vaccine in the United States, with the aim of delivering 100 million doses by January 2021. The award is the biggest yet from "Operation Warp Speed", the White House program aimed at accelerating access to vaccines and treatments to fight the coronavirus that causes COVID-19. "What this Warp Speed award does is it pays for production of 100 million doses, which would be delivered starting in the fourth quarter of this year, and may be completed by January or February of next year," Novavax Chief Executive Stanley Erck told Reuters.
- 07/07/2020
|
U.S. government awards Novavax $1.6 billion for coronavirus vaccine
- U.S. government awards Novavax $1.6 billion for coronavirus vaccine
- 07/07/2020
|
Coronavirus update: U.S. cases reach 2.9 million and death toll tops 130K, as 38 states see cases on the climb
- New coronavirus cases continue to surge Monday, with the U.S. re-emerging as a global hot spot, while Wall Street continues to defy the dangers after...
- 07/06/2020
|
Emergent BioSolutions inks coronavirus vaccine manufacturing deal with J&J
- Shares of Emergent BioSolutions Inc. were up 1.1% in premarket trading on Monday after it announced a five-year deal with Johnson & Johnson to manufacture the drug substance for the drugmaker's still-investigational COVID-19 vaccine. J&J; will pay $480 million for two years of Emergent's contract development and manufacturing services. The two companies had previously announced in April a deal to reserve manufacturing capacity for J&J;'s vaccine candidate. Emergent has also announced coronavirus vaccine manufacturing deals with AstraZeneca , Novavax and Vaxart Inc. as part of a new strategy to build out manufacturing capacity for COVID-19 vaccines before they have proven their efficacy or safety. Emergent's stock has gained 55.8% since the start of the year. The S&P; 500 , in comparison, has declined 3.1%.
- 07/06/2020
|
Emergent signs five-year deal backing J&J COVID-19 vaccine
- Under the deal, starting next year Emergent will provide large-scale manufacturing services to produce the drug substance over five years, with the first two years valued at about $480 million. The news follows a $135 million deal struck by the two companies in April, to use Emergent's manufacturing facilities to speed up the development and production of its vaccine candidate.
- 07/06/2020
|
Emergent to make drug substance for J&J's COVID-19 vaccine candidate
|
Emergent BioSolutions Signs Five-Year Agreement for Large-Scale Drug Substance Manufacturing for Johnson & Johnson’s Lead COVID-19 Vaccine Candidate
- Emergent BioSolutions Inc. (EBS) today announced a five-year manufacturing services agreement with Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, for large-scale drug substance manufacturing for Johnson & Johnson’s investigational SARS-CoV-2 vaccine, Ad26.COV2-S, recombinant based on the AdVac® technology. Emergent will provide contract development and manufacturing (CDMO) services to produce drug substance at large scale over five years, valued at approximately $480 million for the first two years.
- 07/06/2020
|
Emergent Biosolutions (NYSE:EBS) PT Raised to $93.00 at Wells Fargo & Co
- Emergent Biosolutions (NYSE:EBS) had its target price increased by Wells Fargo & Co from $85.00 to $93.00 in a research note published on Thursday morning, The Fly reports. The firm currently has an overweight rating on the biopharmaceutical company’s stock. A number of other equities research analysts also recently weighed in on EBS. Zacks Investment […]
- 07/06/2020
|
Better Coronavirus Stock: Emergent Biosolutions vs. Regeneron | The Motley Fool
- Both of these companies could play a huge role in ending the COVID-19 pandemic.
- 07/05/2020
|
Why Emergent BioSolutions Stock Soared 47% in the First Half of 2020
- This biotech has emerged as the manufacturing partner of choice for companies developing COVID-19 vaccines.
- 07/04/2020
|
Emergent Biosolutions Inc (NYSE:EBS) Shares Purchased by Jane Street Group LLC
- Jane Street Group LLC raised its stake in Emergent Biosolutions Inc (NYSE:EBS) by 8.6% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,434 shares of the biopharmaceutical company’s stock after purchasing an additional 432 shares during the period. Jane Street Group […]
- 07/04/2020
|
5 Booming Biotech Stocks to Buy
- These five biotech stocks have already gone on heaters of 30% or more in 2020, and all of them still have plenty of upside to spare.
- 07/03/2020
|
These 3 Things Could Send Novavax's Stock Soaring to New Heights | The Motley Fool
- Here's why the company's amazing run on the stock market year to date could continue.
- 07/02/2020
|
Amgen (AMGN) Looks Good: Stock Adds 8.2% in Session
- Amgen (AMGN) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
- 07/02/2020
|
This Under-the-Radar Stock Is a Better Way to Bet on Coronavirus Vaccines
- Emergent BioSolutions has become the go-to manufacturing partner for companies looking to develop vaccines for the coronavirus.
- 07/01/2020
|
Race for a COVID-19 vaccine has drug makers scaling up manufacturing — before one is developed
- Inovio Pharmaceuticals Inc. has yet to share results from the Phase 1 trial for its COVID-19 vaccine candidate, but has already received millions of dollars in funding to scale up manufacturing capacity.
- 06/29/2020
|
3 Reasons Why Emergent Biosolutions (EBS) Is a Great Growth Stock
- Emergent Biosolutions (EBS) could produce exceptional returns because of its solid growth attributes.
- 06/29/2020
|
Why Vaxart Shares Are Vaulting Higher Again | The Motley Fool
- Momentum from last week's big news continues.
- 06/29/2020
|
Ascendis Submits BLA to FDA for TransConhGH in Pediatric GHD
- Ascendis Pharma (ASND) submits BLA to the FDA for TransConhGH for the treatment of pediatric growth hormone deficiency.
- 06/29/2020
|
Vertex's Triple Combo Cystic Fibrosis Pill Gets CHMP Backing
- Vertex (VRTX) is seeking approval in Europe for its triple combo pill, Kaftrio in combination with Kalydeco to treat cystic fibrosis in patients aged 12 and older with most common genotypes.
- 06/29/2020
|
Guggenheim Capital LLC Has $7.46 Million Stock Holdings in Emergent Biosolutions Inc (NYSE:EBS)
- Guggenheim Capital LLC decreased its stake in Emergent Biosolutions Inc (NYSE:EBS) by 0.2% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 128,945 shares of the biopharmaceutical company’s stock after selling 250 shares during the period. Guggenheim Capital LLC owned 0.25% of […]
- 06/28/2020
|
Vaxart says potential COVID-19 vaccine picked for 'Operation Warp Speed'
- Vaxart Inc said on Friday it would test its experimental oral COVID-19 vaccine on monkeys infected with the new coronavirus in a study funded by the Trump administration's vaccine-acceleration program called "Operation Warp Speed".
- 06/26/2020
|
iBio Is in a Healthy Position With Covid-19 Vaccine Push
- The novel coronavirus pandemic has swept away several industries but has been a bit of a blessing for the biotech sector. iBio (NYSEMKT:IBIO) is one company that is benefiting from the hype surrounding the push for a vaccine, as iBio stock gained 490% this year.Source: Shutterstock As I discussed in my previous article, iBio's propriety technology called "Fast Pharming" provides the company with a unique edge in the scalability of a potential vaccine. The plant-based production system helped iBio attract investments from a few institutional investors. However, several investors are currently in two minds about investing in a vaccine inventor or a manufacturer such as iBio.This factor, along with its weak balance sheet, top the primary concerns for iBio at this time. Let's look into these aspects in more detail.InvestorPlace - Stock Market News, Stock Advice & Trading Tips Impact of Fast Pharming I talked about Fast Pharming in-length in my previous article on iBio, however, it's best to go over it again to set up a strong premise.iBio's system combines vertical farming, automated hydroponics and glycan engineering technologies to scale up vaccines, antibodies, and other proteins. This streamlines the manufacturing system with greater consistency and efficiency. It's much quicker to grow more plants to scale up production and relatively inexpensive at the same time. * 10 Consumer Stocks to Buy to Ride the Post-Covid-19 WaveThe production system is currently a novelty in the industry. Also, it represents a significant competitive advantage for iBio to scale up production for the companies involved in creating a Covid-19 vaccine.The company is collaborating with several institutions, including the Beijing CC-Pharming, Infectious Disease Research Institute. However, iBio has not won a contract with a significant vaccine developer.Recently, Moderna (NASDAQ:MRNA) announced a partnership with Swiss company Lonza (OTCMKTS:LZAGY) to scale up production of its Covid-19 vaccine using a new mRNA technology. That makes it imperative for iBio to make some consequential moves now before it loses out on significant contracts. Financial ComparisonSource: Muslim Farooque One of the most impressive things about iBio has been its ability to gain a unique position in an industry with significant barriers to entry.From the table above, we can see that iBio has the lowest market cap compared to the three bigwigs in the biotech sector. Naturally, it has the lowest fixed and current assets in the group. In addition, its free cash flows and margins have been in the negative along with the rest of the industry.Meanwhile, iBio has done significantly better than its peers concerning revenue growth.The real figure to consider at this stage is the research and development expenditure for the four companies along with their internal resources. It is clear that iBio is at a significant disadvantage in this comparison. The company needs to consistently seek ways to pump in more cash. Look Ahead for IBIO StockDevelopers of the Covid-19 vaccine seem to be closing in on the trial phase. Global pharmaceutical giant Pfizer believes that the vaccine should be ready by October. However, that is the best-case scenario, and several experts believe that it could potentially take longer.Nevertheless, vaccine developers are now looking to form partnerships with biotech companies to scale the production of their vaccine candidates.I talked about how Moderna partnered with a Swiss biotech firm called Lonza to scale up production. Similarly, other biotech companies such as the German Vibalogics GmbH and the American Emergent BioSolutions (NYSE:EBS) recently made waves.iBio also made inroads recently. However, as we get closer to the final stages of the vaccine's development, iBio and other biotech companies will be looking to land contracts with the major vaccine developers.The companies with the most success are likely to attract the most attention from investors. iBio's Fast Pharming system could potentially play a huge role in its success going forward. The company estimates an impressive 500 million dose capacity for its Covid 19 vaccine. Bottom Line on iBio Stock iBio is in a robust position as we get closer to a Covid 19 vaccine. Its Fast Pharming system provides it a unique stability technology that could set it apart. It is time for the company to score big with some major vaccine developers as we get closer to the October window.You could play the waiting game to see which manufacturers are making the most waves in the upcoming weeks, but I believe that iBio has excellent potential. And, now is a great time to grab the stock at a discount.As of this writing, Muslim Farooque did not hold a position in any of the aforementioned securities. More From InvestorPlace * Why Everyone Is Investing in 5G All WRONG * America's 1 Stock Picker Reveals His Next 1,000% Winner * Revolutionary Tech Behind 5G Rollout Is Being Pioneered By This 1 Company * Radical New Battery Could Dismantle Oil Markets The post iBio Is in a Healthy Position With Covid-19 Vaccine Push appeared first on InvestorPlace.
- 06/26/2020
|
Vaxart says potential Covid-19 vaccine picked for 'Operation Warp Speed'
- BENGALURU (June 26): Vaxart Inc said on Friday it would test its experimental oral Covid-19 vaccine on monkeys infected with the new coronavirus in a study funded by the Trump administration's vaccine-acceleration program called "Operation Warp Speed".
- 06/26/2020
|
Vaxart says potential COVID-19 vaccine picked for 'Operation Warp Speed'
- Vaxart Inc said on Friday it would test its experimental oral COVID-19 vaccine on monkeys infected with the new coronavirus in a study funded by the Trump administration's vaccine-acceleration program called "Operation Warp Speed".
- 06/26/2020
|
If a coronavirus vaccine is developed, what will be the next challenges?
- Covid vaccine makers face biggest medical manufacturing challenge in history.Companies and governments are racing to scale-up machinery to address a critical shortage in automated filling and finishing capacity
- 06/26/2020
|
Vaxart Rallies On Double Dose Of Positive Coronavirus Vaccine Developments
- Shares of oral vaccine maker Vaxart Inc (NASDAQ: VXRT) are on a strong two-day run after two announcements tied to coronavirus vaccine development.
What Happened: The South...
- 06/26/2020
|
COVID-19: Vaccine makers face biggest challenge in history
- Producing enough COVID-19 vaccine doses to end the pandemic will be the biggest medical manufacturing feat in history. The work is underway
- 06/25/2020
|
Aptevo Therapeutics to receive Seven Year Quarterly Royalty Payment Stream from Pfizer for Sales of Rituximab Biosimilar | | IT Business Net
- Published Articles Suggest the Global Market for Rituximab Biosimilars Could Potentially be over $1 Billion Per Year Royalty Stream Relates to Agreement Acquired in Aptevo Spin-off from Emergent BioSo
- 06/25/2020
|
Vaccine makers face biggest medical manufacturing challenge in history
|
Vaccine makers face biggest medical manufacturing challenge in history
- Developing a COVID-19 vaccine in record time will be tough. Producing enough to end the pandemic will be the biggest medical manufacturing feat in history.
- 06/25/2020
|
Vaccine makers face biggest medical manufacturing challenge in history
- Developing a COVID-19 vaccine in record time will be tough. Producing enough to end the pandemic will be the biggest medical manufacturing feat in history.
- 06/25/2020
|
INSIGHT-Vaccine makers face biggest medical manufacturing challenge in history
- Companies and governments are racing to scale-up machinery to address a critical shortage in automated filling and finishing capacity - the final step in the manufacturing process of putting the vaccine into vials or syringes, sealing them and packaging them up for shipping. "This is the biggest logistical challenge the world has ever faced," said Toby Peters, an engineering and technology expert at Britain's Birmingham university.
- 06/25/2020
|
COVID-19 vaccine makers face biggest medical manufacturing feat in history
- From deploying experts amid global travel restrictions to managing extreme storage conditions, and even inventing new kinds of vials and syringes for billions of doses, the path is strewn with formidable hurdles
- 06/25/2020
|
COVID-19: Vaccine Makers Face Biggest Medical Manufacturing Feat In History
- The supply chain of a potential vaccine stretches from Pune in India to England's Oxford and Baltimore in the United States
- 06/25/2020
|
Vaccine makers face biggest medical manufacturing feat in history
- From deploying experts amid global travel restrictions to managing extreme storage conditions, and even inventing new kinds of vials and syringes for billions of doses, the path is strewn with formidable hurdles, according to Reuters interviews with more than a dozen vaccine developers and their backers.
- 06/25/2020
|
Vaccine makers face biggest medical manufacturing feat in history
- Developing a COVID-19 vaccine in record time will be tough. Producing enough to end the pandemic will be the biggest medical manufacturing feat in history.
- 06/25/2020
|
Race for a COVID-19 vaccine has drug makers scaling up manufacturing — before one is developed
- Inovio Pharmaceuticals Inc. has yet to share results from the Phase 1 trial for its COVID-19 vaccine candidate, but has already received millions of dollars...
- 06/25/2020
|
Vaccine makers face biggest medical manufacturing feat in history
- Developing a COVID-19 vaccine in record time will be tough. Producing enough to end the pandemic will be the biggest medical manufacturing feat in history.
- 06/25/2020
|
Vaccine makers face biggest medical manufacturing feat in history
- Developing a COVID-19 vaccine in record time will be tough. Producing enough to end the pandemic will be the biggest medical manufacturing feat in history.
- 06/25/2020
|
INSIGHT-Vaccine makers face biggest medical manufacturing challenge in history
- From deploying experts amid global travel restrictions to managing extreme storage conditions, and even inventing new kinds of vials and syringes for billions of doses, the path is strewn with formidable hurdles, according to Reuters interviews with more than a dozen vaccine developers and their backers. Any hitch in an untested supply chain - which could stretch from Pune in India to England's Oxford and Baltimore in the United States - could torpedo or delay the complex process. Col. Nelson Michael, director of the U.S. Army's Center for Infectious Disease Research who is working on the government's "Warp Speed" project to deliver a vaccine at scale by January, said companies usually have years to figure this stuff out.
- 06/25/2020
|
Vaccine makers face biggest medical manufacturing challenge in history
- Vaccine makers face biggest medical manufacturing challenge in history
- 06/25/2020
|
Hedge Funds Are Betting On Emergent Biosolutions Inc (EBS)
- The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F […]
- 06/24/2020
|
Myovant's Endometriosis Pain Drug Meets Goal in Study, Stock Up
- Myovant (MYOV) reports positive top-line data from the phase III study on the relugolix combination therapy in women suffering from pain associated with endometriosis.
- 06/24/2020
|
Emergent Biosolutions Inc (NYSE:EBS) Shares Sold by JPMorgan Chase & Co.
- JPMorgan Chase & Co. lowered its stake in shares of Emergent Biosolutions Inc (NYSE:EBS) by 2.5% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 22,757 shares of the biopharmaceutical company’s stock after selling 586 shares during the quarter. JPMorgan Chase […]
- 06/24/2020
|
Agenus Stock Up on Licensing Deal With China-Based Firm
- Agenus (AGEN) signs an exclusive collaboration and license agreement with Chinese company, Betta Pharmaceuticals, for the development and commercialization of balstilimab and zalifrelimab.
- 06/23/2020
|
4 Momentum Picks Screened on Driehaus Strategy
- Richard Herman Driehaus developed an investment approach based on the buy high and sell higher rule.
- 06/22/2020
|
Thrivent Financial for Lutherans Raises Position in Emergent Biosolutions Inc (NYSE:EBS)
- Thrivent Financial for Lutherans raised its holdings in shares of Emergent Biosolutions Inc (NYSE:EBS) by 5.3% in the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 36,776 shares of the biopharmaceutical company’s stock after purchasing an additional 1,836 shares during the period. Thrivent Financial for Lutherans […]
- 06/22/2020
|
Emergent BioSolutions: Revising My Valuation
- Emergent BioSolutions has emerged as a prominent manufacturer for COVID-19 vaccines, both for public and private players. The company is also focused on develop
- 06/19/2020
|
Emergent Makes $75 Million Investment To Boost Viral Vaccine Capabilities
- Emergent BioSolutions Inc. (EBS) said on Thursday that it will invest $75 million in its Massachusetts facility to boost the contract development and manufacturing (CDMO) capabilities of drug substances for live viral vaccines.As part of the investment, the life sciences company will acquire a property adjacent to its Massachusetts viral drug substance manufacturing site to build out its advanced therapy capability. Through the strategic facility acquisition, Emergent seeks to secure the long-term supply chain of the only single-dose smallpox vaccine.The company said it expects advanced therapy CDMO drug substance manufacturing services to be available beginning in 2023.“Emergent’s expansion into advanced therapy CDMO services is based on our biologics expertise and a strong understanding of our customers’ current and future needs,” said Emergent’s EVP of manufacturing and technical operations Sean Kirk. “We are investing in our people, plants, and products to meet the growing demand for precision treatments and to help get these therapies to patients.”The company plans to provide full molecule-to-market CDMO services for viral vector and gene therapy innovators, by offering development services out of its Gaithersburg location, drug substance manufacturing out of its Massachusetts, and drug product manufacturing at its Rockville location.Emergent’s CDMO business has the capability to work with five technology platforms – mammalian, microbial, live viral, advanced therapy, and plasma – across a network of nine development and manufacturing sites, to support the entire drug development life cycle.The investment comes after last week’s announcement that Emergent signed an agreement to manufacture AstraZeneca Plc’s (AZN) potential COVID-19 vaccine in the U.S. in a deal valued at $87 million.Shares in Emergent rose 1.8% to $71.18 in pre-market trading. The stock has advanced some 30% so far this year.Earlier this month five-star analyst Boris Peaker at Cowen & Co. lowered the stock’s price target to $64 from $77 and maintained a Hold rating."We view EBS as the leading biodefense contractor, driven by sales of BioThrax and other biodefense product and services offerings,” Peaker wrote in a note to investors. “However, follow-on U.S. government contracts were smaller than anticipated, creating an impetus to diversify revenue.”The rest of the Street has a bullish outlook on the stock. The Strong Buy analyst consensus boasts 4 Buy ratings versus Peaker’s Hold rating. Meanwhile, the $82.40 average analyst price target implies another 18% upside potential for the shares in the next 12 months. (See EBS stock analysis on TipRanks).Related News: Oxford Biomedica Clinches Manufacturing Deal For AstraZeneca’s Covid-19 Vaccine 5 Promising Covid-19 Vaccines Picked For Trump’s Operation Warp Speed What Would a Merger Mean for Gilead? Top Analyst Weighs In More recent articles from Smarter Analyst: * Carnival Posts $4.4B Quarterly Loss Sending Shares Down 7% In Pre-Market * Google’s $2.1 Billion Fitbit Bid Challenged By Australia’s Competition Regulator * Hertz Drops 7% In Pre-Market After Suspension of $500 Million Share Offering * Lyft Plans To Switch To 100% Electric Cars By 2030
- 06/18/2020
|
The Daily Biotech Pulse: Eloxx Resumes Cystic Fibrosis Study, Rexahn's Reverse Merger, Ultragenyx, Epizyme Await FDA Decisions
- Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 17) * Adverum Biotechnologies Inc (NASDAQ: ADVM) * Affimed NV (NASDAQ: AFMD) (announced completion of dosing of first cohort in Phase 1/2A study of AFM24 in treating advanced EGFR-expressing solid tumors) * Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN) * BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) (announced additional data from Phase 1/2 study of investigational gene therapy for severe hemophilia A) * BioXcel Therapeutics Inc (NASDAQ: BTAI) * Brainstorm Cell Therapeutics Inc (NASDAQ: BCLI) * Cytokinetics, Inc. (NASDAQ: CYTK) * DiaMedica Therapeutics Inc (NASDAQ: DMAC) * Fennec Pharmaceuticals Inc (NASDAQ: FENC) * GENMAB A/S/S ADR (NASDAQ: GMAB) * Ideaya Biosciences Inc (NASDAQ: IDYA) * ITAMAR MED LTD/S ADR (NASDAQ: ITMR) * MannKind Corporation (NASDAQ: MNKD) * Meridian Bioscience, Inc. (NASDAQ: VIVO) * Neubase Therapeutics Inc (NASDAQ: NBSE) * NGM Biopharmaceuticals Inc (NASDAQ: NGM) * Novo Nordisk A/S (NYSE: NVO) * Ocular Therapeutix Inc (NASDAQ: OCUL) * Odonate Therapeutics Inc (NASDAQ: ODT) * Passage Bio Inc (NASDAQ: PASG) * Quidel Corporation (NASDAQ: QDEL) * Sanofi SA (NASDAQ: SNY) (announced positive results for a Phase 3 study of its enzyme replacement therapy avalglucosidase alfa in late-onset Pompe disease) * Sarepta Therapeutics Inc (NASDAQ: SRPT) * SpringWorks Therapeutics Inc (NASDAQ: SWTX) * TELA Bio Inc (NASDAQ: TELA) * TFF Pharmaceuticals Inc (NASDAQ: TFFP) (announced orphan drug designation for tacrolimus for prophylaxis of lung allograft rejection) * Vaxcyte Inc (NASDAQ: PCVX) (went public Friday) * Zai Lab Ltd (NASDAQ: ZLAB) * Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) * Zynex Inc. (NASDAQ: ZYXI)Down In The Dumps (Biotech Stocks Hitting 52-week Lows June 17) * BioCardia Inc (NASDAQ: BCDA) * Hoth Therapeutics Inc (NASDAQ: HOTH) * Lantern Pharma Inc (NASDAQ: LTRN) (went public Thursday)Stocks In Focus Eloxx Resumes Midstage Cystic Fibrosis Study In Europe, Israel Eloxx Pharmaceuticals Inc (NASDAQ: ELOX) said enrollment in its Phase 2 clinical trial for ELX-02 in cystic fibrosis has resumed in Israel and Europe after being temporarily paused in response to the COVID-19 pandemic.Enrollment in the U.S. trial remains paused due to safety concerns, Eloxx said. The company said it's looking to complete enrollment in its Phase 2 proof-of-concept trial and report top-line data as soon as feasible.The stock was soaring 21.31% to $3.70 premarket Thursday. Adamas Pharma Confirms Shelving Of Gocovri Study In Multiple Sclerosis Patients With Walking Impairment Adamas Pharmaceuticals Inc (NASDAQ: ADMS) said that following a comprehensive analysis of Phase 3 data from the INROADS study of ADS-5102 in multiple sclerosis patients with walking impairment, it has reconfirmed its decision not to initiate further late-stage development in MSW.The company noted that further engagement with the FDA regarding a potential path to submission confirmed the need of an additional pivotal Phase 3 confirmatory study.The stock was down 9.09% at $2.60 premarket. Emergent Bio To Invest $75M In Expansion Of CDMO Capabilities Emergent Biosolutions Inc (NYSE: EBS) said it will further strengthen its contract development and manufacturing capabilities by expanding into viral vector and gene therapy by investing $75 million in its Canton, Massachusetts facility.The facility is focused on the development and manufacturing of drug substances for live viral vaccines, including the company's smallpox vaccine.In premarket trading Thursday, the stock was up 1.76% to $71.18.Illumina Buys Cloud-Based Genomic Analysis Software Company Illumina, Inc. (NASDAQ: ILMN) announced the acquisition of Netherlands-based BlueBee, a cloud-based software company that provides genomics analysis solutions for research and clinical customers.The deal will enhance Illumina's capabilities to analyze and interpret the data produced by its sequencing systems, the company said. See also: The Week Ahead In Biotech: FDA Decisions In The Cards For Merck, Epizyme, Evoke And Ultragenyx Roche Reports Positive Results For Late-Stage Breast Cancer Study Roche Holdings AG Basel ADR Common Stock (OTC: RHHBY) said the Phase 3 IMpassion031 study evaluating Tecentriq in combination with chemotherapy met its primary endpoint by demonstrating a statistically significant and clinically meaningful improvement in pathological complete response for the treatment of people with early triple-negative breast cancer regardless of PD-L1 expression.The study is comparing the combination to placebo plus chemotherapy. In the study, fewer patients who received the Tecentriq combination as a neoadjuvant treatment had evidence of tumor tissue detectable at the time of surgery regardless of PD-L1 expression in comparison to the control arm.Tonix Announces Expansion Of Vaccine Collaboration Agreement Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) announced an expansion of its strategic collaboration with Southern Research to include a study of T cell immune responses to SARS-CoV-2 in volunteers who have recovered or remain asymptomatic after exposure to COVID-19.The research is part of an ongoing a collaboration between Tonix and Southern Research to develop and conduct animal testing of Tonix's TNX-1800, a live replicating virus vaccine designed to protect against COVID-19.The data will support the interpretation of animal trial results with TNX-1800, which are expected in the fourth quarter of 2020 and subsequent human trials.In premarket trading Thursday, Tonix shares were jumping 28.39% to 80 cents.Rexahn To Reverse Merge With Ocuphire Pharma Rexahn Pharmaceuticals, Inc. (NASDAQ: REXN) announced an agreement to merge with privately held Ocuphire Pharma in an all-stock deal. The transaction is expected to close in the second half of 2020.View more earnings on IBBFollowing the consummation of the deal, the combined company will change its name to Ocuphire Pharma Inc, and will likely to trade on the Nasdaq under the ticker symbol "OCUP."The combined company will focus on the advancement of its pipeline of ophthalmic drug candidates, Rexahn said.Hutchison Gets Fast Track Designation For Drug To Treat Colorectal Cancer HUTCHISON CHINA/S ADR (NASDAQ: HCM) said the FDA has granted Fast Track Designation for the development of fruquintinib for patients with previously treated metastatic colorectal cancer. The company said it is initiating a Phase 3 registration study, known as the FRESCO-2 study, in refractory mCRC in the U.S., Europe and Japan, with enrollment set to begin in mid-2020.Offerings Leap Therapeutics Inc (NASDAQ: LPTX) said it has commenced an underwritten public offering of its common stock and pre-funded warrants to purchase shares of its common stock.All shares of common stock and pre-funded warrants to be sold in the offering will be offered by the company.The stock slipped 15.08% to $2.14 in after-hours trading.IVERIC bio Inc (NASDAQ: ISEE) priced its upsized underwritten public offering of 24.54 million shares of its common stock at $4.10 per share and the pre-funded warrants to purchase 1.9143 million shares at $4.099 per pre-funded warrant, in each case less underwriting discounts and commissions. All of the securities are being offered by the company.The stock was down 2.03% at $4.35 premarket. IDEAYA, which recently announced an oncology collaboration, priced an underwritten public offering of 6.67 million shares at $15 per share to generate gross proceeds of $100 million. The offering is expected to close on or about June 22.The stock fell was down 9.42% at $16.82 premarket Thursday.Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) announced a common stock offering, with all the shares earmarked for the offering sold by the company.The stock was down 0.33% at $4.49 premarket. Orthopediatrics Corp (NASDAQ: KIDS) said it is commencing an underwritten public offering of its common stock.The stock was down 3.06% at $48.15 premarket. On The Radar PDUFA Dates Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) and its Japanese partner Kyowa Kirin have a tryst with the FDA, as the agency is set to rule on hypophosphatemia treatment candidate burosumab.The regulatory agency will also decide on Epizyme Inc's (NASDAQ: EPZM) regulatory application for label expansion for tazemetostat, this time for follicular lymphoma.Earnings * BioNano Genomics Inc (NASDAQ: BNGO) (after the close) * Urovant Sciences Ltd (NASDAQ: UROV) (after the close)Related Link: Sinovac Makes Headway In Coronavirus Vaccine Race With Positive Preliminary Phase 1/2 Results See more from Benzinga * The Daily Biotech Pulse: Patent Win For Amarin, FDA Nod For Novartis & Merck, Chembio's Coronavirus EUA Revoked(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- 06/18/2020
|
Emergent BioSolutions to Invest $75 Million in Canton Site and Expand Viral Vector and Gene Therapy Capability
- Company acquires property adjacent to its Canton, Massachusetts live viral drug substance development and manufacturing facility to increase campus footprint and build out.
- 06/18/2020
|
Emergent Biosolutions Inc (NYSE:EBS) Stake Cut by Deutsche Bank AG
- Deutsche Bank AG reduced its holdings in Emergent Biosolutions Inc (NYSE:EBS) by 9.7% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 226,335 shares of the biopharmaceutical company’s stock after selling 24,185 shares during the period. Deutsche Bank AG owned […]
- 06/17/2020
|
Emergent BioSolutions to Participate in Virtual Investor Conferences
- GAITHERSBURG, Md., June 16, 2020 -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company’s executive management team will participate in the.
- 06/16/2020
|
Parametric Portfolio Associates LLC Has $10.91 Million Stock Position in Emergent Biosolutions Inc (NYSE:EBS)
- Parametric Portfolio Associates LLC grew its stake in shares of Emergent Biosolutions Inc (NYSE:EBS) by 0.4% during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 188,626 shares of the biopharmaceutical company’s stock after purchasing an additional 784 shares during the quarter. Parametric Portfolio Associates […]
- 06/16/2020
|
9 Pharmaceutical Companies Racing For A COVID-19 Vaccine
- Globally, there are more than 100 vaccines under development — with nine of them in human clinical trials already, asserts equity analyst Sel Hardy, in CFRA Research's flagship newsletter, The Outlook.
- 06/16/2020
|
Pharma Giant to Supply 400 Million Doses of Vaccine in Europe by Year End
- AstraZeneca has reached an agreement with four European Union nations to supply up to 400 million doses of the CCP virus vaccine by the end of 2020.
- 06/14/2020
|
La cursa geopolítica per la vacuna
- Les grans farmacèutiques, entre la dependència de la Xina i el nacionalisme dels estats
- 06/13/2020
|
Better Coronavirus Stock: OPKO Health or Emergent Biosolutions?
- Which stock wins in a battle between a COVID-19 testing leader and the top contract manufacturer for COVID-19 vaccines?
- 06/13/2020
|
Emergent (EBS) to Manufacture AstraZeneca's Coronavirus Vaccine
- Emergent BioSolutions (EBS) inks a deal with AstraZeneca to provide its CDMO services for supporting the manufacturing of the latter's COVID-19 vaccine candidate, AZD1222.
- 06/12/2020
|
Is Emergent BioSolutions (EBS) Stock a Solid Choice Right Now?
- Emergent BioSolutions (EBS) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
- 06/12/2020
|
Moderna vaccine trials moving fast, with final study set for July - The Boston Globe
- Moderna Inc. said it had selected a dose for a final-stage clinical trial of its coronavirus vaccine that should begin in July, as the company moves ahead rapidly with its innovative approach to trying to prevent Covid-19.
- 06/11/2020
|
Emergent BioSolutions Will Manufacture AstraZeneca's COVID-19 Vaccine Candidate
- Small-cap Emergent BioSolutions (NYSE: EBS) has landed another contract to manufacture a possible COVID-19 vaccine, this time with European pharmaceutical giant AstraZeneca. Of course, the contract, said to be worth as much as $87 million, hinges on whether AstraZeneca's vaccine gets approved by the Food and Drug Administration for human use. Emergent is a contract development and manufacturing organization that has relationships with many biotech and pharmaceutical companies (not to mention the federal government).
- 06/11/2020
|
AstraZeneca y Emergent acuerdan fabricación de vacuna contra Covid-19
- La farmacéutica acordó la manufactura de la vacuna inglesa y también la de Johnson & Johnson. Primeras dósis estarían disponibles en un año, como mínimo.
- 06/11/2020
|
Emergent Bio Signs Covid-19 Vaccine Manufacturing Deal With AstraZeneca
- Emergent BioSolutions Inc. (EBS) said on Thursday that it signed an agreement to manufacture AstraZeneca Plc’s (AZN) potential COVID-19 vaccine in the
- 06/11/2020
|
Is Emergent Biosolutions (EBS) a Solid Growth Stock? 3 Reasons to Think " Yes "
- Emergent Biosolutions (EBS) could produce exceptional returns because of its solid growth attributes.
- 06/11/2020
|
Emergent Biosolutions (EBS) Moves to Strong Buy: Rationale Behind the Upgrade
- Emergent Biosolutions (EBS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 1 (Strong Buy).
- 06/11/2020
|
New Strong Buy Stocks For June 11th
- New Strong Buy Stocks For June 11th
- 06/11/2020
|
Emergent BioSolutions Signs Agreement to be U.S. Manufacturing Partner for AstraZeneca's COVID-19 Vaccine Candidate
- Emergent will provide contract development and manufacturing services and secure large-scale manufacturing capacity through 2020 to support AstraZeneca's...
- 06/11/2020
|
AstraZeneca taps Emergent as U.S. partner for potential COVID-19 vaccine
- AstraZeneca has inked manufacturing deals globally to meet its target of making 2 billion doses of the vaccine, including with two Bill Gates-backed ventures and a $1.2 billion agreement with the U.S. government. The company's vaccine is among the first to move into mid-stage trials and the first indication of its effectiveness would likely be available in June or July. There are no approved vaccines or treatments for COVID-19, the highly contagious respiratory illness caused by the novel coronavirus.
- 06/11/2020
|
